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Preface 
Polycystic kidney disease (PKD) is a heritable disorder with diffuse cystic destlUction of 
both kidneys, leading to renal failure in many patients. Two entities can be identified: 
autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive 
polycystic kidney disease (ARPKD). ADPKD is one of the most common inherited 
monogenic disorders, affecting approxin18tely I: 1.000 individuals; ARPKD affects 
I :40.000. The severity of disease in affected patients is highly variable in both ADPKD 
and ARPKD, even within families. ADPKD progresses to end stage renal failure in about 
half the patients, usually after the 4th decade. ARPKD leads to renal failure during infancy 
or early childhood in all cases and is associated with abnormalities of the biliary system in 
the liver, leading to severe liver disease in many children. No direct treatment of the 
fom18tion and subsequent expansion of the cysts is currently available. 
Recent genetic studies characterized the principle genes involved in ADPKD (PKD I 
and PKD2) and localized the gene for ARPKD. Intensive investigations were undertaken 
into the role of these genes during normal life and on how mutations of these genes 
eventually lead to the formation of cysts. It has now become apparent that this cystic 
process involves many different proteins, encoded by many different genes. 
TIle cellular mechanisms involved in cyst formation include abnormal proliferation and 
abnomlal survival of the involved cells, altered transport of fluid into the cysts and altered 
regulation of the extracellular matrix composition. These mechanisms have been explored 
in renal tissues from patients as well as in various experimental models ofPKD. 
Murine (mouse and rat) models of PKD have contributed significantly to the current 
understanding ofPKD. In addition to allowing the systematic analysis of cystic tissues and 
renal physiology during cyst formation, these models have revealed genes and proteins that 
are potentially involved in the molecular pathogenesis of cyst fomlation, including genetic 
factors that modulate the severity of disease. Moreover, aninIal models have and will be 
used to explore therapeutic strategies for patients with PKD. However, none of the 
available murine models of PKD completely parrallels either human ARPKD or ADPKD. 
They differ from human disease states by the clinical expression of disease, the underlying 
genetic defect, or both. 
In the studies described in this manuscript we set out to characterize new murine 
models of PKD and opted in particular to develop tools for the study of polycystin-l, the 
gene product of PKD I. In addition we set out to determine whether 'programmed cell 
death' is part of the cellular phenotype of cystic tissues. 
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Introduction 
The development of renal cysts is a feature of several genetic and lloll~genetic disorders. 
TIle most conmlOll and best understood causes of renal cystic disease in humans are 
genetically determined and include autosomal dominant polycystic kidney disease 
(ADPKD), autosomal recessive polycystic kidney disease (ARPKD) and the juvenile 
nephronophthisis / medullary cystic disease complex, for which the genes have been 
identified and/or chromosomal locations have been mapped. Other causes of renal cyst 
fommtioll include the genetic disorders tuberous sclerosis and von Hippel~Lilldau 
syndrome as well as a large number of genetic malfomlation syndromes associated with 
renal cyst fOlmation. Non~genetic disorders include multicystic dysplasia, simple cysts, 
medullary sponge kidneys, acquired cysts (associated with uremia), Wilms tumor and renal 
carcinoma. 
The current understanding of renal cyst formation is largely based on both clinical and 
experimental observations of Polycystic Kidney Disease (PKD), Here, we will first 
describe the clinical aspects of the two different entities of PKD, including the clinical 
differentiation from each other. Secondly we will sunmmrize what is known about the 
pathophysiology of cyst formation, using data from both human PKD as well as from 
experimental models ofPKD. This includes an extensive summary of the characteristics of 
the various animal and cell models of cyst formation that are currently available, Finally 
we will present a theoretical framework that outlines the relationship of the various 
components of cyst fonnation. 
1.1 Polycystic kidney disease, the clinical entities 
Polycystic kidney disease (PKD) is a subset of renal cystic disorders in which cysts are 
distributed throughout the cortex and medulla of both kidneys. It is the most frequent 
inherited cause of renal failure in man, The most severe forms are seen in children, but the 
most prevelent forms typically become manifest during adulthood. Recent progress in 
molecular genetics has improved the understanding and classification of these diseases and 
consequently has made genetic counseling more accurate, The genetic classification of 
PKD into an autosomal dominant and an autosomal recessive form has replaced the 
previous classification, which was based OIl age at clinical presentation: infantile and adult 
type PKD. This temlinology is now obsolete. 
Autosomal dominant polycystic kidney disease (ADPKD) 
ADPKD is a systemic disorder characterized by the development of both small and large 
renal cysts and is associated with liver, cardiovascular, gastrointestinal and genital 
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abnormalities. It is one of the most common monogenic disorders. Approximately half of 
the patients will eventnally need renal replacement therapy, typically starting after the 
fourth decade. ADPKD is often referred to as adult PKD, but this is a misnomer because it 
has been diagnosed in the fetns, newbom and older child. TI,e disease is genetically 
heterogenous and phenotypic heterogeneity has been demonstrated in different individuals 
within the same family. 
GeJletics 
ADPKD has a worldwide distribution, affects all races and affects males and females 
equally. The disease is caused by a mutation in one of at least three distinct genetic loci. 
Approximately 85% of the patients have a mutation in the PKD 1 gene on cluomosome 16, 
while most of the remaining patients have a mutation of the PKD2 gene on chromosome 4 
(Reeders '85, Romeo '88). TI,e possibility of a third locus, unlinked to PKDI and PKD2 
has been suggested (Daoust '95). ADPKD is inherited as an autosomal dominant trait with 
complete penetrance, but variable expression (Dalgaard '57). Approximately 30% of 
patients is unable to give a family history consistent with ADPKD, suggesting the 
possibility of a high spontaneous mutation rate or, altematively, the possibility that 
enviromnental andIor epidemiologic factors strongly affect the expression of ADPKD. 
With the recent isolation of the PKD 1 and PKD2 genes, direct mutational screening is 
possible. Although mutations of PKD 1 and PKD2 lead to the same clinical phenotype, 
members of PKD 1 families appear to have on average an earlier disease onset with renal 
cyst development, hypertension and renal failure at a younger age than do members of 
PKD2 families (Ravine '92). Evidence is accumulating that germline PKD 1 mutations are 
inactivating. Although relatively few mutations have been described, those characterised 
are mainly predicted to terminate the protein prematnrely due to the introduction of a stop 
or frameshifting change (Peral '96, Peral '97, Roelfsema '97). In addition, an analysis of 
patients with deletions disrupting PKD 1 and the adjacent tuberous sclerosis gene TSC2 
shows that complete PKD 1 deletion is associated with severe early onset polycystic 
kidneys (Sampson '97). Genn1ine mutations identified in PKD2 families were similarly 
predicted to code for tnlllcated polycystin-2 (Mochizucki '96). 
Although the genetic defect is the prinrary cause ofPKD, it does not predict the precize 
clinical course in individual patients. This clinical course is highly variable and differs 
between different families, and also between affected members of the same family 
(Churchill '84, Peral '96). It is generally agreed that mutation analysis does not allow the 
prediction of when and whether renal failure will develop in a given patient. The 
intrafamiliar variability suggests an additional role for other genetic or environmental 
factors as well. 
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Prellatal diagllosis of ADPKD 
Antenatal ultrasound abnonnalities have been reported in ADPKD families, but are usually 
not evident until the third trimester (Pretorius 'S7). Prenatal diagnosis sometimes leads to 
the diagnosis of ADPKD in other family members. If ADPKD is suspected, family 
members should be considered for ultrasound evaluation. This includes the grandparents if 
the parents are younger than 30. 
DNA analysis enables carrier detection and prenatal genetic diagnosis in 'infoffilative' 
PKD I or PKD2 families with suitable pedigrees. Such analysis may provide the diagnosis 
during early pregnancy (Hodgkinson '90). However, given the wide clinical spectrum and 
the treatable nature of renal failure, the question arises whether termination of an affected 
pregnancy is an acceptable option. For that reason is prenatal genetic linkage analysis not 
routinely performed in the USA or Europe (Zenes '92). 
Pathology 
Nephron reconstruction studies revealed that cysts develop as dilations of pre-existing 
renal tubules. With enlargement beyond a few millimeters in diameter, it appears that the 
majority of cysts become completely detached from the tubule of origin (Grantham 'S7b, 
'93). Cysts may arise in any nephron segment, including glomeruli, proximal tubules, 
distal tubules and collecting tubules. This has been indicated by microscopic and electron 
microscopic studies, as well as by the study of cyst fluid compositions (Grantham '93, 
Huseman 'SO). In advanced disease, the kidneys are usually diffusely cystic en enlarged. 
Reported kidney weights in adults ranges from normal to 4 kilogram. Both the outer and 
the cut surfaces show numerous cysts ranging in size from microscopical to several 
centimeters in diameter. The cysts appear throughout the kidney in bOUl the cortex and the 
medulla. 
Microscopically, most cysts are lined by a nondiscript cuboidal epithelium (Gregoire 
'S7). Microscopic polyps are cOlmnon in smaller cysts. In between the cysts normal 
nephron stmctures can always be found by microscopic examination. In advanced disease 
the kidneys often show secondary changes like tubular atrophy, glomerular sclerosis and 
interstitial fibrosis. Ultrastructurally, cyst walls have a generally single layered simple 
epithelium lying on a basement membrane that varies from normal to thickened or 
extensively laminated (Grantham 'S7b, Cuppage 'SO). The epithelial cells are of various 
types, some of which resemble those lining nomlal nephron segments. However, the 
majority appears to be lined by a primitive epithelium that does not resemble nOlmal 
tubule segments. 
ADPKD is associated with hepatic cysts in the majority of adult patients. These contain 
a viscid fluid that resembles serum and are lined by a single layer of columnar epithelium, 
resembling biliary epithelium. In children and adults, about half the patients have also 
increased cOlmective tissue in portal areas and increased numbers of bile ducts (Potter '72). 
15 
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Regardless of these abnormalities it is only rarely that patients with ADPKD present with 
liver dysfunction and/or portal hypertension. This is unlike the situation in patients with 
congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. 
Clinical preselltatioll and course 
Advanced states of ADPKD are easy to diagnose by ultrasound and in less obvious cases 
by CT scan. The patients present with abdominal pain, hematuria, urinary tract infections, 
nephrolithiasis or symptoms of hypertension andior renal failure and have a positive family 
history in at least 70 % of new cases. Most kidneys are bilaterally enlarged and have 
irregular surfaces that can be felt on carefull palpation. An enlarged liver with palpable 
cysts adds further to the diagnosis. Massive proteinuria is rare. The hematocrit may be 
increased above nom,.l, possibly resulting from increased production of erythropoetin by 
the cystic kidneys. Hypertension is a common complication, also in children, even in the 
absence of renal failure. Hypertension appears to be mediated by activation of the renin-
angiotensin system and sodium retention, possibly as a result of locally reduced renal 
blood flow (Harrap '91). Urinary tract infection are connnon complications in adults with 
ADPKD and are less manifest in childhood. These can be very difficult to treat and may 
lead to chronic pyelonephritis, perinephric absces, sepsis and death. 
The diagnosis of earlier cases of ADPKD can be more difficult. Children and 
adolescents are often asymptomatic and may have unilateral cysts or no cysts at all. In 
PKD I only 10% of children younger than 10 years old have cysts that can be demonstrated 
by ultrasound, whereas 95% has cysts at the age df 20 years. TIle probability of 
demonstrable cysts increases to 100% at the age of 30. In less obvious cases, when only 
small cysts are present, diffuse bilateral cystic involvement may only be revealed by CT 
scan. The demonstration of cysts in liver, pancreas and spleen can be of diagnostic help. In 
some patients, analysis of genetic linkage may be useful to identify those predisposed to 
develop ADPKD, provided that at least two affected family members are available for 
DNA testing. 
The clinical presentation in early childhood and in neonates ranges from severe 
neonatal disease indistinguishable from ARPKD to renal cysts noted on ultrasound in 
asymptomatic children. The diagnosis has occasionally been made in utero by ultrasound 
and affected newbonles can present with very severe -disease leading to renal failure and 
neonatal death from pulmonary hypoplasia. However, in the large majority of cases, the 
renal function is well maintained during childhood. 
Co-morbidity from extrarenal manifestations is largely confined to adult patients. 
Hepatic cysts develop later than renal cysts and are rarely found in children. TIlCir 
prevalence reaches 80% after 60 years of age (Grunfeld '84). Most patients remain 
asymptomatic with preserved liver function. Persistent and severe pain may require cyst 
decompression. Infection of hepatic cysts is rare and requires antibiotics and sometimes 
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drainage. Epithelial cysts in other organs are infrequently seen. These include pancreas, 
ovaria, spleen, ovalY, thyroid, endometrium, seminal vesicle and epidydimis. Along with 
the progressive cyst fonnation in the kidney and other organs, patients with ADPKD are at 
increased risk for" a variety of vascular abnormalities. Intracranial aneurysms have been 
found in 8% of patients, compared to 1.2% in the general population, and appear to be 
clustered in families (Iglesias '83, Dalgaard '57, Kaehny '87, Chapman '92). Ruptures of 
aneurysms are the most serious complication in ADPKD and may account for 7% to 13% 
of deaths in ADPKD. Aneurysms of the aorta and cardiac valve abnOimalities have also 
been reported (Hossack '87, '88). It is uncertain whether vascular complications result 
directly from. the genetic defect or merely as a consequence of hypertension and renal 
failure in these patients. In young children extrarenal manifestations have only rarely been 
noted. 
Clillical mallagemellt 
Direct treatment of the cystic process is not possible. The clinical management is largely 
focussed on the symptomatic manifestations of the disease, such as hypertension, 
infections, hematurie, pain, renal failure and cerebral hemorrhage. 
Hypertension occurs io more than half the patients and often antedates the development 
of renal failure and may also affect children with ADPKD (Zeier '93, Iglesias '83, Gabow 
'92). It has been associated with an increase of left ventricular mass and is considered to be 
a risk factor for cardiovascular morbidity as well as for the devevelopement of renal 
failure. Salt restriction is generally recommended and ace~inhibitors are effective first 
choice antihypertensives, with calcium enhy blockers as a good altemative. The use of 
diuretics is considered to be a problem. Allthough helpful in controliog hypertension, 
diuretics have the potential to adversely alter the movement of fluid across the cystwalls. 
In addition, hypokalaemia, a common complication of diuretic use, has been associated 
with the development of renal cysts in normal individuals and may therefore increase the 
growth of cysts in ADPKD. 
Urinary h'act infections may lead to cyst infection, renal absces and sepsis and are 
considered to be risk factors in progression of renal disease (Gabow '92). TI,ese iofections 
may be difficult to treat. Adequate treatment with antibiotics that can penetrate cyst walls 
is critical (Schwab '87). Macroscopic and microscopic hematuria may result from a 
mpturing cyst and is usually self limiting. Reduced physical activity may be recommended 
tempo rarely in cases of protracted bleeding. 
Pain from ADPKD, sometimes associates with perinephric hemorrhage, can ususally 
be treated with analgesics and sometimes bedrest. \Vhen the pain persists for more than a 
few days one must consider the possibility of renal infection, stones or tumor. Pain may 
also be associated with enlargement of one or more cysts. In such cases some relief may be 
17 
Chapter 1 
obtained from percutaneous aspiration or surgical reduction of cysts (Uemasu '93, Elzinga 
'92). 
ADPKD progresses to end stage renal failure in approximately 45% of patients at 60 
years of age (Parfrey '90). Progression appears to be faster in those who have the PKDI as 
opposed to the PKD2 genotype (Gabow '92). Hypertension and renal infections are 
considered risk factors for the development of renal failure and should therefore be 
adequately treated. A slow down of the progression to renal failure by early treatment of 
normotensive patients with angiotensin converting enzyme inhibitors may be 
hypothesized, but has not yet been established. Reduction in dietary protein intake has 
shown disappointing results on slowing progression of renal insnfficiency (Klahr '95). 
Earlier onset ofrenal failure has been related to a youger age at diagnosis, larger kidneys, 
episodes of hematuria, moderate to severe proteinuria and multiple pregnancies (Gabow 
'92). ADPKD patients with end stage renal failure can be dialysed and receive renal 
tranplants equally well as patients with most other renal disorders. 
Patients at-risk for the development of cerebral aneurysms, including those with a 
positive family history, should be screened by cerebral CT and/or MRI sCaIming (Torres 
'90). Asymptomatic at-risk children in ADPKD families are usually followed annually for 
the development of hypertension, hematuria and urinary tract infections. Hypertension and 
urinary tract infections need prompt and adequate treahncnt, in particular also because 
these may enhance progression of the renal lesions. 
Renal prognosis 
For patients with ADPKD, the probability of being alive and not having end stage renal 
disease is about 77% at 50, 57% at 58 and 52% at 73 years of age (Bear '84). The 
prognosis of ADPKD presenting in childhood is variable. Neonatal ADPKD usually 
manifests severe symtoms (McDonald '91), while ADPKD presenting in older children 
generally has a better prognosis. More than 80% of children diagnosed by ultrasound 
maintained a normal renal function throughout childhood (Sedman '87). 
Autosomal recessive polycystic kidney disease (ARPKD) 
ARPKD is characterized by the development of many small cysts in both kidneys and is 
associated with biliary dysgenesis and hepatic fibrosis in all. The severity of these severe 
renal and hepatic manifestations appears to be inversily correlated. ARPKD and congenital 
hepatic fibrosis (CHF) may be different phenotypic manifestations of the same genetic 
abnormality. Many patients die at birth from renal failure and associated pulmonary 
insufficiency. TIle vast majority of patients surviving the neonatal period develop renal 
failure during childhood. ARPKD has been refered to as 'infantile' PKD, but this is 
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incolTect since some patients present later during childhood. Moreover, other forms of 
PKD may present during infancy. 
Genetics 
The incidence of ARPKD is 1:10.000 to 1:40.000 (Cole '90). The disease is inherited as an 
autosomal recessive trait and thus may be seen in siblings, but not in successive 
generations. The sexes are equally affected, heterozygotes are not affected, and the 
recunence rate in successive pregnancies is 25%. The ARPKD locus has been mapped to 
chromosome 6p21.l-pI2, but has not yet been characterized (Zerres '94, Guay-Woodford 
'95). Linkage analysis suggests that ARPKD involves a single defective gene. 
Prellatal diagllosis 
Prenatal ultrasound findings of enlarged kidneys, oligohydramnios and an empty bladder 
can suggets ARPKD, but are not diagnostic (Romero '84). These abnormalities may be 
found in the second trimester but usually are not apparent before 30 weeks gestation 
(Zerres '88). Prenatal genetic diagnosis in at-risk families can be performed by haplotype 
based linkage analysis, provided that DNA of an index patient is available for testing. The 
correct and accurate phenotypic diagnosis of previously affected children is absolutely 
essential for reliable testing. 
Pathology 
The enlarged kidneys maintain their renifOlTI1 shape remarkably well. Cysts are diffusely 
distributed over the cortical and medullary zones, in a radially oriented pattern. In young 
patients the cysts are usually less than 2 nun in size and were shown to be dilated 
collecting ducts by both microdissection studies and immuno-histochemical and electron 
microscopical analysis (Osathanondh '64, Verani '89, Faraggiana '85). In addition, 
proximal tubular cystic lesions have rarely been identified in fetal and neonatal kidneys. 
Microdissection studies and sCaIming electron microscopy demonstrated that obstruction 
of urinary flow is not a component of ARPKD (Kissane '90). During disease progression, 
a pattem more like ADPKD may develop, including the appearance of larger cysts and 
interstitial fibrosis and inflammation. 
In addition to the renal lesions, all patients with ARPKD exhibit hepatobiliary 
abnormalities. These consist of biliary hyperplasia and periportal fibrosis and are often 
associated with dilation of the intra- and extrahepatic biliary tract (Bernstein ' 87, Alvarez 
'81). The lesions are limited to the portal areas, while the parenchyma is unremarkable. 
Although macroscopic hepatic cysts are uncommon, choledochal cysts have been reported. 
During disease progression many patients develop hepatomegaly and portal hypertension. 
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Clillical presentatioll a/ld course 
ARPKD affects both the kidneys and the liver and its expression pattern is variable. The 
disease may be viewed as a spectmm ranging from severe renal involvement and mild liver 
lesions at one end to mild kidney damage and severe liver lesions at the other. The form 
with severe renal disease is the more common. It is well recognized that siblings may 
present at different ages and with different fOlms of the disease. 
Most patients present in infancy (Cole '90). Some die soon after birth from pulmonary 
hypoplasia. Others present with huge flank masses, severe hypertension, urinary tract 
infections and / or renal failure. If the respiratory status and hypertension can be cOlltroied, 
most patients stabilize for several years, then progressively decline. ARPKD may also 
present in older children up to 10 years of age, with abdominal enlargement or 
hepatosplenomegaly (Gagnadoux '89). 
The clinical course is often complicated by hypertension, polyuria, hepatic fibrosis and 
portal hypertension (McDonald '99). Hypertension can be a very severe complication of 
ARPKD, in both infants and children. Its pathophysiology is not well understood. Plasma 
renin levels are usually not elevated (Kaplan '89). If not well managed, hypertension may 
lead to cardiac hypertrophy and congestive heart failure. As expected in children with 
collecting tubular lesions, almost all have a reduced capacity to concentrate urine, leading 
to polydipsia and polyuria (McDonald '99). The senun electrolytes are usually nonna!. 
In children with hepatobiliary involvement, portal hypertension may lead to very 
severe complications, such as bleeding from esophageal varices, portal thrombosis and 
hypersplenism causing thrombocytopenia and anemia. Children with biliary tract lesions 
are also at risk for bacterial cholangitis, which has been noted as early as a few weeks of 
age (Kiiiiriiiiiinen '88). Cholangitis is often a difficult diagnosis and should be considered 
in any ARPKD patient with fever of unknown cause. 
Clinical management 
In neonates with ARPKD severe pulmonary distress may require artificial ventilation. The 
potential reversibility of this condition may be difficult to asses in early stages because 
underlying ineversible pulmonary hypoplasia may be complicated by fluid overload and 
restricted diaplnagmatic motion secondary to massively enlarged kidneys. 
Infants and young children surviving the early stages must be followed closely. The 
urinary concentmting defect is a risk factor for dehydration during a feverish illness. 
Patients with severe polyuria may benefit from thiazide diuretics, which reduce solute and 
free water delivery to the distal neplnon. Hypertension can be treated with calcium channel 
blockers, diuretics and, in the absence of chronic pulmonary disease, with P-blockers. In 
addition many patients respond well to ace-inhibitors, despite the fact that high renillieveis 
are not usually associated with ARPKD induced hypertension. 
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As in other renal disorders, chronic renal failure needs aggressive management of its 
complications: renal osteodystrophy, anemia, growth disturbancy, as well as monitoring 
and support of adequate nutrition. Patients with end stage renal disease will require 
dialysis. Peritoneal dialysis is often succesful even in the face of large kidneys and 
hepatosplenomegaly. Renal transplantation may require the removal of the cystic kidneys 
to control hypertension or to allow space for transplant placement. 
In children and infants with predominant hepatic involvement close monitoring for 
complications of portal hypertension and for cholangitis is mandated. Cholangitis may be a 
particularly difficult problem in inmmnocompromised ARPKD transplant patients. 
Renal prognosis 
Improvements of respiratory and renal supportive treatments during recent years have 
dramatically improved the outcome of patients with ARPKD. Survival of all but the most 
severely affected neonates with pulmonary hypoplasia, is now possible. In one series 
actuarial survival rates revealed that of those surviving the neonatal period, approximately 
80% were alive at I year and 50% at 10 years (Kaplan '89). Systematic data on the 
deterioration rate of renal function are not available. The increased survival of even very 
young patients undergoing treatment for end~stage renal disease, in concert with the 
progressive nature of the hepatic abnormalities in ARPKD, leads to the expectation that 
many of these patients may eventually develop portal hypertension and progressive liver 
fibrosis. Therefore hepatic lesions are not only inherent to human ARPKD but also of 
increasing clinical importance. 
Clinical differentiation between ADPKD and ARPKD in childhood 
Enlarged or cystic kidneys can result from a large numbet of different renal or systemic 
disorders (McDonald '99). TIle differentiation between ARPKD and ADPKD can be 
particularly difficult in the pediatric age group, while it is not an issue in adult patients 
because the vast majority, if not all, patients with ARPKD present during childhood. In 
children, polycystic kidney disease can ususally be differentiated from other inherited or 
syndromic disorders by associated clinical features and other investigations, such as 
ultrasound. The subsequent differential diagnosis of PKD into ADPKD or ARPKD is easy 
in some, but may be very difficult in other pediatric patients (K1UiriiHiinen '88). This 
differentiation is critical because these entities have a velY different prognosis in terms of 
renal outcome and complications and will require a different follow up and clinical 
management. Moreover an accurate diagnosis is crucial for genetic counseling. 
A staged evaluation of difficult cases would include a complete family history, a 
careful clinical histOlY, imaging by ultrasound and intravenous pyelogram, a renal and/or 
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liver biopsy and, in the near future, molecular analysis of the involved genes. The family 
history should be complemented by renal and liver ultrasonography of the parents and 
siblings. If the parents have normal kidneys and are less than 30 years of age, the 
grandparents should also be investigated. Ultrasound indications of ADPKD are 
macrocysts in the kidneys and cysts in liver, spleen, ovary or pancreas. ARPKD kidneys 
are typically echo genic with loss of corticomedullary demarcation and the micro cysts are 
usually less than 0.5 nun, with only occasionally macrocysts more than 2 em in diameter. 
Intravenous pyelogram may show splaying of calices around macro cysts in ADPKD and 
delayed filling with a cortical bI1lsh pattern and tubular striation in ARPKD. Histologic 
examination may reveal cysts in all nepluon segments (lectin staining) including glome11lli 
and a generally nornml liver histology in ADPKD. The cystic lesions in ARPKD are 
largely located in a radially oriented pattem in collecting ducts. The liver may show biliary 
hypelplasia and ectasia, associated with periportal fibrosis. The differentiation is thus 
based in most cases on clinical and family history, age of onset, ultrasound findings and 
occasionally on linkage analysis or histological examination of liver or kidney. 
1.2 Pathophysiology of Polycystic Kidney Disease 
The current understanding of how cysts are formed is largely based on two fields of 
research: genetics and cell biology. Genetic research has localized the genetic defects 
responsible for most cases of ADPKD and ARPKD. The primary disease genes PKD 1 and 
PKD2 were subsequently cloned and sequenced. TIle identified gene sequences allowed 
predictions of the structure and potential function of the corresponding protein products. In 
addition to this genetic approach, cell biological research has identified a unique cellular 
phenotype of cyst-lining epithelia. 
The mechanisms that lead from the genetic defects to the cellular pathophysiology of 
cyst fonnation and ultimately to disease, are largely unknown and represent one of the 
main challenges to PKD research to date. 
HumanPKD 
Molecular gelletics 
The gene defects responsible for the vast majority of PKD patients have recently been 
localized. The ADPKD genes, PKDl and PKD2, were subsequently cloned and 
characterized. TIle gene for ARPKD has been mapped to chromosome 6p21.l-pI2, but has 
not yet been cloned (Mucher '98). 
ADPKD is caused by a gennline mutation in one of at least 3 unlinked genes. 
Responsible for most cases are two unlinked genes, PKD 1 and PKD2, which code for the 
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predicted proteins polycystin-I and polycystin-2. Mutations in the PKD 1 gene account for 
85-90% of cases. Based on sequence and motif analysis polycystin-I is thought to be a very 
large transmembrane glycoprotein, 450 kD in size (Hughes '95). Although full length 
PKD I-eDNA has been synthesized, polycystin-I has not yet been stably expressed in 
eukaryote cells in vitro (Ibraghimov '97). At least three other transcripts, that are 
approximately 97% identical to PKD 1, are expressed from multiple copies of the genomic 
region containing PKD 1 exons 1 - 31. It is not known whether these transcripts code for 
protein (The Eur Cons '94). 
The large extracellular region of polycystin-I contains several different protein motifs, 
suggestive of protein-protein and protein-carbohydrate interactions (Sandford '97). The 
cytosolic region includes phosphOlylation sites and other putative signaling motifs. 
Polycystin-l is thought to function as a plasma membrane receptor. 
POlycystin-2 is also predicted to be an integral membrane protein and may be part of a 
Ca'+ ion channel family (Tsiakas '97). In vitro data indicate that polycystin-I and 
polycystin-2 can interact to foml heterodimers and that polycystin-2 can also foml 
homodimers in a domain separate from its heterodimeric interaction with polycystin -1 
(Qian '97, Tsiakas '97). Wilson et al demonstrated by yeast 2-hybrid and functional studies 
co-localisation, co-association and potential interaction of polycystin -1 with cell-cell 
adhesion and focal adhesion molecules (Wilson '99b, '99c). 
The proposed role of polycystin -1 as a membrane receptor has led to the suggestion 
that the C-terminal domain may directly interact with cellular signaling proteins. This idea 
was supported by in vitro studies, which has turned up a number of potentially interacting 
proteins in addition to polycystin-2, including G-proteins (Pamell '98) and regulators of G-
protein signaling (Kim '99), suggesting that polycystin -I may function as a G-protein 
coupled receptor. Expression ~It,dies indicated that polycystin-2 can mediate the activation 
of AP-I, a transcription factor that regulates different cellular programs such as 
proliferation, differentiation and apoptosis (Arnauld '99). Co-expression of polycystin-2 
with the C-temlinus of polycystin -1 augmented this polycystin-2 mediated activation. 
Thus, polycystin -1 is thought to be involved in cell-cell and/or cell- matrix interactions 
through its participation in multiprotein signaling complexes. 
The PKD I mRNA is expressed in most, if not all tissues and cell lines examined (11le 
Europ Cons '94, Ward '96). To investigate the in vivo expression of polycystin-I itself, 
many groups have developed antibodies against fragments of the predicted protein. In each 
report the renal expression of polycystin-I was predominantly localized to It,bular epithelia 
of fetal, adult and cystic kidneys. 111e most intense staining was usually observed in the 
ureteric bud of fetal kidneys and in cyst-lining epithelia from ADPKD patients. To our 
opinion, the data published so far have not been completely consistent and clear, as further 
addressed in Chapter 3. 
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The mechanism by which a mutation of the PKD 1 gene leads to the fonnation of cysts 
is not clear. Recent evidence indicates that cysts are lined by cells that underwent a 'second 
hit' mutation of the wild type (normal) allele, suggesting that cyst fonnation is caused by 
the absence of functional polycystin-l, rather than the presence of abnormal polycystin-l. 
Loss of heterozygosity (LOH) by a second hit somatic mutation, has been demonstrated in 
cyst-lining epithelia of both PKDl and PKD2 (Brasier '97, Watnick '98, Koptides '99, Wu 
'98). However, the precize role of LOH needs to be fmiher clarified because in these 
studies, LOH was demonstrated in only a minority of the cysts. 
Cellular pathophysiology 
In general, renal cysts are epithelial fluid filled cavities that initially arose as progressive 
dilations of nonnally developed renal tubules. These early cysts have an open connection 
to the tubular lumen. However at later stages many cysts become discOIUlected and may 
enlarge progressively. 111is process of cyst fomlation does not affect all nephrons equally. 
It was estimated that, cysts in ADPKD develop in only 1-10% of the nephrons, suggesting 
that factors other than the initial mutation (present in all cells) are also involved in the 
development of the lesions. 
Cellular abnomlalities of ADPKD cystic tissues have been reported by many 
investigators. It should be noted however, that the vast majority of data is based on studies 
using end-stage kidneys and therefore may not represent earlier stages of cyst formation. 
This summary will focus on the three key features of cyst formation and cyst 
expansion: Proliferation, secretion and extracellular matrix abnormalities. 
Abnomlal proliferation of the cyst lining cells plays a cmcial role in the development 
and subsequent expansion of the cysts in all described human renal cystic diseases (Gabow 
'91). An increased number of proliferating cells has been documented in both cystic and 
non-cystic tubules of ARPKD as well as ADPKD, suggesting the possibility that 
proliferation may be a primary event in cyst fonnation (Nadasdy '95). Proliferation has 
been associated in cystic epithelia with a high level of 'programmed cell death' (apoptosis) 
and upregulation of apoptosis related genes, such as bcl-2 (Woo '95, Lanoix '96). 111is 
suggests that pathways of proliferation and apoptosis are abnomrally regulated in ADPKD. 
Evidence from both human and rodent PKD indicates that the epidermal growth factor 
receptor (EGFR) axis is particularly involved in the pathophysiology of abnormal cell 
proliferation. It was found that the EGFR is overexpressed and mislocalized to the apical 
cell membrane, as opposed to the basolateral membranes, in human ADPKD and ARPKD 
as well as in early and late stages of murine PKD (Wilson '93, Lee '98, Richards '98). This 
apical EGFR is functionally active in vitro (Sweeney '98) and can be stimulated by EGF, 
which has been demonstrated in mitogenic concentrations in ADPKD and ARPKD 
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cystfluid (Wilson '93). Moreover, inhibition of the EGFR has been associated with a 
reduction of the cystic process in experimental models (Richards 98, Sweeney 99). 
TIle secretion of fluid is another key feature of cyst fonnation, requiring the 
transformation of nomlal absorptive epithelium into secretory cystic epithelium. In 
ADPKD, most cysts eventually become disconnected from the nephron of origin as well as 
from the influx of glomerular filtrate. The cysts therefore require transepithelial secretion 
to prevent a collapse of the cystwall. This secretion appears to be driven by the cystfluid 
itself: Intact isolated cysts in culture can secrete fluid in the presence of either cystfluid or 
by activation of the cAMP signal transduction pathway. In the absence of stimuli however, 
these epithelia absorb similar to wild type tubules. These data indicate an important role 
for cystfluid secretagogues (Sullivan '96). Such agents, including A TP and specific 
lipidfractions, have indeed been demonstrated in cystfluid from both human and murine 
PKD ( Wilson '99a, Grantham '97). 
The extracellular matrix and basement membranes play an important role in the 
maintenance of tissue organization and integrity. It can be hypothesized that in PKD 
abnonnal regulation of the extracellular matrix and basement membranes is required to 
give way to the expanding cysts. Several abnonnalities of the extracellular matrix have 
been reported in human and rodent renal cystic diseases. Thickened basement membranes 
as well as altered biosynthesis of several basement membrane and cell adhesion 
macromolecules have been reported in advanced ADPKD (Granot '90,Carone '93, Wilson 
'96, '99b). In addition, in vitro studies suggest that increased degradation of basement 
membrane components by metalloproteases may contribute to the lesions by pennitting the 
cysts to grow (Rankin '99). Abnonnal matrix and cell functions may be interrelated since 
the interactions between cells and extracellular matrix are reciprocal: the cell has a major 
role in matrix synthesis and degradation, whereas matrix composition and signaling affects 
cell shape, division, differentiation and gene expression. It was suggested that abnormal 
matrixMreceptor interactions may contribute to cyst fomlation by interfering with 
fundamental cell processes, such as cell differentiation, polarity and proliferation (Wilson 
'99b). 
Many of these cellular phenomena are also present - and some were initially observed -
in either cellular or whole animal models of cyst fonnation. TIle detailed analysis allowed 
by these models has and will have an important role in the study of the cellular and 
molecular pathophysiology of human PKD. In the following we will summarize the 
characteristics of the various experimental models, in the context of their contribution to 
the CUlTent understanding ofPKD. 
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Models of PKD 
The systematic study of the pathophysiology and potential therapeutic options of human 
renal cystic diseases is hampered by the lack of human tissues from early disease stages, 
as well as by the variable clinical expression of disease. In order to better understand the 
factors involved in the development of cysts and in the process of disease progression, 
many investigators have focussed on either animal models, whole organ models or cell 
models of renal cyst formation. In this Chapter we will summarize the currently available 
models, in view of their contribution to the understanding of the pathofysiology of renal 
cystic diseases. 
Animal models of PKD 
TIle study of animal models has the potential of identifying genes and gene products 
involved in the cystogenic process. They also provide the opportunity to study factors that 
detenlline the severity and progression of renal cystic diseases. In addition, these models 
may be cmcial for the development of therapeutic interventions. Such models are usually 
genetically transmitted, resulting from either a spontaneous or an artificially induced 
mutation. In the following sunmlary we categorized them as spontaneous mutations, 
transgenic models and chemically induced models. 
SpolltalleOIlS lIlutatiolls 
This summary is limited to those rodent models of PKD that have been reported 
adequately in the recent literature (Table. I). For rodent models less well described andIor 
not currently available for experimental investigations, we refer to the literature (Gorer 
'40, Fox '70, Ribacchi '77, Rupple '55, Lozzio '67). Cystic diseases have also been 
reported in many other species including cat, dog, pig, sheep, horse, springbok, rabbit, 
raccoon and pigeon. (Jones '90, Scott '86, Crowell '79, Fox '71, Iverson '82, McKenna 
'80, Wijeratne '80, Eaton '97, McAloose '98, Hamir '96, Van Alstine '84). However, none 
of these non-rodent species are used for systematic investigations. 
The CBAICa-KD 1/I0/lse 
Autosomal recessive disease of the renal interstitium was identified in 1971 in an inbred 
CBAICa mouse strain (Lyon '71). Affected homozygotes were called 'kdkd' for 'kidney 
disease'. They were nonnal at birth, but at 10 weeks the kidneys of affected mice 
developed focal peritubular mononuclear cell infiltrates and cystic dilations of both 
medullary and cortical tubules. At 4 weeks of age, tubulointerstitial fibrosis developed and 
the glomemli became sclerotic. An urinary concentrating defect and progressive renal 
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failure were demonstrated in later disease stages. Lyon proposed that these mice were a 
model of the juvenile nephronophthisis - medullary cystic disease - complex (IN/MCD). 
Later it was reported that kdkd mice inherited a T-cell-mediated autoimmune 
interstitial nephritis, in which tubulointerstitial antigens in association with class I major 
histocompatibilty antigens are targeted by T cells (Kelly '87). The model may be used to 
study the mechanisms by which immune cells in the renal interstitium and their cytokines 
contribute to the fonnation of cysts. 
Table. I 
Model 
Mouse 
CBAJCa-KD 
PCY 
CPK 
Xpl 
CFWwd 
CBAIN 
JCK 
BPK 
KAT2J 
Rat 
Chi 
CY 
WPK 
Inherit. 
AR 
AR 
AR 
XD 
AD 
XR 
AR 
AR 
AR? 
AR 
AD 
AR 
a. not allelic to CY 
11," pey lIIotise 
Proposed 
model of 
IN-MCD 
ADPKD 
ARPKD 
OFDI 
ADPKD 
? 
ARPKD 
? 
IN-MCD 
ADPKD 
ARPKD 
Chromo Human 
Chromo 
9 3 
12 2 
X X 
X 
II 
10 
8 19p 
5 
5' 
Refs. 
Lyon71, Kelly87 
Takahashi86, Naga095 
Russel77, Simon 94 
Sweet 80, Feather 97 
Werder84 
Rahilly92 
Atala93, lakouboya 95 
Nauta 93,95, Guay-W.96 
lanaswami97 
Oh11089, Inage93 
Kaspareit91, 
Nauta Y2K 
In 1973, polycystic kidney disea,e was recognised in a KK mouse strain (Takahashi '86). 
Due to poor reproduction of the original strain, a congenic pcy strain was developed in 
DBAl2 mice, DBAl2FG-pcy/pcy. TIre pcy locus has been mapped to a locus on 
chromosome 9, homologous to human chromosome 3 (Takahashi '91, Nagao '95). Tvt'O 
modifying loci were localized to chromosomes 4 and 16 resp.(Woo '97b). 
DBAI2FG-pcy/pcy mice express an autosomal recessive disease with clinical and 
mOlphological aspects of human ADPKD. A slowly progressive disease leads to end stage 
renal failure at the age of 8 months. TIre progressively enlarging cysts develop in all 
nephron segments and are lined by a single layer of hyperplastic epithelia. At later stages 
of disease interstitial inflanunation was noted and 10 % developed cerebral aneurysms. On 
another genetic background, the C57 IFB/6 mouse, the histological lesions and the clinical 
phenotype progressed much slower (Nagao '91). 
Progression of the cystic lesions has been associated with increased mRNA levels of a 
number of growth related proteins, including PCNA, TGF-Jl, PDGF-a, PDGF-Jl, IGF-I and 
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bFGF (Nakamura '93a). In contrast, but consistent with other models (Gattone '90), EGF 
mRNA levels decreased with age in affected pcy animals. Further, abnOlmalities of 
phosphoinositide metabolism and abnonnal ratios of membrane lipids have been noted in 
cystic kidneys (Aukema '92a, '92b). In addition, the pcy model was used to explore the 
effect of a number of therapeutic interventions and dietary restrictions: Dietary protein 
restriction (Aukema '92c, '99), soy protein diets (Tomobe '98), n-3 fatty acid enriched 
diets (Yamaguchi '90) and methylprednisolone (Gattone '95a) were shown to retard the 
disease progression in this model. 
The CPK 11I0llse 
In 1977, autosomal recessive PKD was detected in an otherwise healthy C57 IBL/6J strain 
of mice at the Jackson Laboratories (Russel "77). The cpk gene was localized to 
chromosome 12 (Davisson '91, Simon '94) and the human cpk homologue is predicted to 
be on 2p23-25 (Guay-Woodford '93). Affected homozygotes of the cpk mutation, which 
appear nOInlal at birth, develop massive cystic enlargement of the kidneys and die in renal 
failure at 4 weeks of age (Preminger '82). TI,e ontogeny and morphology of the cyst 
fommtion was extensively studied by a number of investigators, using light and electron 
microscopy and microdissection of intact nephrons (Preminger '82, Nidess '84, Fry '85, 
Avner '87a, Gattone '88). The earliest cysts can be detected in 17 day old fetuses and 
consist of dilations of proximal nephron segments (Avner '87a). During disease 
progression, the site of the cystic lesions shifts from juxtamedullary proximal tubules to 
cortical and medullary collecting tubules. TI,e expansion of the cysts is associated with 
prominent hyperplasia of the cyst-lining epithelia.(Avner '87a, Gattone '88). The 
abnonnalities in affected mice are limited to the kidney. However, the cystic cpk gene has 
produced hepatic fibrosis and ductal dilatations, similar to human ARPKD, when bred into 
DBN2J mice (Fry '85) and dilatations of the biliary and hepatic ducts in CD-l mice 
(Gattone '96). 
Early stages of proximal tubular cyst formation were correlated with increased Na-K 
ATPase activity in proxinral tubules (Avner '89). TIlis occurred before significant 
epithelial hyperplasia was present, suggesting that increased Na-K pump activity and 
cellular hyperplasia were early components of cystogenesis. Subsequent studies indicated 
abnormal cellular localization of the Na-K ATPase (Avner '92). In proximal tubules the 
enzyme (a -1 and P-l subunits) were localized to the basolateral cell membranes in both 
control and cystic tubules. Although apical Na-K ATPase expression is a transient feature 
of early development in nOlmal collecting ducts, the percentage of cystic collecting 
tubules with apical Na-K ATPase remained significantly greater than in controls. The 
persistence of apical expression may be a manifestation of the relatively undifferentiated 
phenotype of the cyst-lining cells and if the enzym is functional, this may playa role in 
abnoInlal transcellular fluidtransport in PKD. 
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AbnOlmalities of the EGF-EGFR axis (epidennal growth factor and its receptor) have 
been studied extensively in the cpk model. 111is axis is thought to be important in 
regulating cell growth and maturation in the mature kidney (Uchida '88) and may 
modulate solute and fluid transport in the collecting duct (Breyer '88). A number of 
investigators reported decreased expression of EGF precursor genes in cystic cpk kidneys 
(Gattone '90, Lakslmranan '93, Horikoshi '91). Horikoshi et al. found decreased EGF 
concentrations and activity in semm and urine obtained from cpk/cpk animals. Gattone et 
al. observed that subcuteneous EGF administered to neonatal cpk/cpk mice ameliorates the 
disease process (Gattone '95b). In cystfluid however, both the activity and concentration 
were increased, when compared to urine (Horikoshi '91). Lakslllnanan et al. described a 
number of immunreactive EGF-like substances in cystfluid in mitogenic concentrations 
(Lakslnnanan '93). In addition, the receptor for EGF (EGFR) was shown to be 
overexpressed and mislocated in cystic kidneys (Orellana '95). In collecting duct cysts 
EGFR was localized to the apical instead of the basolateral cell membranes. This raises the 
possibility that EGFR mislocalization and overexpression may be mechanisms whereby 
EGF-like proteins stimulate hypelplasia of the cystic epithelia. 
A relatively tindifferentiated cellular phenotype of cyst-lining epithelia has been 
suggested by a number of observations in affected mice. Proliferation of cystic epithelia 
was linked to overexpression of the oncogenes c-myc, c-fos, c-Ki-ras, consistent with an 
increased rate of cellproliferation and an altered state of differentiation (Cowley '9\, 
Harding '92). A delay in terminal differentiation is suggested by persistent poshlatal 
expression in cystic kidneys of the Cux-l gene. This gene is essential for normal 
development of Malpighian hlbules in Drosophila and is also expressed in embryonic 
mouse kidneys, but dowmegulated in poshlatal mouse kidneys (Vanden Heuvel '96). An 
abnomrally high expression was also noted for the sulfated glycoprotein-2 (SGP-2) mRNA 
in cystic epithelia (Harding '91). SGP-2 is secreted by various epithelial cell types and is 
progressively down regulated during nOlmal development in the mouse kidney. This 
protein may be involved in the promotion of cell-cell interactions and apoptosis. A 
correction of this relative overexpressed SGP-2 was observed in parallel with the benificial 
effect ofEGF administration to affected pups (Gattone '95b). An additional indication of 
delayed differentiation is the poshlatal persistence of apical localization of Na-K-ATPase 
and of the EGFR (see earlier sections). This polarization defect may relate to the observed 
decreased expression of the epithelial cell adhesion molecule E-cadherin (Rocco '92), 
since this molecule is believed to be involved in guiding the sequential differentiation and 
polarization of renal epithelia. 
The basement membrane of cpk cysts is ultrastructurally unremarkable (Avner '88a). 
The components collagen type-N and laminin were nOlmally distributed in early cystic 
tissue (Ebihara '88). However, in more advanced stages increased mRNA levels of both 
were associated \vith focal decreases of inununoreactive protein. Despite these alterations, 
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the viscoelastic properties of the cystic tubular wall was not different from controls 
(Grantham '87a). 
Additional observations in cpk mice includes the increased expression of a number of 
different molecules, including: endothelin (ET-I) and its receptor, proliferating cell nuclear 
antigen (PCNA), TGF-p and TNF-a (Nakamura '93a, '93b), cAMP (Yamaguchi '97). 
Further studies will be required to link these observations to specific cystogenic processes. 
AbnOlmalities of the glucocorticoid metabolism were reported by Crocker et al. and 
were suggested to playa role in the pathophysiology of the cystic process (Crocker '87). 
This may relate to a significant downregulation of the Ke 6 gene, as demonstrated in a 
number of different mouse models of PKD, including cpk (Aziz '93). The Ke 6 gene 
encodes a 17P-hydroxysteroid dehydrogenase that can regulate the concentration of 
biologically active estrogens and androgens (Fomitcheva '98, Ramirez '98. 
Glucocorticoids increase renal Na-K ATPase activity and stimulate intracellular 
alkalinization (Igarashi '83). Elevation of the intracellular pH is a proven stimulus to 
cellular proliferation and may therefore contribute to hyperplasia of cystic epithelia. 
Blockade of the glucocorticoid action in affected cpk mice, prolonged the survival of these 
animals (OgbOlll '87). 
Several experimental interventions of the cystic process in cpklcpk mice have provided 
insight into the mechanisms of cyst formation and may suggest targets for future treatment 
strategies in human disease states. The weekly subcutaneous administration of taxalle 
(Taxol) in 10-day old cpk/cpk mice prolonged the life span and slowed the progression of 
the cystic lesions (Woo '94). This therapeutic effect was related to the ability of taxanes to 
promote microtubule assembly (Woo '97a). The beneficial effect ofEGF administration to 
cystic animals (see earlier) indicates the role of the EGF/EGFR axis for nomlal renal 
development. A recent report by Gattone et al. suggests that stimulation of the collecting 
duct cell by the vasopressin receptor contributes to the cystogenic process (Gattone '99). 
They found increased expression of this receptor in cystic cpk kidneys and noted 
amelioration of cyst enlargement and of renal failure following blockade of the receptor 
with experimental dmgs. Activation of this arginine vasopressin type-2 receptor is known 
to stimulate the production of cA:rv1P, a substance known to promote cyst enlargement. 
The CFIVwd mOllse 
In 1984, Werder et al. described a genetically detemuned renal cystic disease in a 
Carworth Faml White (CFW) mouse colony and suggested this to be a model of human 
ADPKD, based on its clinical, genetical and histological characteristics (Werder '84). 
Affected CFIVwd animals develop progressive cystic destruction of the kidneys and die in 
renal failure at the age of 12-18 months. The cysts were localized in both the renal cortex 
and medulla and included also glomemlar cysts. The lesions were accompanied by 
interstitial fibrosis and infiltration of the renal tissue by immune cells. Interestingly, the 
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expression of disease was significantly modulated by the microbiological environment. 
Under standard conditions over 90% of affected mice died of renal failure at 2 years of 
age, whereas only 4 % of the mice were affected if raised under gel1nfree conditions. The 
renal disease was associated with hepatic cysts in 15% of cases and occasionally with 
aneurysms of tl,e thoracic aorta. 111e genetic basis of this model is not clear. The study of 
an F2 intercross with AKR mice, suggested the possibilty of an autosomal dominant mode 
of inheritance with incomplete penetrance (Werder '84). 
The CFWwd model illustrates that genetically determined renal cyst fOl11lation can be 
profoundly modulated by enviroltlllental factors. Unfortunately, further studies into the 
mechanism of this modulation have not been reported. 
The CRAIN mOllse 
In CBAIN polycystic kidney disease is associated with an X-linked recessive B cell 
immunodeficiency syndrome (Rahilly '92). All mice more than 3 months old exhibit PKD. 
At birth the kidneys appeared normal, but postnatally they progressively enlarged and 
fOl11led cysts up to I nilll in diameter throughout the parenchyma. The cysts were localized 
to glomeruli and all tubular segments, except collecting ducts. Cyst fOl11lation was 
associated with basement membrane thickening of the tubular wall, and in older animals 
with interstitial fibrosis, mononuclear cell infiltrates and glomerulosclerosis. The liver is 
unaffected in these animals. This model, as well as the CRAICa-KD model (see earlier 
section) offers an opportunity to study the relationship between the inilllUne system and the 
formation of renal cysts. To our knowledge no further studies on the renal lesions in this 
model were reported. 
The JCK mOllse 
Autosomal recessive PKD was identified in a e-mye transgenic line of mice (Atala '93). 
Thejekmutation Guvenile cystic kidneys) appears unrelated to the e-mye transgene since it 
segregates freely from it. 11,e animals develop early cystic lesions in the renal cortex at 3 
days and subsequently a slowly progressive cystic destruction of the cortical and medullary 
parenchyma. 11,e localization of the cysts to specific nephron segments has not yet been 
reported. Affected mice die at 6 months of age. No histological abnol11lalities were found 
in any other organ. The jek gene was mapped to chromosome II and two additional 
regions, that were associated with disease severity, were identified on chromosomes 1 and 
10 (Iakoubova '95). Based on its mapping position, a candidate for Olle of these modifying 
loci (on Chr 10) may be the bpk/jepk gene (Guay-Woodford '96). The relatively long 
lifespan offers a unique opportunity to study the pathophysiology of cyst fOl11lation and 
progressive expansion. 
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The BPK mOllse 
We had the opportunity to study the phenotype of this new model of autosomal recessive 
polycystic kidney disease (Chapter 2.1). In addition to renal abnonnalities much like those 
described for the extensively studied cpk model, affected bpklbpk mice also express 
proliferative abnonnalities of the biliary tract. The hyperplastic biliary lesions provide an 
unique opportunity to culture and study the affected cells in this model (Chapter 2.2). The 
association of renal and biliary lesions is also a characteristic feature of human ARPKD. 
The affected bpk gene was localized by Guay-Woodford et al. to a 1.6 cM interval on 
chromosome 10 (Guay-Woodford '96). hlterestingly bpk co-localized with jcpk and 
complementation testing indicated that these two loci are allelic. A further detailed 
discussion is provided in Chapter 2. 
The KA T2J mOllse 
Recently a new C57BLl6J mouse mutant was identified at the Jackson Laboratory 
(Janaswami '97). Affected mice exhibit autosomal recessive PKD in association with 
facial dysmorphism, dwarfmg, male sterility and anemia. The renal lesions were localized 
to the proximal tubules and to Bowman's capsule. Approximately half die before weaning 
and the survivors die between 6 and 12 months of age. TIle phenotype has not been 
reported in much detail. TIle affected gene was localized to a segment on chromosome 8 
that is homologous to human chromosome 19p. During the mapping studies it was noted 
that disease severity was more variable in the intercross progeny than in the parental C57 
strain. This variability could be linked to three modifying loci that could be localized to 
mouse Chr I, 2 and 19 (Upadhya '99). This model clearly illustrates that genetic factors, 
other than the primary mutation, may significantly affect the clinical manifestations of 
PKD. 
The Xp J mOllse 
This X-linked model of limb morphogenesis expresses polydactyly and urogenital 
malfonnations including renal cysts (Sweet '80). It was recently found that the mutated 
gene colocalizes on the X-chromosome with the oral-facial digital syndrome type 1 
(OFDl), a cause of human glomerulocystic kidneys disease (Feather '97). The renal 
lesions of this mouse model have not been described in much detail. 
The Chi rat 
This recessive model of rellal cystic disease arose in \-Vistar rats, following a spontanous 
mutation called chi (OIUlo '89, Inage '91, '93). Unlike human ARPKD this model is 
characterized by skeletal abnonnalities associated with slowly progressive renal disease. 
Cysts in advanced stages of disease had lectin binding characteristics of collecting ducts. 
Early cysts have not yet been characterized. Hepatobiliary lesions have not been reported 
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in this model. Further studies may reveal whether chi could be a model for juvenile 
nephronophthisis, in which renal cysts and more moderate skeletal abnormalities have also 
been reported (Mainzer '70). 
The Cy rat 
Autosomal dominant PKD in a Sprague-Dawley rat colony was reported by Kaspareit-
Rittinghausen (Kaspareit-Rittinghausen '91) and later in more detail by others (Schafer 
'94b, Cowley '93). The model was initially called Han-SPRD and the affected gene was 
later called cy. There is an incomplete dominant mode of inheritance: TIle disease is more 
severe in homozygotes than in heterozygotes. Homozygotes develop cysts in all nephron 
segments throughout the kidney and die in renal failure, at 3-4 weeks of age. 
Heterozygotes develop cortical and outer-medullary cysts. Approximately 75% of the cysts 
are derived from proxinlal tubules. There is a considerable gender effect: cy/+ males 
develop progressive renal failure and usually die within a year(Gretz '95). Females have 
milder renal disease. Liver cysts were only noted in 2 year old cyl+ females (Kranzlin '97). 
This gender effect appears to be testosterone related (Cowley '97). Hypertension is present 
in advanced heterozygous disaese (Kaspareit '91), but is not a consistent finding in earlier 
stages of disease (Braun '96, Ogb0111 '95c). In contrast to the phenotypical similarities 
with ADPKD, is the cy mutation not a genetic model of human PKD 1 since it does not 
localize to the homologous region in rats, as discussed in more detail in Chapter 2.3 of this 
thesis. Cy was later mapped to rat chromosome 5 (Bihoreau '97). 
The pathophysiology of cyst fonnation has been studied extensively. Hyperplasia of 
tubular epithelia and increased expression of oncogenes has been documented in both early 
and late stages of cyst development (Cowley '93, Ramassubu '98). Changes of the 
extracellular matrix include thickening of basal lamina and increased expression of 
collagen type-IV in advanced lesions as well as focal thickening of BM and collagen type-
IV overexpression in early cysts (Schafer '94a, Schaefer '96). Obstruction of the renal 
tubules has been studied by micropuncture methods and was found to be present in some 
but not all cysts (Tanner '96). Obstmction appears to be a component, but not the prinlary 
event in this model. The role of the renal endothelin system has been studied by Hocher et 
aI., who found increased endothelill-l (ET-I) expression in cyst-lining epithelia of both cy 
affected rats and human ADPKD (Hocher '98). The system was activated and participated 
in the regulation of bloodpressure, renal bloodflow and glomemlar filtration. 
Abnonnalities of the cell polarity as described for end stage human ADPKD and for cpk 
cysts, was not seen in early cy-cysts (Obermuller '97). 
The progression of disease can be affected by a number of measures. Accelaration of 
the lesions and of renal failure was noted after unilateral nefrectomy (Gretz '94), dietary 
protein overload, potassium depletion, induction of acidosis (Cowley '96). Progression of 
disease can be ameliorated by dietary protein restriction (Ogbom '95a), soy proteins 
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instead of casein proteins(Ogborn '98), dietary flaxseed (Ogborn '99), treatment with 
potassium citrate/citric acid (Tanner '98), taxanes (Martinez '97), methylprednisolone 
(Gattone '95a) and angiotensine converting enzyme inhibition (Ogbom '95c). 
The WPKrat 
The wpk model is described in more detail in Chapter 2.4. The renal phenotype is much 
like human ARPKD, exhibiting rapidly progressive cyst fomlation in homozygotes, 
proteinuria, hypertension and a collecting tubular cell type in the vast majority of cysts. 
Localization studies of the affected gene are in progress. 
Transgenic mouse models 
In addition to these spontaneously developed genetic models of PKD, murine polycystic 
kidney disease has been associated with a number of artificially induced gene dismptions 
and overexpression models, as summarized in the following section. The recently acquired 
ability to study the function of genes by modifying the specific genetic background of 
mice, has produced a number of interesting PKD-like diseases (Table 2). 
Table 2. Transgenic mouse models exhibiting renal cysts 
MOllse Model Genetic defect 
PKDl Knockout of mouse pkdl gene 
PKD2 Knockout of mOllse pkd2 gene 
ORPK Dismption of possible cell cycle control gene, TgN737Rpw 
JCPK Dismption (Chlorambucil) ofunknolVn gene 
SBM C-myc oncogene overexpression 
AP-21l knockout Deficiency of transcription factor- apoptosis inhibitor 
BcI-2 'knockout' Deficiency of apoptosis inhibitor bcl-2 
PAX2 Overexpression / deficiency of transcription factor 
SV 40 early region Expression of the viral transfonnation antigen Hlarge-T' 
SR2-3 chimeric v-src proto oncogene, chimeric overexpression 
TGF- a TGF- a overexpression 
KGF Hepatic overexpression of KGF 
HGH / GRF / IGF-I Growth hormone overexpression 
HGF/SF Hepatocyte growth factor / scatter factor overexpression 
ET-l Endothelin 1 overexpression 
Tensin Knockout, Focal adhesion protein 
Knockout of huml/II PKD genes 
Mutations of either the PKD 1 or the PKD2 gene are responsible for most patients with 
ADPKD. The identification and characterization of these genes has enabled the 
development of murine knockout models. 111e mOllse pkd 1 gene was dismpted by the 
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introduction of a truncation mutation, This mutation leads to renal cystic disease with 
perinatal lethality in homozygotes. Heterozygotes exhibit some renal cysts and hepatic 
abnormalities, at old age only (Lu '99). Unlike patients with ADPKD these heterozygotes 
had a nonnal renal structure until the second half of life and renal failure was never 
observed (Lu '97). Somatic inactivation of the mouse pkd2 gene resulted in an ADPKD-
like disease including renal and hepatic cystic lesions in heterozygotes (Wu '98). A more 
detailed characterization of the clinical and cellular abnOlmalities in this pkd2 knockout 
model will further establish its value as a model of human ADPKD. 
ORPK 
The ORPK model was identified after random insertional mutagenesis (Moyer '94). The 
disrupted gene was called TgN737Rpw and subsequently mapped to chromosome 14 
(human Chr.13) (Yoder '95). Sequence analysis revealed motifs common to several cell 
cycle control genes, The disease expression in mutant animals can be ameliorated by 
expressing wild type TgN737Rpw as a transgene (Yoder '96, '97). Affected OIpk/OIpk 
mice manifest renal cysts and hyperplastic biliary abnomlalities, similar to human 
ARPKD. The formation of collecting tubular cysts was associated in this model with 
increased expression and mislocalization of the EGF receptor to the apical cell membrane, 
in parallel with similar observations in endstage cysts of human ADPKD and in epk/cpk 
mice (see earlier sections) (Richards '98, Sweeney '98). Moreover, in a cross with EGFR 
deficient mice, the double homozygotes had an increased lifespan and less cysts, indicating 
a direct role for EGFR in collecting tubular cyst fonnation (Richards '98). 
Jepk 
The jepk mutation results from a chlorambucil induced mutation (Flaherty '95). 
Homozygotes express severe early onset cystic lesions in all nephron segments, associated 
with pancreatic and biliary abnormalities and die before 10 days of age. Heterozygotes 
present with glomerulocystic disease. Interestingly, it was fonnd that the jepk mutation co-
localizes on chromosome 10 with bpk, a phenotypically different PKD mutation as 
described in Chapter 2.1, and complementation testing indicated that these two mutations 
are allelic. This implies that distinct phenotypes can result from different mutations within 
the same gene. It should be noted however, that the chemically induced jepk mutation may 
well consist of a large deletion involving multiple genes. 
SBM, AP-2, Bc/-2 
The SBM mouse expresses PKD induced by the overexpression of e-mye (Trudel '91). 
This proto-oncogene is thought to be involved in the regulation of cell proliferation and is 
transiently expressed during normal nephrogenesis. C-mye was found to be overexpressed 
in cystic epithelia of human ADPKD and of affected epk mice. The development of renal 
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cysts in SBM is associated with approximately 10 fold increased indices of both 
proliferation and apoptosis in cystic and noncystic tubules. Interestingly, c-myc induced 
apoptosis iu this model appears to be p53 and bcl-2 independent since the expression 
pattern of these apoptosis associated genes was unaffected and because the c-myc induced 
lesions could also be produced in p53(-.-) mutants, as well as in bel-2 overexpression 
mutants (T11Idel '97, '98). 
AP-2 transcription factors are expressed during embryonic development and may be 
involved in the regulation of embryonic cell survival since they are capable to suppress c-
myc induced apoptosis in vitro. AP-2-P knockout mice express lethal PKD at birth (Moser 
'97). Followiug a stage of apparently nOlmal renal development cystic lesions arise in 
association with dowmegulation of the bcl-2 inhibitor of apoptosis and massive apoptotic 
cell death in the distal nephron. 
Bcl-2 is another inhibitor of apoptotic cell death and expressed predominantly iu adult 
progenitor cells and more widely in embryonic tissues. Transgenic mice overexpressing 
bcl-2 exhibit increased cell survival and lymphomas. Transgenic mice lacking bcl-2 display 
cystic kidneys, growth retardation, atrophic lymphoid tissues and accelerated cell death of 
lymphocytes (Veis '93). 
These three observations suggest that PKD may result from a critical iulbalance of the 
regulation of cell proliferation and programmed cell death. 
PAX2 
PAX2 is member of a transcription factor family involved iu emblyonic development. Its 
role during renal development has been elegantly reviewed by Eccles (Eccles '98). This 
factor is expressed during renal development in association with cell proliferation as well 
as with the initiation of epithelial differentiation and down regulated postnatally. In 
contrast, PAX2 is persistently expressed postnatally iu the proliferative cystic epithelia of 
PKD and multi cystic dysplasia. Overexpression of PAX2 in transgenic mice leads to 
microcystic tubular dilatations and glomemlar abnormalities similar to congenital 
nephrotic syndrome. 11le critical role of PAX2 to renal development is additionally 
established by the deficiency models. Mutation of PAX2 leads to renal and ocular defects 
in both human disease states and in mouse models. The renal defects include agenesis, 
hypoplasia and cystic lesions. Although the renal cystic lesions were frequently observed 
in a number of mutant mouse models, they are rare in patients with PAX2 mutations. 
SV40 early region 
The early region of simian virus 40 (SV40) encodes the antigen 'Iarge-T'. In addition to its 
viral functions, this antigen is capable to transfonn and immortalize tissue culture cells. 
Transgenic mice expressing this antigen develop tumours and renal cysts (Mackay '87, 
Kelley '91). The induction of both hllnours and hypelplastic cysts by a single transfol1ning 
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gene suggests that these may represent different manifestations of the same pathological 
process, different only in the degree of escape from nonnal cell cycle control. 
Interestingly, this combination of multiorgan tumours and renal cysts is a well known 
feahlre of the human diseases hlberous sclerosis and VOIl Hippel-Lilldau disease. 
SR2-3 chimeric mice 
Succesfull introduction into the mouse embryo of SR2-3 embryonic stem cells containing 
the v-src retroviral vector SR2 gave rise to chimeric mice with dominantly inherited cystic 
kidneys (Boulter '92). Since the v-src oncogene activity in the kidneys of chymeric mice 
was low, it is not certain whether the hyperplastic abnormalities in these mice are directly 
caused by the expression of the v-src oncogene as seen in SV40 and c-myc transgenic 
mice. Altematively the disease may be caused by a dominant mutation that arose either 
spontaneously or by insertion of the retroviral vector at a cystic locus. 
Overexpression of growth factors 
Overexpression of a number of growth factors known to playa role in the physiology of 
nonnal renal epithelia, has been associated with cyst fomlation. 
Overexpression of TGF- a has not only been documented as feature of cystic disease, 
but also causes cysts in transgenic mice (Lowden '94). TGF- a is the fetal ligand of the 
epidennal growth factor receptor (EGFR) in developing kidneys and involved in the 
regulation of cell proliferation and differentiation as well as extracellular matrix synthesis. 
Transient overexpression of TGF- a in transgenic mice during one poshlatal month has 
been associated with increased renal size and the development of renal cysts (Lowden '94). 
This provides evidence that endogenous stinmlation of the EGFR can produce renal cysts. 
Abnonnal regulation of the TGF a IEGF/EGFR axis has been suggested by a number of 
studies of human and murine PKD (see earlier sections). 
Keratinocyte growth factor (KGF) is a potent mitogen of epithelial cells and a renal 
morpho gen. Hepatic overexpression in h"ansgenic mouse embryo's resulted in increased 
KGF semm levels and cystic dilatations in fetal collecting ducts in association with 
hyperplasia of the biliary system, much like human ARPKD (Nguyen '96). Additional 
hyperplastic abnonnalities were noted in a number of other organs including lung, 
intestine, pancreas, skin and hair. KGF overexpression during late gestation resulted in 
perinatal lethality. 
Transgenic overexpression of human growth hormone (hGH) and of hGH releasing 
factor (GRF) has induced increased body growth as well as a number of organ defects, 
including cystic tubules, nephron atrophy and glomerulosclerosis (Doi '88, Quaife 
'89,Wanke '91). Additional lesions included hepatomegaly, hepatocellular carcinoma and 
myocardial fibrosis. Insulin-like growth factor I (IGF-I) levels were increased in both hGH 
and GRF transgenic mice. In order to deteffi1ine whether IGF-I mediates the somatic 
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effects of hGH, these effects were studied in IGF-I transgenic mice expressing increased 
IGF-I levels and very low GH levels. Although these animals express some renal changes 
including glomemlar enlargement, no interstitial or cystic lesions were observed in these 
models. This indicates that the renal cyst fOllllation induced by hGH overexpression is not 
mediated by IGF-I. 
Hepatocyte growth factor/scatter factor (HGF) is a renal mOIphogen, thought to playa 
role in normal renal tubulogenesis as well as in renal regeneration after acute rcnal failure. 
Its overexpressioll in transgenic mice induced polycystic kidneys and glomemlosclerosis 
(Takayama '97). 
Elldothelill-l 
Overexpression of the endothelin-l gene under its natural promotor in transgenic mice 
induced rcnal cysts, interstitial fibrosis and glomentlosclerosis, leading to progressive renal 
failure (Hocher '97). TIlese abnomralities are also features of human PKD and have been 
associated with elevated endothelin-I tissue levels in cystic cy rats (Hocher '98). This 
suggests a potentially mediating role for the endothelin system in the development of these 
lesions in PKD. 
Tensill 
Tensill is a focal adhesion protein and widely expressed in many different tissues during 
embryogenesis. Interestingly, tensin is said to co-localize with Polycystin-l, the primary 
affected protein in most patients with PKD (Wilson '99b). Transgenic mice lacking tensin 
initially develop nonnally. After several months however, they exhibited renal failure and 
cystic renal lesions (1.0 '97). Ultrastnrcturally the renal lesions are associated with 
dismption of cell-matrix junctions and abnormal polarity of the tubular cells, whereas no 
junctional abnOlTImlities were noted in unaffected tubules. These data indicate the 
cystogenic potential of defective focal adhesion complexes. 
Chemically il/duced (ll/imalmodels 
Several chemicals will cause cystic kidney lesions when administered to a number of 
experimental animal species. These include glucocorticoids (McDonald '90), 
Tetrahydrocarbazole-3-acetic acid (McGeoch '76) and the antioxidants Diphenylamine 
(Evan '76), Diphenylthiazole ( Carone '74, Ehara '94) and Norhydroguaiaretic acid 
(Gardner '86, Goodman '70). Although these models have interesting features in connnon 
with specific aspects of human renal cysts, none of them represents the complete 
phenotype of cyst fonnation in developing kidneys that are typical of one of the genetically 
detennined diseases. They indicate the potential toxicity of the respective dnlg. These 
models have limited value to the exploration of cystogenesis in PKD. The pathophysiology 
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of drug induced cystogenesis is unknown. Most of these drugs affect a large number of 
different cell systems. It is unknown which of these are involved in the cystogenic process. 
Moreover and in contrast to the genetic animal models, drug induced cystogenesis is based 
on postnatal interference only and therefore does not reflect the developmental natnre of 
humanPKD. 
Summary of animal models 
Genetically detennined polycystic kidney disease has been identified in a large number of 
murine models. These models have all contributed to the understanding of human PKD. 
The various genes primarily disrupted or abnonnally expressed are all candidate mediators 
of the cystogenic process in human PKD. Observations in these models regarding the 
pathophysiology of cyst fonnation have contributed considerably to the understanding of 
human PKD. In addition some were used to explore potential therapeutic interventions of 
PKD. 
The research potential varies from model to model. In general, transgenic models have 
identified cystogenic properties of a large number of specific genes and gene products. 
Although renal cysts were present in all, do most transgenic models not present all 
characteristic features of either human ARPKD or ADPKD. The best exceptions to this 
might be the pkd2 knockout mouse and the ORPK mouse. In contrast to the transgenic 
models do spontaneous murine models of PKD often manifest a remarkable phenotypical 
resemblance to human PKD. However, the genetic defects in these spontaneous models 
have not yet been characterized in much detail. TI,e characterization of the affected genes 
and gene products as well as of the genes that affect disease severity in these models may 
contribute to the future understandulg of the cystogenic process. 
The ideal animal model for the study of either human ARPKD or ADPKD has yet to be 
defined. Such a model would obviously be based on a homologous genetic defect and 
express an identical phenotype, both clinically and histologically. In addition, this model 
would allow the study of cellular pathophysiology, of physiological parameters like renal 
funcion and bloodpressure, as well as of therapeutic interventions. Based on genetic and 
phenotypic characteristics, we arbitrarily suggest as best suitable for such studies, the 
models listed in Table 3. 
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Table 3. Selected animal models 
Phenotype Mutation Characteristics 
Clinlhistol 
ADPKD Mouse pc)' Slow progression allows Shldy of interventions 
pkd2 Gene homologous to human PKD2. Phenotypical 
similarity; needs further characterization. 
Rat c)' Well characterized and extensively studied 
Rat allows physiological and interventional studies 
ARPKD Mouse cpk Well characterized and extensively studied 
Biliary abnomlalities when bred into DBA/2J mice 
O/pk Gene characterized. 
Similar to CPK, and also biliary lesions. 
bpk Similar to CPK, and also biliary lesions 
Enables cell model of hyperplastic biliary cells 
Rat wpk Rat allows physiological and interventional studies 
Renal phenotype like ARPKD and mouse models. 
III vitro models of cyst formation 
TIle in vitro systems of cyst fonnation pennit highly controled experimental conditions 
that allow the precise study of abnormalities of cellular metabolism and function involved 
in cyst development. 
Rellalorgan clIlture 
The culture of metanephric renal explants from fetal mice enables the study of 
cystogenesis because cysts can be induced, in tissue undergoing advanced differentiation 
in chemically defined medium in vitro (Avner '88b). TIle process of cyst fomlation and 
cyst enlargements can be experimentally isolated from the effects of glomemlar filtration, 
endothelial-mesangial interactions, phenomena related to intratubular flow and the effects 
of growth factors and transport substances in serum or urine. 
In tIus system, proximal tubular cysts can be induced by triiodothyronine and 
glucocorticoids, amid a background of nOlmal organotypic epithelial differentiation (Avner 
'84, '87b). It was found that this cyst induction was linked to increases in Na-K-ATPase 
activity and was completely inhibited by specific Na-K-ATPase blockade with ouabaine 
(Avner '85). This suggested that abnormal transtubular fluid transport under these 
conditions led to accumulation in discrete nephron segments and ultimately to cyst 
fomlation. Additional studies in these models demonstrated that EGF may act as a 
cystogen and that EGF-receptor inhibition abolished this process (Avner '90, Pugh '95, 
Sweeney '99). Such studies have delineated mechanisms by which cysts may be produced 
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in nonnally developing tubules, including growth factor induced epithelial proliferation 
and abnommlities of tubular fluid transport. 
The culture of fetal mouse kidneys has also extensively been used to study nonnal 
nephrogenesis and recently to explore the role during nonnalnephrogenesis of polycystin-
I, the PKD I gene product. It was found that synthesized fragments of the extracellular 
domain of polycystin-I inhibited branching tubulogenesis when added to the culture 
medium of a metanephric organ culture system. As suggested by the author, this effect 
might result from competitive inhibition of polycystin-I function, indicating that 
polycystin-I may play a role in branching morphogenesis of the ureteric bud (Van 
Adelsberg '98). 
This experimental system is thus particularly suited to study under well standardized 
conditions, specific aspects of normalnephrogenesis as well as of renal cyst fonnation. 
Cell clIl/llre systems 
Cells derived from patients with PKD can potentially provide model systems that express 
critical characteristics of the cystic renal tubule. Cultured cells that retain features of cystic 
epithelia provide a tool to characterize the ion and solute transport systems, the 
proliferative properties and the epithelial response of cystic tubules. The creation of cysts 
in vitro requires cells that proliferate in a supportive matrix to foml a confluent epithelium 
that accumulates intracavitary fluid. Cells used for such systems may either be isolated in 
primary culture from renal cysts or be derived from immortalized epithelial cell lines. 
However, the harvesting for primary culture of cyst-lining cells of interest, and in 
particular the definition and harvesting of tubular segment specific nonnal control cells, 
introduces a critical selection to these experiments, given the highly heterogenous cell 
population of the nephron. It is further noted here, that cystderived cells are usually 
obtained from end stage kidneys and may not represent the initial disease process. 
The immortalized MDCK (Madin-Darby canine kidney) epithelial cell line, expressing 
characteristics of the distal nephron, has extensively been used to study the in vitro 
fonnation of epithelial monolayers, tubules as well as cysts. When grown in three-
dimensional collagen gels, MDCK cells fonn spherical cysts composed of polarized 
epithelial cells circumscribing a central lumen (McAteer '87). The fonnation of !tlbules 
instead of cysts can be induced by the adddition of HGF to the culture medium 
(Montesano '91, '97). The use of chemically defined culture media enabled the s!tldy of 
specific factors that affect proliferation and fluid transport (Ye '92, Grantham 
'89,Yamaguchi '97). 
The isolation and culture of ADPKD derived cystwalls yields epithelial cells that 
proliferate and may fonn micro cysts when cultured in a collagen matrix (Mangoo '89). 
However, such cystfonning properties were also observed in a separate study using cells 
from nonnal human kidneys (Neufeld '92). Thus, a genetic defect is not required to 
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develop a cystic phenotype in vitro. In addition to this three-dimensional system, many 
investigators have focussed on ADPKD derived monolayers of polarized epithelial cells in 
culture. Such studies have revealed abberant epithelial cell growth regulation, increased 
production of extracellular matrix constituents and the secretion of substances that may 
affect transcellular transport characteristics (Wilson '92, '93, '99a, Du '95). Similarly, 
PKD-derived murine cell cultures using the cpk mouse and the cy rat models as a cell 
source, have also been reported. Primary cultures of cpk cells exhibited a normal 
proliferation rate and a twofold increase above normal of collagen type-IV and laminin 
synthesis (Taub '90, Rankin '92), while cellcultures derived from cysts of affected cy rats 
were used as a model of in vitro cyst formation (Pey '96). 
Alltogether, cultures of cyst-lining cells provide opportunities to shldy the unique 
cellular PKD phenotype, in isolation from its nonnal multicellular environment in cystic 
tissues. Cells that retain specific feahues of cyst-lining epithelia may in particular be used 
to study the proliferative, secretory and matrix abnonnalities associated with this cystic 
phenotype. 
Relationship of experimental models to human PKD. 
The various experimental models have generated theories that are not mutually exclusive, 
but rather complementary. It is clear that the pathogenesis of cyst formation is a complex 
and multifactorial process. It is a relatively COl1ll110n response to mutation or manipulation 
and it is likely that several different mechanisms can result in this superficially common 
change. In Figure 1. we provide a theoretical frame work that outlines the relationship of 
the various components of this conlllon cystogellic pathway, 
In this framework a key consideration is the apparent loss of coordinated control of 
tubular diameter. Under nonnal conditions this diameter is strictly controled, by yet 
unknown mechanisms. Cells divide either during development or to replace dead cells and 
cell divisions can hardly be observed once the hlbule has reached its progranmled 
diameter. It is hypothesized that cysts may f01ll1 when this negative feedback on cell 
proliferation fails, while at the same time the monolayered organization of the tubular 
epithelium is maintained and provided that the extracellular matrix gives way and that the 
intraluminal flow of glomerular filtrate is nonnally present. 
The initial defect in llllman PKD is genetically detennined. However, such a defect is 
not a prerequisit for the formation of renal cysts since nOll-genetic, acquired cysts do also 
occur, in both human disease states and animal models including chemically induced cysts 
and cysts associated with end stage kidney disease. The extent to which a PKD mutation 
leads to stmctural lesions and disease is variable. In ADPKD only about 1 % of the renal 
hlbules develop cysts and manifestations of the disease is highly variable, also within 
affected families. A number of factors have been recognized that may detennine disease 
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severity. First of all, there are indications that cysts in ADPKD result from clonal 
expansion of cells that underwent a mutation of the unaffected allele (2"' hit) (Qian '96, 
Brasier '97, Watnick '98, Wu '98, Koptides '99). It can only be speculated that the 
frequencies of such 2'd hits may vary between individuals and may be determined by both 
genetic and environmental factors. Gender and genetic background appear to modify the 
disease course in both murine and human PKD (Kaplan '89, Gretz '96, Schieren '96, 
Zerres '96, Gabow '92). Several disease modifying genes, have been identified and 
localized ill mice (Iakoubova '97, Wright '97,Upadhya '99, Woo '98). In addition, a 
number of envirOllllental factors that may modulate disease severity have been recognized, 
including infections (Werder '84), hypertension (Gab ow '92) and testosterone levels 
(Cowley '97, Fomitcheva '98). 
The cellular defects induced by the affected gene may lead directly to the abnormal cell 
functions that have been associated with renal cystic conditions, such as: I}. Abnormal cell 
cycle control associated with increased apoptosis and increased expression of oncogenes, 
growth factors and growth factor receptors (Winyard '96, Veis '93, Tmdel '91, Moser '97, 
Calvet '93, Klingel '92, Nauta '95, Wilson '93, Orellana '95); 2). AbnolTIlal sorting of 
growth factor receptors ( Falkenstein '94, Orellana '95, Sweeney '98), cell adhesion 
molecules ( Du '95 ) or transport proteins (Wilson '91, Avner '92 ) 3). Abnormal 
composition of the lipid membrane (Aukema '92b ) 4). Abnomml regulation of cell-matrix 
receptors and adhesion molecules, possibly including the polycystins (Wilson '99b) and 5). 
AbnOlTI1al extracellular matrix and basement membrane production ( Cuppage '80, Wilson 
'92, Schafer '94a). TI,ese cellular abnormalities may directly dismpt the hypothesized 
diameter control systems and induce increased epithelial cell proliferation that escapes the 
nonnal control of tubular diameter, leading to cystic dilatation and ultimately to cyst 
formation. This process could fitrther be enhanced by substances in the cyst fluid with 
mitogenic and/or secretion stimulating properties including BGF, cytokines and lipids, as 
has been demonstrated in vitro using both human and lllurine cystfluids (Gardner '91, 
Grantham '97, Moskowitz '95, Sweeney '96, Yamaguchi '97, Slade '98). 
Although early cysts are thought to drain into the tubular lumen, they often obstruct 
subsequently from cellular debris or epithelial hyperplasia, leading to cysts isolated from 
the originating nephron. In these obstructed cysts alterations in sodium pump polarity ( 
Wilson '91, Avner '92 ) and sodium pump-mediated transtubular transport could lead to 
net intra tubular fluid accumulation. Subsequent increases in hlbular wall tension lllay 
filrther stimulate epithelial proliferation and cyst enlargement. Although interstitial 
changes are not a consistent finding in early cystogenesis, they are markedly present 
during late stages of ADPKD and include the accumulation of a collagen type-IV, laminin, 
fibronectin, macrophages and fibroblasts. These are thought to play a role in cyst 
enlargement, and ultimately in the development of interstitial fibrosis and renal failure 
(Grantham '97 ). 
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The subsequent decline in glomemlar filtration rate results from the loss of non-cystic 
parenchyma in association with interstitial fibrosis and mass replacement by fluid filled 
cysts. 111is process may be further enhanced by ischaemia, urinary tract infections and 
uncontroled hypertension. 
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Figuur 1. Theoretical framework of cystogenesis 
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Aims of this thesis 
Experimental models provide unique opportunities to study the pathophysiology as well as 
the clinical aspects of Polycystic Kidney Disease (PKD). While genetically detennined 
renal cyst fOlmation has been reported in a number of different animal models, none of 
these exhibits all genotypic and phenotypic characteristics of either ADPKD or ARPKD in 
human patients. In Chapter 1.2 we provide a review of the literature regarding the 
characteristics of the currently available animal models. 
In order to further elaborate mechanisms involved in PKD, we set out to identify and 
characterize the clinical and histopathological phenotypes of two new murine models of 
PKD, the 'bpk mouse'and the 'lI'pk rat' (Chapters 2.1 and 2.4). In this process we also 
explored the genetic basis of the lI'pk mutation as well as of the existing 'cy rat', a model of 
ADPKD (Chapters 2.4 and 2.3). We aim to compare these new models to existing PKD 
models. Since we noticed that renal and hepatic lesions in bpk mice are hypelplastic, as 
they are in human PKD, we also set out to develop a bpk cell culture system that would 
enable further explorations of the proliferative nahlre ofPKD epithelia (Chapter 2.2). 
Since PKD can be regarded as an abnonnality of nonnal renal mOlphogenesis and 
differentiation and since 'programmed cell death' is thought to playa key role in these 
developmental processes, \ve opted to detennine whether cyst formation is associated with 
abnOlmal regulation of 'progranuned cell death' (Chapter 3.1). 
The recent genetic identification and analysis of the PKD I gene has revealed the 
aminoacid sequence of the predicted geneproduct, polycystin-!. To investigate the 
expression of polycystin-l in human tissues we set out to develop antibodies to fragments 
of the predicted polycystin-I protein and to test these antibodies on tissue sections and 
homogenates of fetal, adult and cystic human kidneys. We aim to compare the results of 
these studies with those of others (Chapter 3.1). 
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Renal and biliary abnormalities in a new murine model of 
autosomal recessive polycystic kidney disease 
Abstract 
CUlTent models of autosomal recessive polycystic kidney disease (ARPKD) fail to 
demonstrate biliary abnommlities in association with renal cysts. We therefore studied a 
new murine model of ARPKD in which dual renal tubular and biliary epithelial 
abnormalities are present. Affected homozygous animals typically die I month postnatally 
in renal failure with progressively enlarged kidneys. Renal cysts shift in site from inner 
cortical proximal tubules at birth to collecting tubules 20 days later as determined by 
segment specific lectin binding. Increased numbers of mitosis were demonstrated in 
proximal and collecting tubular cysts. In addition, epithelial hyperplasia was demonstrated 
morphometric ally in the intra- and extrahepatic biliary tract of affected animals. The 
number of intrahepatic biliary epithelial cells was increased by 50% at postnatal day 5 and 
by 100% at postnatal day25 (p<O.OI ). Despite an increased frequency of "chaotic" portal 
areas in mice with renal cysts, no intrahepatic cysts or shape abnOlmalities of the biliary 
lumen were detected using biliary casts and morphometry. Additionally there was 
nonobstructive hyperplastic dilatation of the extrahepatic biliary tract which was linked in 
all animals to the presence of renal cysts. The hyperplastic abnormalities in both renal and 
biliary epithelium make this new mouse strain a good model for the study of the dual organ 
cellular pathophysiology of ARPKD. 
Introduction 
Autosomal recessive polycystic kidney disease (ARPKD) is a congenital disorder 
generally leading to end stage renal failure within the perinatal period or early childhood. 
The disease is highly associated with hepatic abnomlalities which can lead to cholangitis 
and portal hypertension (1-5). The expression of disease in both kidney and liver is 
variable and has led to a number of different disease classifications (6-8). On the basis of 
extensive family and clinical studies, it now appears that ARPKD is a single autosomal 
recessive disease complex with a wide clinical spectnun in which renal cystic disease is 
linked to biliary tract abnormalities and congenital hepatic fibrosis (CHF) (9,10). This 
disease complex includes the clinical entities previously classified as infantile polycystic 
disease, juvenile polycystic kidney disease, autosomal recessive polycystic kidney disease, 
autosomal recessive polycystic liver disease, biliary duct ectasia, Caroli's disease and CHF. 
In the different clinical entities of this disease complex, liver lesions are variable. They 
consist of proliferation and dilatation of intrahepatic bile ducts in conjunction with 
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progressive fibrosis of portal connective tissue (9,11). Epithelial hyperplasia seems to be a 
hallmark for both hepatic and renal abnormalities (12,13). In both organs hyperplasia may 
be related to the expression of abnOlmal developmental programs (11,14,15). 
Studies into the mechanisms of the formation and progressive enlargement of renal 
cysts have focussed largely on animal models (16). The C57BLl6J cpk/cpk (CPK) mouse 
has attracted considerable interest as a genetic model for ARPKD (12,17,18). However the 
absence of hepatic lesions in affected animals is an important shortcoming of this model. 
Hepatic lesions have thus far only been identified in aged CPK animals which are 
heterozygous for the cystic trait (19,20). In the current study we describe a new mutant 
strain of Balb/c mice in which ARPKD is expressed in conjunction with abnonnalities of 
the intra- and extrahepatic biliary system. 
Materials and methods 
Animals 
In 1985 polycystic kidney disease was recognized in an inbred strain of otherwise healthy 
Balblc mice at the National Instihltes of Health. These animals were subsequently 
maintained as an inbred strain for over 25 generations at the University of Minnesota and 
expressed renal cystic disease as a stable autosomal recessive trait. In 1990, heterozygous 
breeding pairs from the Minnesota colony were obtained from Dr R Venlier and an inbred 
colony was established at the University of Washington. In the CUlTent study affected 
homozygous BPK malb!c Eolycystic Kidneys) mice were obtained from the controlled 
breeding of animals known to be heterozygous for the cystic disease. Wild type Balblc 
mice (Simonsen Laboratories Inc. Gilroy, Cal.) served as controls. All animals were fed 
standard mouse chow containing 24% protein. 
Light microscopy 
For histologic analysis, kidneys were obtained from cystic and control animals at postnatal 
days 0, 5, 10, 15,20 and 25 and livers were obtained at postnatal days 5, 15 and 25. No 
livers were included at day 0 because identification of bile ducts proved to be inaccurate at 
this age due to the inIDlaturity and small size of the ducts and the relatively heterogenous 
background caused by extensive hematopoetic activity. Histological analysis of the liver 
sections was performed blind by an experienced pediatric pathologist (J.R.). Other 
stmctures and organs were studied at only one postnatal age. Heart, sternum, spleen, brain, 
intestine and salivary gland were obtained at day 25, which is the age of terminal disease 
in BPK mice. Gallbladders, connllOn bile ducts, choledochoduodenal junctions and 
pancreases were studied at day 10 when the moderately enlarged kidneys do not cause 
mechanical obstl1lction of the biliary tract. 
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The tissue was fixed in 3.5% paraformaldehyde for 30 minutes at 4°C, washed, 
dehydrated in graded acetone, infiltrated and embedded in Immunobed® plastic 
embedding medium (Polysciences Inc, Wanington, Pa, USA). Sections of 3 microns were 
mounted on glass and stained with hematoxylin. Additionally, staining for bilimbin was 
perfonned, using Fouchet's reagent, on paraffIn embedded liver sections from 10 day old 
mice. 
Immllllolocalizatioll 
Cyst localization was studied by segment specific lectin binding using Dolichos Bifloms 
Agglutinin (DBA) as a marker for collecting tubules and Lotus Tetragonolobus Agglutinin 
(LTA) as a marker for proximal tubules (21,22). Renal cysts from 6 BPK mice per age 
group on days 0, 5, 10, 15 and 20 postnatally were lectin-profiled at 3 different depths of 
the tissue following standardized embedding and serial sectioning. Depths were chosen as 
10, 30 and 50 % of the thickness of each embedded kidney. In each section all cysts were 
classified as either DBA positive, LTA positive, or negative for both LTA and DBA. No 
cysts were positive for both lectins. 
Biliary tract epithelium was identified utilizing a rabbit pOlyclonal antibody against 
human cytokeratin (Accurate Chemical & Scientific Corp), which has reactivity with 
developing rodent biliary epithelium as previously demonstrated (23). 
The inllnunostaining procedure used was our previously described postembedding 
technique specifically developed for inununolocalization of antigens and lectins in plastic 
sections of developing murine tissue (24,25). Etched and trypsinized Immunobed® 
sections were incubated ovemight at 40C followed by 30 minutes at room temperature 
with either biotinylated lectins (6.25IJg/ml for LTA and DBA; Sigma) or , after blocking 
with nomlal goat se111m (l :50 for 30 minutes) with the cytokeratin antibody (l :250). This 
was followed for lectins by aviden-peroxidase (I :500) for 90 minutes and for antibody 
staining by sequential incubations in bridging goat anti rabbit IgG (1 :40) for 90 minutes 
and rabbit peroxidase-antiperoxidase complex (1:100) for 45 minutes. Sections were then 
stained with 0.05% diaminobenzidine, 0.0 I % hydrogen peroxide and counterstained with 
hematoxylin. 
Mitotic indices 
Mitotic figures in both cystic and normal tubular walls were counted in lectin stained 
kidney sections from 0,5, 10 and 20 day old BPK and control mice. The tissue was fixed, 
embedded in plastic and stained with segment specific lectins as described in the section 
on immunolocalization. We analyzed 6 mice per age group. Data were obtained at 3 
different depths at 10, 30, and 50% of the thickness of the tissue and pooled for each 
kidney. Data are expressed as mitotic indices, being defined as the mean number of mitotic 
figures per 1000 cells in each group. 
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COllllfillg ojportal structllres alld bile duct morpltometlJ' 
Due to the pattemed arborization of the biliary tract, it was essential to standardize depth 
and angle of liver sections for histologic and mOlphometric analysis, In each case the 
major left lobe was embedded with the convexity to the surface of the plastic, Sections 
were cut parallel to the surface of the liver at a depth of 30% of the thickness of the liver. 
In this maIlner a standardized population of peripheral and more central bile ducts was 
consistently obtained, Sections from control and BPK livers were blinded to the observer 
(IN.) prior to analysis, Stmctures were counted in one liver section from each of 5-7 
animals from both control and BPK groups at postnatal days 5,15 and 25, In each section 
all veins, portal areas, bile ducts and biliary epithelial cells were counted, A portal area 
was identified when a vein was accompanied by at least one bile duct. A biliary epithelial 
cell was defined as an epithelial cell lining a bile duct. In addition computer assisted 
morphometric analysis (Sigmascan®) was perfomled at day 15 and 25 on the same coded 
sections as used for the counting of stmctures. Surface area of the section and surface area 
and circumference of each bile duct lumen were analyzed) as well as a size independent 
measure of circularity of bile duct profiles. This Hshapefactor lr was defined as the square 
root of the surface area divided by the circumference (26), 
E I eetl'o 11111 i eroseo P J' 
For electron microscopy, representative samples of kidney, liver and common bile duct 
obtained on postnatal days 5, 15 and 25 were fixed in a mixture of 2% paraformaldehyde / 
2,5% glutaraldehyde for 2 hours at 40 C and postfixed in 0.5% osmium tetroxide for I hat 
40 C. The tissue was then dehydraded through a series of graded acetone and infiltrated 
and embedded in SPIIIT® (Polysciences), Ultrathin sections were mounted on copper mesh 
grids and stained with uranyl acetate and lead citrate, 
Microjii casts ojtlte biliary tract 
Casts of the biliary tract of 3 control and 3 BPK animals of 20 days of age were made 
using yellow silicone mbber ( Microfil®, Canton Bio-Medical Products, Inc, Boulder, 
Colorado, USA), This age was chosen in order to pemnt the study of potential liver lesions 
as late as possible during their development prior to the stage of terminal renal disease. 
The common bile duct was punctured with a 30 G needle and silicone mbber infused into 
the biliary tract under a pressure of 30 cm H20, The duct was ligated after the nlbber was 
visualized in the distal duct radicals using a stereomicroscope. TIle liver was fixed in 
graded alcohol, digested in 1% potassiuIll hydroxide, fmiher cleared in a I: I mixture of 
glycerin and 70% ethyl alcohol and examined for cystic dilatations by stereomicroscopy, 
Pl'essure-jlow study 011 cllOledoc/lOduodellaljllllctiolls 
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In addition to the study of cholestatic features by serum biochemistry, light microscopy 
and electron microscopy, pressure-flow studies of the choledochoduodenal junction were 
performed in a limited number of lO-day-old animals. At this age, bile duct cannulation 
was technically feasable. Unlike older mice, interference of the progressively enlarging 
kidneys with the bile flow could be excluded at this stage. In 4 control and 4 BPK mice the 
outflow resistance of the common bile duct was calculated from a pressure-flow study 
using constant pressure (27). The BPK mice presented with massive dilatation of the 
extrahepatic biliary tract typically present in all affected animals. TI,e flow of 0.9% saline 
at a constant pressure of 30cm H20 through a 30 G needle was measured and the 
resistance calculated and reduced by the baseline resistance of the needle. TIlis baseline 
resistance was 25 +/- 2 cm H20/iJLlsec and constant in the pressure range from 10 to 50 
cm H20. During these experiments the duodenum was opened in order to permit free 
outflow. Backflow into the pancreatic duct was never observed. 
Blood chemistry 
Plasma urea nitrogen values were obtained from 9 control aninmls and from II BPK 
animals at 3 distinct postnatal developmental stages. Plasma conjugated and unconjugated 
bilirubin were obtained at day lOin 6 control and 5 BPK animals. Samples were analyzed 
by Kodak Ektachem 700 spectrophotometry. 
Statistics 
Data are expressed as means and standard deviations. Differences between control and 
BPK animals studied at a single tinle point were analyzed by a paired two tailed t-test. 
Strain effects studied at multiple time points were analyzed by ANOV A .. When significant 
overall strain effects were present the Bonferroni method of adjustment for multiple 
comparisons was used to determine the specific ages at which this effect was significant. 
An effect was considered to be significant when p<0.05. 
Results 
Clinical 
In a series of 219 mice bom from proven breeding pairs, 21 % were found to be affected 
by the cystic trait. This percentage was relatively stable (20%-25%) over a 5-year period 
of inbreeding at the University of MiImesota and the University of Washington. Males and 
females were equally affected. At birth affected BPK mice were clinically normal and 
subsequently developed progressive renal enlargement with massive abdominal distension, 
which was detectable iIl all affected mice by physical examination at the age of 2 weeks. 
Renal failure and death followed at the age of 4 weeks. At the ages of 2 and 4 weeks 
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plasma urea values of affected animals deviated significantly and progressively from 
control values (At day 15: 31 +/- 9 VS. 18 +/- I mg/dL, p<O.OI and at day 25: 88 +/- 14 
vs. 24 +/- 4 mg/dL, p<O.OI). Plasma bilintbin was not different in the 10 day BPK and 
control animals (0.08+/-0.11 vs 0.18+/-0.13 mg/dL for conjugated bilintbin and 0.02+/-
0.02 vs 0.03+/-0.05 mgldL for unconjugated bilimbin). 
Kidneys 
Morphologic alterations in BPK kidneys were present at all postnatal stages (figl). At birth 
they consisted of tubular dilatations and early cyst fomration in the inner cortical zone. 
During successive postnatal stages, tubules underwent progressive cystic enlargement, 
with consequent nephron destruction. During postnatal life there was a gradual shift in site 
of cystic nephron involvement from proxinral tubules to collecting tubules as defmed by 
lectin binding (table I). A small proportion of the cysts did not bind LTA or DBA .. 
Binding of both LTA and DBA never occulTed in the same cysts. 
Table 1. Localization of renal tubular cysts during cystogenesis as a 
percentage of total cysts ',b 
Age (days) Proximal Collecting 
o 97 (3) 
5 73 (5) 
10 58 (6) 
15 38 (5) 
20 II (4) 
a According to segment-specific lectin binding 
b Expressed as mean with SD in parenthesis 
o 
13 (3) 
23 (5) 
46 (4) 
78 (7) 
Unclassified 
3 (3) 
14 (5) 
19 (6) 
16 (4) 
11 (3) 
Ultrastructurally, cyst lining epithelial cells from 5 day old affected animals were 
unremarkable and nOlTllally differentiated as compared to age-matched controls (fig 2A). 
Most cysts were lined by cells with the morphology of nonnal proxinral tubules, Microvilli 
were well fomred and cell junctions, basal lamina and the distribution of cell organelles 
were nOlma!. In 15 day old animals the cyst lining cells were slightly flattened and had 
fewer and shorter microvilli in cysts of both proximal and collecting tubules. The apical 
cell junctions and the interdigitating pattern of cell-cell contacts were nomra!' Compared 
with controls, the mitochondria were decreased in number and slightly swollen as were the 
apical micro vesicles. By day 25, cyst lining cells were even more flattened and 
microvesicles rare (fig 2B,C). Proximal hlbular characteristics were rarely seen in direct 
correlation with the lectin profiling studies. Most cyst-lining epithelium had collecting 
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Fig. I. Kidney sections fWlIll'ontrol ami BPK mice (hematoxylin x9{l). 
A Balbk controllissue on tlay O. B Pro:o;imal tubular cysts were present 
at birth in the inner corte); of BPK kidneys. C On day 25 there was 
massive cystic enlargement and destruction of normal archi!e.:lure of the 
entire kidney 
tubular features. The opposing lateral surfaces of cyst-lining cells were decreased and the 
interdigitation simplified both laterally and basally with replacement by small membrane 
bound spaces at the basal and basolateral surfaces. Intratubular polyps, piling of cells, wall 
thickening, intercellular space expansion or luminal projections were not observed. Despite 
gross dismption of overall renal architecture in the latter stages of disease progression, the 
basal laminae were intact, ullsplit and of normal thickness. 
There was a significant increased number of mitosis in cyst lining epithelial cells from 
both early proximal cysts at day 0 and 5 and early collecting tubular cysts at day 5 and 10 
(table2). Undilated tubules in cystic kidneys demonstrated mitotic indices similar to age 
and segment matched control tubules. The numbers of cystic collecting tubules at day 0 
and of UIldilated collecting tubules in cystic kidneys at day 20 were insufficient to allow 
appropriate statistical analysis. 
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Fig. 1. Tra!lSmi~~ion eh-,:tron mkroscopy of renal li"sions on day 5 and 
25. A Pro\illlJ.l IUbule, of as-day-{J\d BPK moo"". One app.;';lrS norm:!! 
and the other is dilated forming a C) sL The lining cells of the dilated 
tubule mainMin pro,\irnallUbule charJcteriltics similar \0 those of the 
normal tubule which include mic[O\iJli, an apical·\-aruoiar network, 
normal intrJc~llular organ~lle" PJ<.Jl nuclei <Ind a reglilar basal lamina 
(x 5,300). B Colle-cting tubuk of BulWc control on day 25 demOllmate, 
a principil cell (cOlta). indudillg a fairly ,mooth apicil membrane, 
S8 
Hg.2A,H 
ext~nsi\'e infolding~ of the W>;l! region, a lad; of lateral cdl processes 
and intcrdigit.1tions, SCJ.ITC mitochondria which are scattered randomly in 
the C)'topla<;m and, in wolr.lSI 10 the neighboring intercalated cdl (right), 
a lack of apical tubu\oyc,icuiar membrane structures (x 13,300). C 
Colle.:ting tubular cpt ofBPK on day 25. C)':lt~lining cells with morpho-
logicJ.! characteristics of prindp.I\ cell" Organelle numbers and basal 
organization are decreased compared \Iith controls (x 5,300) 
Table 2. Mitotic indices in renal hlbules and cysts a,b 
Age 
(days) 
Proximal Tubules 
Control BPK BPK 
tubules noncystic cystic 
tubules tubules 
day 0 3.9 (0.6) 3.7 (0.5) 9.3 (1.3)' 
day 5 4.0 (1.1) 5.5 (2.7) 7.5 (1.5)' 
day 10 4.8 (1.2) 5.3 (1.6) 5.3 (1.9) 
day 20 3.2 (1.2) 3.7 (1.3) 4.3 (1.3) 
*' p < 0.05 compared with control tubules 
a Mitotic indices = mitotic figures per 1.000 cells 
Control 
tubules 
4.1 (0.5) 
2.5 (1.0) 
2.5 (1.2) 
2.2 (1.5) 
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Collecting Tubules 
BPK BPK 
noncystic 
tubules 
3.6 (0.8) 
4.0 (1.4) 
3.2 (1.3) 
cystic 
tubules 
7.2 (1.6)' 
7.3 (1.7)' 
3.8 (1.1) 
Fig. 2 C 
b Mean with SO in parenthesis of mitotic indices in lectin-defined proximal and collecting 
tubular segments of control and homozygous BPK mice 
Lil'er 
The liver size of 10 day old BPK mice was not different from controls as detenllined by 
the ratio of wet liver weight to body weight ( BPK:2.9 +/- 0.12%,Controls: 2.8 +/- 0.04% ). 
Liver weight ,vas not affected by the animal's sex at this age. 
Light microscopy revealed an increased frequency of lIchaotic" portal areas in BPK 
mice. These consisted of portal areas where the portal vein was surrounded by multiple, 
in'egularly shaped bile ducts and epithelial cell proliferation (fig3). In a blinded study on 1 
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Fig. J, Liver sections of IS·day-old mic", (h~matox}'lill x 170). A A 
repre;enlatll-e portal area in Balbic co[]tmlli<~ue II ilh el)thro.:)le, in the 
portal vein (v), accomp.1nied by 1\\0 bile duct" n A representative 
"chaotic" portal an:-d in BPK ti"ue. n\O portal veim (\') afe accom· 
panied by multiple, irregularly shaped bili' duelS 
a 
Fig. 4. Common bile dLiclS of IS.tlay-ohl mice (hematoxylin x 120). The 
Mea indicated by an amm-1icIU/ is ,hown at higher power (x 2.'i0) in the 
imert. A Tissue from a control Balb/c 1l10u;;e with $Ome attached conllec-
ti\'e ;lnd pancreatic li~~lIe. B The common bile duct of an affected BPK 
mon'e. Note the nomu1 cellular compmition oftbe tinct wall cOffipdTCd 
with control tissue (inurn 
section of each of 6 BPK and 6 control animals of 15 days old, a trained pediatric 
pathologist (J.R.) identified 8.3 +1- 2.6 such portal areas in BPK and 2.3 +1-1.2 in control 
mice (p<O.Ol). No other abnormalities were seen. There were no cystic abnormalities or 
signs indicative of portal or periportal fibrosis. Staining for bile was negative in all 
sections. 
Ultrastlllcturally, the intrahepatic ducts in the BPK and age matched control mice were 
lined by similar, morphologically nomml epithelium. Cell organelles, junctions, 
appositions and basement membranes were unremarkable. The hepatocytes exhibited no 
evidence of bile inspissation or blunting of canalicular microvilli and had a 1l00IDal 
distribution of hepatocellular organelles. 
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Standardized liver sections from age-matched control and BPK animals obtained for the 
counting of portal stnlctures, were comparable with regard to section size and number of 
vein profiles (table 3). During postnatal development considerable liver growth was 
accompanied in both strains by an increase in recognized portal areas (veins accompanied 
by bile ducts), a decrease of bile ducts per portal area and a decrease of epithelial cells per 
bile duct (p<0.05 for all three age effects). 
In BPK tissue there was marked epithelial hyperplasia. Biliary epithelial cells were 
increased by 50% at day 5, by 60% at day 15 and by 100% at day 25 when expressed per 
square mm of the section and compared with control values. This was associated with an 
increased number of bile ducts per square nun. Proliferation of bile ducts in BPK animals 
occulTed in different pattenlS in the different poshlatal age groups. In 5 day old mice it was 
associated with an increase of bile ducts per portal area, while the number of portal areas 
was normal. In older animals bile duct proliferation was associated with an increased 
number of recognized portal areas. 
Qll(lIltitatioll of bile dllct shapes 
Despite the earlier noted increase in Ifchaotic ll portal areas in BPK mice, computerized 
morphometric analysis did not reveal any consistent abnormalities in bile duct surface 
area, circumference or "shape factor lf • Subgroups of bile duct profiles categorized 
according to their shape factor were represented equally in control and BPK livers. 
Casts of the intrahepatic biliary tree of 20-day-old BPK mice were not different from 
controls. No cysts, dilatations or von Meyenburg complexes were identified. 
Extrahepatic biliary tract 
Dilatation of the cystic, the hepatic and the common bile ducts was clearly visible after 
laparotomy in all poshlatal homozygous BPK animals. This finding was linked to the 
presence of renal cysts in all instances. The outer diameter of the common bile duct was 
<0.25 mm in all control mice and between 004 and 1.5 mm in BPK mice (p<O.OI). No 
gender difference was noted. The duct walls of dilated bile ducts demonstrated cellular 
profiles which were not different morphologically from normal bile ducts other than an 
increased number of epithelial cells (Figo4). Ultrastmchlrally the dilated ducts were lined 
by intact cuboidal epithelium with an intact microvillar surface. Apical tight junctions gave 
way to complex interdigitations of the lateral cell membranes. Cytoplasmic organelles 
were dispersed throughout the cell. The underlying basement membrane was unfrayed and 
of nomml caliber and underlaid by collagen and fibroblasts with an active endoplasmic 
reticulum. The ultrastructural morphology did not differ from controls (fig 5). 
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Fig. S, Epithelial lining of 
a dilated common bile duct 
from a 30-d3y-old llPK 
mOLl<C. The cell fealure, m-<' 
1101 di,;tinguished from 
control ductal epithelium 
including ,upcrfidJI 
micrO\illi, apkl! {lrgan~ne<; 
and e~te!lSi\"e \:IlsolaterJl 
inf(llding;; (x 5,300) 
The gallbladder was not dilated and had a nOlmal histology. The weights of the sutured 
undrained gallbladder in 10 day old BPK and control mice were 0.9 +/- 0.2 mg and 1.2 +/-
0.6 mg respectively. 
CllOledocllo-dltodellal jlt Ilet/oll 
Light microscopy of the choledochoduodenal junction did not reveal any abnormalities. 
The intraduodenal segment of the conllron bile duct was serially sectioned and found to 
be open and free of stenosis, fibrosis and inflamr~_1atiol1.There was no restriction of the bile 
flow into the duodenum as measured by pressure flow studies. The calculated resistances 
at 10 days of age were 4, 4, 6 and 8 cm/f.lLlsec in BPK mice and 6, 7, 9 and 14 cmlf.lLlsec 
ill control mice. 
Light microscopy of organs other than kidney or liver was unremarkable. No cystic or 
other abnormalities were seen and there were no signs of illflanmlation or fibrosis. 
Discnssion 
The BPK mouse demonstrates autosomal recessive progressive hlbular cyst formation 
associated with biliary abnormalities. This association is a well recognized feature of the 
human ARPKD /CHF disease complex (9). At one end of the clinical spectrum are patients 
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Table 3. Portal structures in standardized liver sections at different postnatal 
developmental stages a 
Day 5 Day IS Day 25 
Surface area (nnn2) Contr 19 (6) 39 (2) 55 (9) 
BPK 28 (3) 40 (8) 51 (12) 
Veins/nnn2 Contr 8.7 (1.8) 7.7 (1.2) 604 (0.9) 
BPK 6.8 (1.2) 8.0 (0.7) 7.0 (1.1) 
Cells/mm2 Contr 27 (8) 29 (8) 21 (5) 
BPK 40 (19) 45 (6) * 43 (10) ** 
Cells/Bileduct Contr 16 (4) 14 (I) II (2) 
BPK IS (5) 12 (1) II (2) 
Bile ducts/nnn2 Contr 1.7 (0.3) 2.1 (0.5) 2.0 (0.3) 
BPK 2.6 (0.7) 3.7 (0.5) •• 3.8 (1.0) ** 
Bile ductslPortal area ContI 1.5 (0.2) 104 (0.1) 1.3 (0.1) 
BPK 2.5 (0.5) •• 1.6 (0.2) 1.7 (0.3) 
Portal area/ll1ll12 Contr 1.1 (0.2) 104 (004) 1.5 (0.2) 
BPK 1.0. (0.1) 2.3 (0.2)** 2.3 (0.6) ** 
Portal area/lOO Veins Contr 13 (2) 18 (3) 23 (3) 
BPK IS (2) 28 (2) ** 32 (6) ** 
• p<O.05 vs. controls 
.* p<Q,Q I vs. controls 
a 
mean with SD in parentheses 
with lIclassic" ARPKD who present neonatally with renal failure, only microscopic hepatic 
abnonnalities and no clinical symptoms of liver disease. At the other end, are patients with 
CHF, presenting in early childhood with symptoms of portal hypertension and cholangitis 
but with nom1al renal function and only microscopic renal lesions. The clinico-
pathological classification of ARPKD introduced by Blyth and Ockenden was based on the 
variable degree of renal and hepatic involvement as well as the age at presentation (6). It is 
now accepted that the different clinical entities introduced by Blyth and Ockenden are 
different manifestations of the sallle genetic defect (5,9). TI,e increased survival of even 
very young patients undergoing treatnlent for end-stage renal disease, in concert with the 
progressive nature of the hepatic abnonnalities in ARPKD, leads to the expectation that 
many of these patients may eventually develop portal hypertension and progressive liver 
fibrosis. Therefore hepatic lesions are not only inherent to human ARPKD but also of 
increasing clinical importance. 
Studies of the pathophysiology of human ARPKD are hampered by its low incidence, 
variable clinical expression and advanced pathology at presentation. As a consequence, 
research has largely focused on animal models. The animal model studied most 
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extensively to date is the C57BLl6J cpk/cpk mouse strain (CPK) which expresses a lethal 
ARPKD much like the human disease (12,17,18,28). However, the validity of this model 
has been questioned since unlike its human counterpart, biliary abnormalities could not be 
demonstrated in affected animals. Extensive studies identified hepatic cysts only in aged 
heterozygous breeders of the CPK strain but not in homozygous animals with renal cysts 
(19,20). TIle invariably present biliary abnornlalities demonstrated in cystic BPK mice not 
only emphasize the value of this strain as a new model of dual organ epithelial 
pathophysiology in ARPKD but also suggests it may have value as a model for the study 
of biliary dysgenesis. 
The pattern of renal cyst fOlmation and the progression of renal failure in the BPK 
strain are similar to those described for the CPK strain and, in latter stages, to those of 
human ARPKD. The two murine models demonstrate similar ultrastructural features of 
cyst-lining epithelium, although dilatation of intercellular spaces, previously noted in 
proximal tubular lesions of CPK animals (12), was not a feature of BPK mice. The 
localization of cysts to lectin-defined segments has yielded a number of interesting 
observations. The lesions in early stages of disease in BPK mice consist of dilatations 
exclusively localized to proximal tubules. These proximal tubular cysts most likely 
develop in functioning, non-obstmcted nephrons as indicated by the normal cellular 
ultrastlllcture. This is consistent with microdissection data from the CPK model (12). The 
contribution of proximal tubular cysts to the total population of cysts decreases during 
disease progression. This is most likely due to restriction of proximal tubular cystogenesis 
to a specific developmental stage in the context of ongoing nephrogenesis and progressive 
formation of collecting tubular cysts (12). Regression of proxinral tubular cysts has never 
directly been demonstrated in vivo but has been demonstrated in vitro (29,30). Although 
proxinlal tubular cyst formation has not yet been demonstrated as an early feature of 
human ARPKD it should be emphasized that little tissue from early disease stages has 
been available for detailed microdissection or lectin profiling analysis. Of particular 
interest in this regard is a recent histopathological study of ARPKD kidneys in which two 
of five specinlens demonstrated slight positive staining for lectin markers specific for 
proximal tubules (31). 
The histological picture of latter BPK disease stages is dominated by collecting tubular 
cysts. This is sintilar to data from patients with end stage ARPKD in which systematic 
innmmohistologic and microdissection studies have localized most cysts to collecting 
tubular segments (12, 32). In addition to proximal tubular cysts and collecting tubular 
cysts, there was a small population of BPK cysts which could not be localized by lectin-
profiling to either one of these segments (Table I). Whether these cysts originate from a 
different neplnon segment or represent phenotypic changes of preexisting proximal or 
collecting tubular cysts can only be detelmined by further studies. Involvement of nephron 
segments other than the proximal tubule or the collecting duct has not been suggested by 
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ultrastlUctural analysis in the BPK strain and does not playa role in the cystogenesis of the 
CPK strain or ARPKD. 
The intrahepatic abnormalities in standardized liver sections of BPK mice consist of 
hyperplasia of the biliary tract and an increased number of "chaotic" portal areas. In human 
CHF and related liver disorders, similar lesions have been described and attributed to a 
defective remodelling of the ductal plate (11). According to cunent views this plate is 
fonned during nOlTllal liver development by transfOlmation of hepatocytes into a double 
epithelial sheet surrounding the intrahepatic portal veins. During further development, this 
plate is then remodelled into multiple and later single bile ducts. The increased number of 
bile ducts and the abnomlal shapes of bile duct profiles in liver sections of patients with 
ARPKD or CHF have been attributed to insufficient breakdown of the ductal plate and an 
anest of the normal remodelling process (II). The demonstrated increased number of bile 
ducts per portal area in early BPK disease stages is consistent with a remodelling defect, 
such that remodelling of the ductal plate has started but not been completed to the stage of 
single bile ducts. Further, the accelerated posOlatal development of the biliary tract along 
the portal venous tTact in BPK mice, indicated in our data by the increasing numbers of 
portal areas, relative to controls, suggests additional abnol1naJities of the ductal plate 
remodeling process. Whether the multiple, inegular shaped bile ducts observed in a limited 
number of portal areas from affected mice represents the curving biliary plates described 
for the 'ductal plate malfomlation' in human disease by Jorgensen (13) cannot be 
concluded from this study. A separate study utilizing stereological reconstruction from 
serial sections is required to resolve this issue. 
The observation in tIils study of an increased number of "chaotic" portal areas 
consisting of abnOlmal numbers and shapes of bile duct profiles was made by an 
experienced observer in a blinded Shldy. It was therefore smprising and in contrast to data 
from human studies that no consistent abnonnalities in bile duct shape or size could be 
demonstrated by quantitative mOlphometry (33). It appears that the number of "chaotic" 
portal areas relative to the number of normal portal areas was insufficient to affect the 
quantitative morphometric analysis. The absence of intrahepatic fibrosis and cystic biliary 
dilatations in BPK mice contrasts with data from most patients with advanced CHF and 
related disorders (3,9,34). It should be emphasized however that the early lethality of the 
renal disorder in the murine model necessarily restricted this study to early stages of liver 
disease. 
Dilatations of the entire extrahepatic biliary tract with the exception of the gallbladder 
were strikingly present in all animals with cystic kidneys at all postnatal ages and never 
seen in unaffected animals. Biliary outflow restriction as the primary cause of this 
dilatation and of the intrahepatic biliary hyperplasia was excluded by the absence of 
gallbladder dilatation, nOlmal serum bilirubin, the nOlTllal ultrastructure of the liver and 
connnon bile duct, and the nonnal resistance of the choledochoduodenal junction. 
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Moreover the massive lumenal dilatation in conjunction with the apparently nonnaHy 
stmctured wall, in which increased numbers of biliary cells were paralleled by hyperplasia 
of the surrounding stroma, suggests a primary hyperplastic abnonnality. Although the 
common bile duct dilatation invariably present in affected BPK animals has not been 
specifically associated with human ARPKD, it is a well recognized finding in patients with 
Caroli's disease (35). It thus appears that extrahepatic biliary dilatation is part of the 
variable hepatobiliary phenotypic expression of the ARPKD/CHF disease complex. 
The renal and hepatic abnormalities demonstrated in this model suggest a common 
pathogenetic pathway. In both organs, epithelial hyperplasia is an early feature of the 
lesions although the specific patten1S of renal and biliary hyperplasia are somewhat 
different. The hyperplasia of tubular cystogenesis and the hyperplasia of the extrahepatic 
bile duct both are associated with luminal dilatation. In contrast intrahepatic biliary 
epithelial hyperplasia in affected BPK mice is expressed as an increased number of bile 
ducts and thus elongation, rather than dilatation, of the biliary tract. 
Differences in the three-dimensional stmctural consequences of hyperplasia in kidney 
and liver may reflect the fact that these organs are in different developmental stages at the 
time that lesions develop. Since the renal cystic lesions develop in a segment specific 
pattern in preexisting, stmcturally nomral nephrons (12), elongation of hyperplastic 
segments is anatomically restricted by the attachment at both ends to fixed normal tubular 
segments. Uncontrolled growth of cells in such spacially restricted tubular segments would 
then lead to expansion perpendicular to the long axis of the tubules, i.e. dilatation. 
Similarly, elongation of the extrahepatic bile duct is restricted by the attaclmrent to liver 
and duodenum, and thus localized cellular proliferation would lead to dilatation. In 
contrast the proliferative elongation of the intrahepatic biliary tract is part of the pattern of 
nonnal murine postnatal development, as illustrated by our data from control mice (table 
3). The intrahepatic biliary tract is not physically restricted by attachment to other organ 
stntctures until the nom1al developmental process is complete. It would be of interest to 
know whether biliary hyperplasia continuing beyond the end point of biliary tract 
development would lead to increased numbers of bile ducts per portal area and luminal 
dilatations, and whether such abnormalities would be accompanied by fibrotic changes in 
the portal areas as seen in human disease. At present, such a course of events can only be 
speculated since affected BPK anin,als die of renal failure prior to this developmental 
stage. 
We conclude that the presence of intra and extrahepatic biliary hyperplasia in 
conjunction with progressive, hyperplastic renal tubular cyst formation make the BPK 
mouse strain an excellent model for the study of the ARPKD/CHF disease complex. 
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Biliairy epithelial cells from mice with congenital polycystic 
kidney disease are hyperresponsive to epidermal growth 
factor 
Abstract 
Epithelial hypelplasia is an early feature of the renal and biliary lesions in autosomal 
recessive polycystic kidney disease (ARPKD). To explore the cellular basis of this 
hyperplasia we isolated, cultured and characterized biliary tract epithelium from conmlon 
bile duct explants of mice with ARPKD (the BPK mouse) and controls. Primary cultures 
resulted in dense colonies of contact inhibited epithelial cells with a homogenous growth 
pattem. Colony growth in senun free basal medium (BM) of BPK derived cells was not 
different from controls. Supplementation of BM with epidermal growth factor (EGF) 
induced a proliferative response in BPK derived cells that was significantly increased over 
controls as assessed by 3H-Thymidine uptake and expressed as percent change over growth 
in BM (BPK 239% and controls 131% ofBM growth). In contrast no differences between 
BPK and Control derived cells were found with regard to the effects of BM 
supplementation with IGF I, IGF II, aFGF, KGF, HGF or TGFfi. 
Primary culture of biliary epithelium may provide a useful in vitro model for the study of 
the cellular pathophysiology of ARPKD. Our data demonstrate that increased epithelial 
sensitivity to EGF-like proteins may playa role in biliary epithelial proliferative changes 
which parallel renal tubular epithelial proliferation in ARPKD. 
Introduction 
Genetically detelmined polycystic kiduey disease (PKD) affects about one person in 
thousand and is responsible for significant morbidity and mortality (I). Usually it is the 
hallmark of a unique autosomal dominant (ADPKD) or autosomal recessive (ARPKD) 
disorder. TIle cystic renal tissue is characterized by fluid accumulation in progressively 
enlarging dilatations of preexisting renal tubules which lead to distortion of renal 
architecture and ultimately to renal failure. Renal failure develops in about half of patients 
with ADPKD and in virtually all those patients with ARPDK that survive the perinatal 
period (2). ARPKD typically presents perina tally or during the first years of life. Many 
patients die at birth from pulmonary hypoplasia which is thought to result from 
oligohydramnis and inadequate prenatal renal function. In contrast ADPKD typically is a 
disease of adults with disease manifestations generally developing during the second half 
of life. However a small proportion of patients may present during childhood. PKD is 
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highly associated with liver disease. Hepatic lesions develop in 50-90% of patients with 
ADPKD and in all patients with ARPKD (1). In ADPKD proliferative intrahepatic biliary 
lesions resulting in discrete cyst fOlTImtion are characteristic. In ARPKD the lesions are 
variable and consist of proliferation and dilatation of intra- and extrahepatic bile ducts 
(trductal ectasia"), and periportal fibrosis as well. The clinical course of the associated liver 
disease, is generally mild in ADPKD and much more severe in patients with ARPKD and 
may include cholangitis, portal hypertension and ultimately liver failure (3-5). Genes 
responsible for human ARPKD and ADPKD have been localized (6,7). In addition the 
ADPKD gene has been identified in part (7). 
Studies into the pathophysiology of PKD have largely focused on the renal lesions 
using a variety of in vivo and in vitro experimental models (8). Such studies demonstrate 
that two basic criteria are necessary for renal tubular cyst formation: 1) increased tubular 
epithelial cell proliferation and 2) altered transtubular fluid transport (9-11). The 
mechanisms responsible for aberrant renal tubular epithelial cell growth are not known. 
Recent reports suggest a role for abnormal regulation and/or activation of the TGF-
alEGF/EGFR axis (8, 12-17). It has been theorized that the presence of mitogenic 
quantities of TGFa and/or EGF-like peptides in cyst fluid coupled with aberrant apical 
tubular epithelial expression of EGF-R may drive an autocrine/paracrine cycle of cellular 
proliferation. 
In contrast to the focus on renal pathophysiology in PKD, little is known about the 
pathophysiology of the hepatic lesions. Studies at the cellular level have been hampered by 
the low availability of human hepatic tissue and the lack of an aninral model. Recently we 
reported a new spontaneous mutation in Balb/c mice which is a new model of human 
ARPKD, the BPK strain (18). In BPK mice renal cystic lesions are associated with intra-
and extrahepatic hyperplastic lesions of the biliary tract. The disease is transmitted in an 
autosomal recessive pattern and leads to terminal renal failure and death in affected 
animals at the age of 1 month. The demonstrated hyperplastic abnormalities in both renal 
and biliary epithelium makes this new strain a good model to study the dual organ cellular 
pathophysiology of human ARPKD. Studies were therefore undertaken in order to 
establish a cellular model of the abnomral growth regulation of biliary epithelia in murine 
ARPKD. 
Methods 
Animals 
All experiments were approved by the Institution Animal Use and Care Committee. 
Throughout the experiments we have maintained stable colonies of wild type Balblc 
control mice (Jackson Laboratories) and Balb/c BPK mice. The BPK strain expresses PKD 
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in an autosomal recessive pattenl and arose from a spontaneous mutation in 1985 in an 
otherwise healthy Balb/c colony at the National Instihltes of Health. TIle BPK strain has 
been maintained as an inbred strain at the University of Washington since 1990. Recently 
we reported the presence of hepatic as well as renal lesions in these mice (18). In the 
current experiments 15-25 day old offsprings from wild-type matings served as controls, 
while affected BPK animals of the same age were obtained from matings of known 
heterozygotes for the BPK trait. The age group was chosen such that affected mice can be 
readily identified by physical examination while terminal renal failure is not yet present. 
Affected mice demonstrate enlarged kidneys as well as macroscopically dilated 
extrahepatic bile ducts. 
Culture mediulIl 
Two types of media were initially used in culture of biliary epithelium. Eagle's minimal 
essential medium (EMEM) was supplemented with 10% fetal calf semm, 20 mM N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES), 2 mM L-glutamine, 100 
microgr/ml streptomycin sulfate and 100 IUlml penicillin (19). The second medium 
consisted of equal volumes of Dulbecco's modified Eagle's medium (DMEM) and Ham 
FI2 supplemented with HEPES (10 mM), sodium bicarbonate 13.4 mM (15 ml 7,5% per 
L), glutamine (2 mM), transferrin (6.2 x 10,8 M), insulin (2,7 x IO,8M), triiodothyronine (2 
x 10,9 M), Hydrocortisone (2,9 x 1O'8M), selenic acid (6.8 x 10,9 M), prostaglandin EI (7.1 
x 10,8 M), penicillin (50 UlI), streptomycin sulfate (50 microgr/mL) and nystatin (50 
U/ml). Since the two media gave equal results and since semm would interfere with the 
intended studies we used the semm free medium as basal medium (BM) throughout the 
current study. 
Preparatioll of clIltllre dishes 
Explants were grown on either coated or uncoated 35 nun plastic culture dishes (Falcon, 
Oxnard, CAl. Coating was perfomred with either Vitrogell-100 (Celltrix, Palo Alto, CAl, 
or with Matrigel (Collaborative Research, Lexington, MA) to determine the most 
reproducible culture conditions. Vitrogen was used after dilution at 4°C with equal 
volumes of culture medium. Matrigel was used according to the instructions of the 
manufacturer. Dishes were coated with approximately 100 microL, placed in the incubator 
at 37° C for 30 minutes, than filled with 2 ml culture medium and kept at 3r, 5% CO, for 
use the same day. In preliminary studies Vitrogen coating gave the best results in terTIlS of 
colony growth, viability and cellular morphology and was therefore utilized for all of the 
subsequent studies. For electron microscopy explants were grown on Vitrogen coated 22 x 
22 mm coverslips placed in 35 mm culture dishes. Growth and 'H-TIrymidine 
incorporation studies were performed on explants grown on Vitrogen coated 10 x 10 mm 
coverslips placed in 35 mm culture dishes. 
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Comlllon biledllcl explalltatioll alld primary cultures 
Mice ,vere killed by decapitation and laparotomy was perfonned under sterile conditions. 
The COllllllon bile duct was carefully dissected from extraneous tissue and from the 
pancreatic duct. The common bile duct was transsected proximally at the origin of the 
cystic duct and distally near the choledocho-duodenal junction, immediately placed into 
ice cold culture medium and transferred into a laminar flow hood. 
Under the stereomicroscope the duct was then cut into 0.2 nun' explants. Each control 
duct thus provided approximately 6 explants, while markedly enlarged BPK ducts 
provided approximately 30 explants for culture. Explants were transferred to fresh medium 
free culture dishes and incubated ovemight at 37' C, 5% CO, to pennit attachment. The 
next lnoming 2 ml of culture medium was gently added to each dish and subsequently 
changed every 2 days. 
[mill IIl1ollist%gical cllal'acterizalioll 
The presence of specific epithelial cell markers was tested on both intact tissue and 
cultured cells which grew from cultured explants using: 1) a rabbit polyclonal antibody 
against human cytokeratin which previously was shown to bind specifically to murine 
biliary epithelial cells (Accurate Chemical and Scientific Corp., Westbury, NY, no. ax 
1698) (18) and 2) Lectin Dolichos Bifloms Agglutinin (DBA) which also showed specific 
binding to biliary epithelium in preliminary studies. Monoclonal anti Vimentin antibody 
(Bio Genex, San Ramon, CAl staining was used as a marker for fibroblasts. 
Inununohistology was perfomled using our previously described methods (20). 
Bile ducts from control mice were rapidly fixed in 3.5% parafomaldehyde (pH 7.4) for 
30 minutes at 4' C. Fixed tissue was then washed, dehydrated through a graded acetone 
series and infiltrated and embedded in Immunobed plastic embedding medium 
(Polysciences, Warrington, PAl. Immunobed sections (3 micrometer each) were etched 
with alcoholic NaOH, trypsinized and incubated ovemight at 4' C with biotinylated DBA 
(6.25 microgrlml) or after blocking with normal goat semm (I : 50) with anticytokeratin 
antibody (I : 250) or with anti-vimentin. This was followed for DBA by aviden peroxidase 
(I : 500) for 90 minutes, for the cytokeratin antibody by sequential incubations with 
bridging goat anti rabbit IgG (I : 40) for 90 minutes and rabbit peroxidase-anti peroxidase 
complex (1 : 100) for 45 minutes, and for the anti Vimentin monoclonal by biotinylated 
anti mouse (I : 200) for 90 minutes and avidin peroxidase (I : 500) for 90 minutes. 
Sections were then stained with diaminobenzidine 0.05%, hydrogen peroxide 0.01%. 
Cells which were identified as outgrowth from cultured explants were stained after fust 
passage. Multiple primary cultures grown for 10 days were incubated in 0.25% uypsin, 
0.1% ethylenediamine tetra acetic acid (EDTA) for 30 seconds and after aspiration of the 
supematant for another 10 minutes at 37' C, 5% CO,. The cells were then harvested, 
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washed, seeded on multiwell microscope glass slides and cultured for 48 hours. n,e slides 
were then fixed in methanol (-20' C) for 10 minutes and dried. Staining was performed 
with the same antibodies as given for intact tissue. Prinlary antibody was applied for I 
hour, and secondary antibody and peroxidase for 30 minutes each. This was followed by 
diaminobcnzidine staining as described for intact tissue. 
Electroll microscopy 
Transmission electron microscopy \vas performed on both intact bile ducts and cultured 
biliary epithelial cells from BPK and control animals. Connnon bile ducts were fixed in 
2% parafOimaldehyde, 2.5% glutaraldehyde for 2 hours at 4' C and postfixed in 0.5% 
0,04 for I hour at 4' C, then dehydrated through a series of graded acetone and infiltrated 
and embedded in Medcast (Ted Pella Incorp., Redding, CA.). Primary cell cultures grown 
on Vitrogen coated glass cover slips were fixed in 1% paraformaldehyde, 1.25% 
glutaraldehyde for 2 hours at 4' C and postfixed in 1% 0,04 for 30 minutes at 4' C, then 
dehydrated through graded ethanols and infiltrated and embedded in Medcast. Ultrathin 
sections were mounted on copper mesh grids and stained with uranylacetate and lead 
citrate. 
Assessmellt o/mitogellic (Icth'ily 
The mitogenic activity of control and BPK derived cell cultures was quantitavely assessed 
using serial colony size measurements and by 3H-111ymidine incorporation assay. Colony 
drawings made using a CK,-TRC-2 Olympus inverted microscope with a BH,-DA drawing 
attachment were analyzed using computer assisted morphometry (SigmascanR). Colony 
size was measured with 99% reproducability. Colony growth curves were prepared using 
daily surface area measurements of control (n ~ 36) and BPK-derived (n~19) primary cell 
cultures. In addition the mitogenic effect of various polypeptide growth factors \vas 
assessed by serial surface area measurements and by a 3H_ Thymidine incorporation assay 
as follows. Control and BPK derived primary cell cultures were grm>1l on Vitrogen coated 
glass coverslips in basal culture medium (BM). After 6 days of culture the media were 
replaced by BM, with or without supplementation with one of the following polypeptide 
growth factors: human Insulin-like Growth Factor I and II (IGF I and II, 25 ng/ml, U.S. 
Biochemical Corp., Cleveland, Ohio), mouse Epidermal Growth Factor (EGF, 20 ng/ll1l, 
Sigma), bovine acidic-Fibroblast Growth Factor (aFGF 12 ngiml, Sigma), human 
TransfolTIling Growth Factor fi (TGF n, 2.5 ngi1l11, Collaborative Research Corp., Bedford, 
Massachusetts), human Hepatocyte Growth Factor (HGF, 20 ngiml, Coil. Research COlp.) 
and human recombinant Keratinocyte Growth Factor (KGF, 12 ng/ml, a generous gift from 
Dr. Stuart. A. Aaronson, Bethesda) (21). Each experimental group consisted of 28 primary 
cultures. 
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The effect of serum and growth factor supplementation over basal growth was assessed 
by both surface area increase during the first 24 hours and by 'R TIlymidine incOlporation 
following this 24 hour incubation. 'R TIlymidine (5 microCilml) was added to freshly 
prepared basal or growth factor-supplemented medium. After 6 hours incubation the cover 
slips were transfered to scintillation vials and washed with 10% trichloracetic acid. The 
cells were then dissolved in Protosol (Dupont) and mixed with Aquassure scintillation 
cocktail (Dupont). Counts were expressed as des integrations xlO,2 per minute (dpmIO") 
and related to the surface area of the colony at the start of the 'R-Thymidine incubation 
(dpm.IO"). In order to visualize light microscopically the distribution of mitogenic activity 
in individual colonies we used a 9-hour Nocodazole (0.2 microgr/mL) induced alTest of 
mitosis prior to fixation. 
Statistics 
Data are expressed as means and standard deviations. Differences between growth factor 
supplemented growth and basal growth were analyzed by unpaired two tailed t-test. 
Interactions of growth factor effects and strain effects were tested by analysis of variance. 
Results 
Explantation and primary culture conditions. 
In all BPK mice fusifollll dilatation of the entire extrahepatic biliary tract was seen in 
association with renal cystic disease (18). TI,e outer diameter of the connnon bile duct was 
increased in all cases as compared to control values (250-1500 micrometer vs. < 200 
micrometer). 
TIle tedmique of stereomicroscopic fragmentation of the explants did not allow 
standardized sizing of cultured fragments. The optinlal tissne fragment size was 
approximately 0.2 mm'. Smaller pieces yielded inconsistent cnlture results. For adequate 
attachment of the explants to the cnlture dishes a collagen coating was indispensable. The 
attaclmwnt efficiency was 90% for Vitrogen 100 and Matrigel-coated dishes alike and less 
than 10% for uncoated dishes. Explants cultured on coated dishes formed an expanding 
cellular outgrowth in 90% of cases, which was first noticable after 2 days of culture. This 
plating efficiency was not different for Vitrogen 100 and Matrigel coated dishes. With 
continuing growth better results were obtained with Vitrogen 100 where cellular outgrowth 
was consistently homogenous during 10 days of culture. 
In contrast, cultures grown on Matrigel for more than 5 days occasionally fOIDled cell 
free patches in initially homogenous cell colonies. This was interpreted to be due to the 
fragility of the substratum and the early breakdown of the coating. Vitrogen-IOO coating 
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Fig.I. Common bile duct epithelium prior to culture. (A) Inset: Overview of an intact undilated 
common hileduct (hematoxylin x 200). Transmission electron microscopy: Epithelial lining of a 
dilated common bile duct from a 30 day old BPK mouse. The cell features are undistinguishable 
from control ductal epithelium including superficial microvilli, apical secretion vesicles, 
extensive basolatcral infoldings and an intact basement membrane (x 6000). (B) At higher 
magnification rough endoplasmatic reticulum with ribosomes as well as free ribosomes can be 
identified. Apically tight intercellular junctions including desmosomes can be identified (x 
32.000). 
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was therefore used for the cutTent studies. In preliminary studies two different types of 
culture media were compared. TIle serum-supplemented and the senllu-frce media 
produced similar culture results in temlS of attaclmlCnt, plating efficiency, colony growth 
and cell density up to 10 days of culture. Based on these findings and on the requirement 
of defined culhue conditions for the intended experiments on cell grO\vth, \ve used the 
serum free medium as basal medium (EM) throughout the cuncnt experiments. 
Characterization of the cells 
Cells ill fwd 011 the pril1lalJ' explullts. 
Before microsurgical dissection, the explants consisted of ducts lined by an epithelial 
monolayer and surrounded by connective tissue (fig. I). In some cases explallted bile ducts 
were attached to pancreatic andlor to fatty tissue. This could clearly be identified and 
removed using the stereomicroscope. Only lIclean" ducts were used for the culture 
experiments. The duct walls of dilated bile ducts demonstrated cellular profiles that were 
not different from normal bile ducts other than an increased number (not density) of 
epithelial cells. Ultrastmcturally the dilated ducts were lined by intact cuboidal epitelium 
with an intact microvillar surface. Apical tight junctions gave way to complex 
interdigitations of the lateral cell membranes. Cytoplasmic organelles were dispersed 
throughout the cell. The underlying basement membrane was intact and of nonnal caliber 
and underlayed by collagen and fibroblasts with an active endoplasmatic reticulum. TIle 
ultrastmctural 1ll0lphology did not differ from controls. 
During culture the explants were covered entirely by a single layer of cuboidal 
epithelial cells (fig.2). These cells had ultrastmctural characteristics much like those seen 
in vivo (fig.1). Unlike the epithelium in vivo no basement membrane could be identified at 
this stage. The underlying tissue consisted of a loose stroma with ultrastmcturally viable 
stromal cells. During culture multiple ductular Shl.lctures could be observed in most 
explants. The cells lining these ducts invariably had the ultrastmctural appearance of 
epithelial cells not different from the explant covering cells in figure 2. 
Cellular outgl'owth from the pl'imal'Y explauts. 
Cellular outgrowth was first seen after 3 days of culh"e at the edges of most explants 
(fig.3). This outgrowth expanded progressively and developed into a dense confluent cell 
colony in which the cell density was homogenous up to 10 days of culhlfe (fig A). 
Fibroblast-like cells were never seen. Two different growth pattenls were recognized in 
these cell colonies. The outer rim of the colony with a width of approximately 20 cells 
exhibited a relatively low cell density and a high mitogenic activity as illustrated by the 
nocodazole-induced anest of mitosis (fig.5). The central area of the cell colonies was made 
up of densily packed cells with low mitogenic activity. 
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Fig.2 Common bile duct explant cultured for 7 days. Inset: Overview demonstrating the 
complete coverage of the explant by a dense epithelium as well as the presence of multiple 
ductular structures within a loose and apparently viable stroma (hematoxylin x 100). 
Transmission electron microscopy: Epithelial characteristics include apical microvilli, tight 
junctions and extensive intercellular digitations. Note the reduced number of secretary granules 
and the absent basement membrane as compared to the in vivo epithelium shown in Fig I. 
(x 8000) 
Ultrastmcturally a unifonn sheet of cells could be identified. Cultured cells fonned 
tight mono layers with the characteristics of polarised epithelia including numerous apical 
microvilli, tight junctions, extensive intercellular digitations, and the apical distribution of 
secretory granules and mitochondria (fig.6). Compared to the intact biliary epithelium, the 
cultured cells were more spread and exhibited no basement membrane at this stage. 
Immunocytochemical staining revealed specific binding of anti cytokeratin antibody to 
the apical cell membrane of biliary epithelial cells in intact tissue (fig.7) as well as to the 
cultured cells in a delicate filamentous pattem (fig.8). Similarly DBA staining revealed 
specific apical binding to biliary epithelial cells in vivo and positive staining of the 
cultured cells. Biliary epithelial cells of intact tissue as well as cultured cells did not 
express vimentin. 
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Fig.3 Representative example of a tightly confluent cellular outgrowth from a common bile duct 
explant (dark central area) cultured for 3 days in basal medium (hematoxylin x 50). 
Fig.4 Primary epithelial cell culture from a common bile duct explant cultured for 10 days in 
basal medium. Note the homogeneity and high density of the epithelial monolayer (hematoxylin 
x 300) 
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Fig.S Homogeneous epithelial monolayer cultured for 7 days. Mitogenic activity, (visible as 
dark nuclear chromatin aggregates) is confined to the periphery of the colony. For better 
visualisation these cells were arrested in mitosis for 9 hours using Nocodazole (0.2 J.lg/ml) 
incubation (hematoxylin x 50). 
Celllliar growth stlldies 
Linearity of colony growth up to 10 days of culture under basal conditions was 
demonstrated in both BPK and control derived cell colonies (fig.9). Basal growth of BPK 
derived celIs was not different from controls. 
Cellular growth was assessed by measurement of: I) 6 hour 'H-Thymidine uptake and 
2) 24 hour colony size increments. Data are expressed relative to colony size. TIlcse two 
parameters conelate well when measured simultanously in individual cell colonies grown 
in basal medium (r = 0.75). Because the size of individual colonies varied considerably we 
wondered whether size is a detbllninant of colony growth. Under basal medium conditions 
no such correlation could be demonstrated between colony size and percent cellular growth 
as assessed by either thymidine uptake or colony size increments. 
The effects of individual growth factors on 'H-Thymidine uptake are presented in 
Table I. The results of two sets of experiments are presented separately. As compared to 
uptake under basal medium conditions we found a stimulatory effect of over 130% for 
EGF, KGF and aFGF in cells derived from both BPK and control mice. TGFB significantly 
inhibited the thymidine uptake of both cell populations (61% of basal uptake). HGF and 
IGF-I inhibited the thymidine uptake to a lesser extent and in control cells only.The 
proliferative response to exogenous EGF was significantly different for BPK and control 
cells. This observation was later confirnled by the second set of experiments. BPK derived 
cells demonstrated a higher proliferative response to EGF than conh·ol cells (mean increase 
over BM-growth for BPK 239% and for control 131%, p < 0.001). A similar pattern of 
growth factor induced proliferative responses was noted when measuring colony size 
increments (Table 2). TI,is parameter appeared to be less sensitive than the thymidine 
uptake assay. 
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A 
Fig.6 Ultrastructural characteristics of a cellular monolayer cultured from a common bile duct 
explant derived from a 20 day old Balh/C control mouse and cultured for I week. A:. Overview, 
featuring elongated cells with a rough apical surface, microvilli, extensive intercellular 
digitations, apical secretory vesicles, iysosomes, mitochondria and large nuclei with indentations 
and a regular chromatine pattern (x 18.750). B: Rough endoplasmatic reticulum with ribosomes 
as well as frce ribosomes can he identified at higher magnification. Tight apical cell-cell contact 
includes desmosomcs (x 82.500). 
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Fig.7 Longtudinal section of a nomlal 
conmlon bile duct stained with a polyclonal 
anticytokeratill antibody (diaminobenzidine 
x 200). 
Fig. 8 First passage biliary epithelial cells 
stained with polyclonal anti human 
cytokeratin antibody (diamirlObenzidille x 
200). 
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Table 1. The effect of growth factor supplementation on the uptake of'H-Thymidine by 
control and BPK cell cultures. 
Control BPK 
Exper. Factor dpmimmL Percent dpm/nunL Percent 
ofBM ofBM 
BM 39 (17) 29 (16) 
EGF 46 (17) lIS 76 (31)' 262 ## 
IGF-I 29 (12) * 74 29 (15) 101 
HGP 29 (S) * 75 29 (19) 100 
2 BM 39 (19) 30 (24) 
EGF 56 (30) * 143 65 (42) ** 217 # 
aFGF 54 (17) * 139 40 (29) 133 
KGP 61 (32) * 156 49 (30)" 169 
IGP-ll 50 (44) 109 30 (16) 100 
TGPJl 24 (IS) * 61 18 (19) * 64 
The uptake of 3Hw Thymidine by primary biliary cell cultures derived from BPK and control 
animals in the presence or absence (BM) of various growth factors. Data from 2 sets of 
experiments arc presented separately and expressed as mean (sd) desintcgrations per minute per 
surface area of the cell colonies (lO·2dpm/mm2) (11=25-30 for each data point ), The growth factor 
data are additionally presented relative to the thymidine uptake in defined basal medium. 
* p<.05, growth factor vs BM; ** p<.OO I, growth factor vs 8M 
# p<.05, BPK vs control; ## p<.OO I, BPK vs control 
Table 2. The effect of growth factor supplementation on 24-h colony growth of 
control and BPK cell cultures. 
Control BPK 
Percent Percent 
Factor Growth ofBM Growth ofBM 
BM 32 (17) 26 (11) 
EGF 42 (14) ## 131 42 (17) ## 157 
aPGP 36 (9) 110 30 (12) 113 
KGF 30 (14) 93 30 (18) 114 
HGP 29 (19) 90 26 (14) 99 
IGP-I 29 (9) 80 23 (10) 85 
IGP-II 33 (22) 102 30 (14) 112 
TGP3 28 (15) 87 18 (8) ## 67 
Colony growth of primary biliary cell cultures derived from BPK and control animals in the 
presence or absence of various growth factors, Data arc expressed as mean (sd) perccntual 
increase of surface area during 24·h observations (n=25·30 for each data point), Growth factor 
data are additionally presented relative to growth in basal medium (% over BM). #ff p<.OO I, 
BPK vs control 
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\Ve have recently reported a new murine model of autosomal recessive polycystic 
kidney disease expressed in the Balblc BPKlBPK mouse strain (18). In affected animals 
both renal tubnlar and biliary intra- and extrahepatic epithelial hyperplasia were early 
features of disease as in human ARPKD. \Ve noted that this dual organ epithelial 
hyperplasia preceded the overall disruption of nannal organ architecture that is 
characteristic of more advanced disease stages. Our cunent data on in vitro growth 
characteristics of biliary epithelial cells from I3PK mice may therefore reflect early 
mechanisms involved in the development of hepatic lesions in PKD. 
Our system of primary cultures of extrahepatic biliary cells carries several potential 
advantages over culture systems based on cell isolation from hepatic tissue. The relative 
simple stl1lcture of the common bilednct pennits isolation by lnicrosurgelY only. The 
excellent homogeneity of the obtained epithelial cell population makes further isolation 
steps unnecessary. This prevents the potential hazard of unwanted selection of epithelial 
cell subsets by stringent isolation procedures. Moreover surgical isolation allows 
straightforward matching of control cells. The confounding effect of isolation steps 
mandatory for whole organ derived cell suspensions can be omitted. Since such steps are 
based on physical and biochemical cell properties they may act differently on control and 
affected cells, consequently complicating the matching process. 
Biliary epithelial cells have been isolated and cultured by others from either the 
intrahepatic biliary tract or the gallbladder from various animal species (l9, 22-24). None 
of these methods could be used in the CUlTent study. The reported methods necessary for 
isolation and consequent propagation of biliary cells from liver homogenates potentially 
affect the characteristics of the obtained cell population through less than perfect 
purification and through selection. Methods using the gallbladder as an epithelial cell 
source could not be used in the cunent study because of its small size in mice and foremost 
since the gallbladder was the only apparantly unaffected part of the biliary tract in the 
murine disease model. 
The linear growth pattem which was maintained up to ten days of culture allows the 
comparison of the growth characteristics of BPK and control derived cell colonies. The 
two parameters used in this study to assess colony growth, surface area increment and 
thymidine uptake, conelate well when measured simultaneously in individual colonies 
under basal medium conditions. However the effect of growth factor supplementation on 
these 2 parameters (Table 1) was disparate in some cases. The fact that growth factor 
effects on colony size were assessed over the first 24 hours of factor supplementation 
while the thymidine uptake was measured during the following 6 hours may explain this 
apparent disparity. 
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Because the colony growth curves of BPK derived cell colonies in selUm free basal 
medium were not different from controls, we had the opportunity to test the proliferative 
response of the cells to specific growth factors. Several significant growth factor effects 
were noted in both BPK and controls. Only EGF repeatedly induced a significantly higher 
effect in BPK derived cell colonies when compared to controls. The potential biological 
significance of the increased sensitivity of BPK derived bilialY epithelial cells to EGF is 
highlighted by the reported secretion of EGF from the circulation into the bile in an 
immunoreactive and biologically active fonn. Moreover the appearance of intact EGF in 
bile of suckling rats is several-fold higher than in adult rats (25). In addition cultured bile 
duct epithelial cells are known to be capable of receptor mediated binding and endocytosis 
ofEGF (26). 
Such findings parallel data from renal cystogenesis in PKD. Overexpression of the 
EGF receptor and of it's messengcrRNA has been demonstrated using whole kidney 
homogenates from both human (12) and murine (13) cystic kidneys. In additon abnormal 
localization of the EGFR to the lumenal membrane of renal tubular epithelia in contrast to 
the nOimal basolateral localization has been reported for human as well as murine PKD 
(14). The biological significance of these findings is demonstrated by the report of 
mitogenic concentrations of EGF in cyst fluid (15), the increased EGF induced mitogenic 
response of human cyst derived cells (16) and die cystogenic properties of EGF in 
metanephric organ culture (27) and in cultures of normal kidney cells in collagen gel (28). 
In conclusion we report a reproducable semm free cell culture system in which 
minimal selection by isolation procedures and excellent homogeneity of the cell colonies 
provide optimal conditions for the study of normal and abnomral biliary epithelial cell 
growth in murine PKD. The demonstration of increased sensitivity of BPK-derived cells 
specifically to the proliferative effect of EGF contributes to the hypothesis that epithelial 
hypelproliferation is an underlying pathogenic mechanism of the renal and biliary lesions 
in PKD and that abnormal regulation of the EGFIEGF receptor is involved in this process. 
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autosomal dominant polycystic kidney disease type 1. 
Abstract 
Human autosomal dominant polycystic kidney disease (ADPKD) is a high incidence 
disorder, leading to renal failure in many patients. The majority of cases results from a 
mutation in the PKD I gene. The only well documented animal model of ADPKD is the 
Han:SPRD-Pkd sh·ain. Its genetic basis is unknown as yet. In the cunent study we 
determined whether the disease in these rats is genetically linked to the rat homologue of 
the PKDl gene. We used the protamine gene as a polym01phic marker (Prllll) of the 
PKD I region. Matings of Han:SPRD-Pkd with BB rats and backcross of the offspring 
with BB yielded animals infoffimtive for linkage analysis. This analysis revealed random 
segregation of the defect and the PI'1Il1 marker, indicating that the model is not caused by 
a mutation in the PKD I gene. We conclude that the Han:SPRD-Pkd rat strain is not a 
genetic model of PKD I. 
Introduction 
Human polycystic kidney disease (PKD) is one of the most common inherited disorders 
(Welling 1996). Two subtypes can be recognised: Autosomal dominant PKD (ADPKD) 
typically presenting during adult life and autosomal recessive PKD (ARPKD) leading to 
renal failure, either prenatally 00 during early childhood. These subtypes are distinct in 
terms of clinical presentation, histopathology and paUem of inheritance. ADPKD has an 
incidence of I in 1000 and gives rise to considerable morbidity. The major feature of the 
disease is cystic enlargement of the renal tubules leading to destmction of the normal renal 
architecture, typically resulting in end stage renal failure during adult life (Gabow et al. 
1992). 
Recent shldies in affected families explored the genetic basis of ADPKD. Locus 
heterogeneity has been established with at least two genes that independently can cause the 
disease. The locus involved in 85% of the families with ADPKD (now called PKD I) has 
been linked to the tip of the short ann of chromosome 16 (Reeders et al. 1985). Most of the 
remaining cases of ADPKD have been linked to a locus on chromosome 4 (PKD2) ( 
Kimberling et al. 1993, Peters et al. 1993 ). In addition, families have been reported in 
which the mutation must have occurred in a third gene which has not been localised as yet 
(Daoust et al. 1995). The PKDl gene has been identified by the European Polycystic 
Kidney Disease Consortium (1994). This group analysed a chromosomal translocation 
associated with ADPKD that dismpts a gene encoding a 14 kb transcript in the PKD I 
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candidate region. Mutation analysis in PKD 1 patients cOllfInned that the gene involved is 
the PKD I gene. Recently full length genomic and cDNA sequences of this gene have been 
published ( Intemational Polycystic Kidney Disease Consortium 1995, Hughes et al. 1995 
). The gene product, Polycystin, is predicted to be an integral membrane protein with 
several extracellular domains. These domains are suggested to be involved in protein~ 
protein interactions or protein-carbohydrate interactions. Polycystin may therefore playa 
role in cell-cell and cell-matrix conllmnications (American PKDI Consortium 1995). 
The study of genetically transmitted PKD in animal models has the potential of 
identifying specific cystogcnic gene products as well as biological and environmental 
factors that modulate the formation and progressive enlargement of the cysts. Genetically-
transmitted renal cystic diseases have been described in mouse, rat, rabbit, cat, dog, 
antelope and pig (Avner et al. 1990, Nauta et al. 1993, Aziz 1995). 11,e Han:SPRD-Pkd rat 
strain described by Kaspareit-Rittinghausen and subsequently in more detail by others is 
the best documented animal model of inherited PKD with an autosomal dominant 
inheritance pattem, resembling several fcatures of the human disease (Kasparcit-
Rittinghausen et al. 1991, Gretz 1992, Cowley et al. 1993). This model has been used to 
study the cystogenic process as well as the progressive nature of renal cystic diseases ( 
Gretz et al. 1994, Schafer et al. 1994, Tones et al. 1994, Zeier et al. 1994, Cowley et al. 
1996 ). 
In contrast to the detailed documentation of the Han: SPRD-Pkd phenotype no 
information is available as yet on the genotype of this rat model of PKD, We wondered 
whether the disease in these rats results from a mutation in the PKD 1 gene, This gene is 
involved in most human cases of ADPKD and is conserved in rodents (European PKD 
Consortium 1994). Here we report a linkage analysis of the disease with the PKDI region 
using the protamine gene PrlJl 1 as a genetic marker. According to recent reports tIns 
polymOlphic gene is located near the PKD 1 gene in humans as well as in rats (Yeung et 
a1.l993, 1994, Kobayashi et a1.l995) . 
Materials and methods 
Allill/ois olld breedillg program 
Han: SPRD-Pkd rats heterozygous for the PKD mutation were kindly provided by Dr. F. 
Deerberg in Hannover. A breeding colony was established and maintained for 5 
generations using brother-sister matings, Animals homozygous for the disease die at 3 
weeks of age and can be identified by physical examillation I to 2 weeks after birth. 
Heterozygotes are detected either retrospectively when h'ansmitting PKD or at postmortem 
by renal histology. 
The polymorphic Prmi locus was selected as a genetic marker linked to the PKD I 
gene. This Prllli locus exhibits a diallelic "restriction fragment length polymorphism" 
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(RFLP). Southem blots ofEcoRI digested genomic rat DNA were hybridised with a Prm} 
cDNA probe. TIlis revealed 2 different DNA fragments, sized approximately 9 and 12 kb. 
All rats of our Han:SPRD-Pkd colony are homozygous for the 12kb allele (see results). In 
order to obtain infOlmation with respect to the Prml RFLP, a crossbreeding program was 
set up using a Han:SPRD-Pkd male known to be heterozygous for PKD and 2 female BB 
rats and backcross of the offspring with BB (Yeung et al. 1993). BB rats are maintained at 
our instihltion as an inbred colony and were kindly provided by Dr H.A. Drexhage, Dept 
of Immunology, Erasmus University. This strain was selected for the crossbreeding 
experiments because it proved to be homozygous for the 9kb allele (see results). Backcross 
of 9 females with BB males «BBxSPRD-Pkd)FlxBB) yielded informative N2 offspring 
being either unaffected or heterozygously affected by the disease causing mutation. The 
offspring was killed at 3 weeks of age for DNA isolation and histological detennination of 
heterozygosity. 
DNA isolation 
Genomic DNA was isolated from spleen using the simplified mammalian DNA isolation 
procedure according to Laird et al. (1991). DNA was digested ovemight with the 
restriction enzyme EcoRI at 37°C, separated on a 0.7% agarose gel and blotted overnight 
to Hybond-N+ (Amersham) in lOx SSe. Southem blots were hybridized with a 32p_ 
labeled mouse cDNA Prm} probe (kindly provided by Dr. R. Yeung, Fox Chase Cancer 
Center, Philadelphia), overnight at 55°C in 10 x Denhardts, 10% dextran sulfate, 3 x SSC, 
0.1% SDS, SmicrogrimL salmon spenn DNA .. Blots were briefly washed twice in 3 x 
SSC, 0.1 % SDS at room temperahlfe, followed by 20 minutes at 60°C in 0.3 x SSC, 0.1 % 
SDS. The signal was detected using a phosphor imager. 
Statistics 
Linkage was tested using both chi-squared and lod score analysis using the MLINK 
program ofthe LINKAGE package ( Lathrop et al. 1984 ). 
Results 
Southem blot analysis of EcoRI digested genomic DNA samples of Han:SPRD-Pkd rats, 
using Prm} as a probe revealed homozygosity for the 12 kb allele in all tested animals. To 
obtain an infommtive situation for the Prill} RFLP, other rat strains were analysed. The 
inbred strain of BB rats showed homozygosity for the 9kb fragment. TIlerefore this strain 
was selected to set up a cross with Han:SPRD-Pkd. Nine female crosses of BB x 
Han:SPRD-Pkd (FI) were backcrossed to BB resulting in an N2 in which six out of 9 
litters included offspring with cystic kidneys (heterozygotes) as detected by histOlogy at 3 
weeks of age (fig. I). The remaining 3 unaffected litters consisted of at least 10 animals 
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A B 
Figure 1. Representative kidney sections of Han:SPRD-Pkd x BB backcross progeny at the age 
of three \'leeks. Panel A: Unaffected animal. Panel B: Affected animal with early cysts in the 
subcortical region. Arrow = glomerulus, C = renal cortex, M = renal medulla. (Hematoxylin x 
100 ) 
each. Four of the couples that produced affected litters had a second N2 litter. Within the 
total of 10 affected litters PKD could be demonstrated in 22 of 60 female and 29 of 67 
male animals. The cysts were histologically similar to the lesions in Han:SPRD-Pkd rats. 
Samples from 42 cystic animals were used for DNA analysis. Given the previously 
established tight linkage (3.9% recombination) between Prllll and the Eker mutation, 
located adjacent to the rat homologue for PKD I, it was to be expected that of the cystic 
animals (heterozygous for the pkd mutation) a majority of approximately 96.1 % would be 
heterozygous at the Prill I locus and that only 3.9% would be homozygous for the 9 kb 
Prml allele as a consequence of a recombination between the disease locus and the Prllll 
polymOlphism (Yeung et al. 1993). In our experiments we observed however that 23 out of 
42 affected rats were homozygous for the 9kb allele (Figure 2, Table I). 
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Figure 2. Absence of linkage between the PKD phenotype and the protamine gene, Prml. The 
probe detected a 12-kb DNA fragment in the Han:SPRD-Pkd strain and a 9-kb DNA fragment in 
the BB strain. The 12-kb fragment did not cosegregate with the presence ('affected') or absence 
Cunaffected') of renal cysts in the Han:SPRD-Pkd x BB backcross progeny (N2). 
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A chi-squared test against the expected prop0l1ion of recombinants yielded significant 
evidence against such tight linkage (chi-square = 29S.4, P < 10'6 ). Lod score analysis also 
provided strong evidence against linkage, a region of 36 cM on either side of the Prill I 
locus can be excluded as location for the PKD locus in the Han:SPRD-Pkd rat. 
Discussion 
This study indicates that the Han:SPRD-Pkd strain is not a genetic model of PKD I. This is 
concluded from the absence of genetic linkage of the SPRD-Pkd mutation with the PrlllI 
gene. Consistent with previous reports Prill I was found to be a diallelic genetic marker 
expressing DNA fragments with an estimated size of 9 and 12 kb respectively (Yeung et 
al. 1993). TIle apparent difference in size when compared to fragments reported by Yeung 
et al. ( 9.5 and 15 kb) is most likely based on inaccuracy of sizing in this size range. The 
validation of Prill] as a marker of the PKD I locus is based on the following combination 
of reports. The human Prill I gene was localised near the PKDI gene (Reeders et al. 1990). 
In rats the PrlllI gene has been located on chromosome 10 and linked to a gene involved in 
the Eker rat model of Renal Carcinoma (lodscore = IS) (Yeung et al. 1993). The genetic 
distance between the PrmI gene and the Eker mutation was estimated to be 3,9 cM. The 
Eker mutation has recently been located within the rat homoloque (Tsc2) of the human 
tuberous sclerosis 2 (TSC2) gene (Yeung et al. 1994). As in humans ( European PKD 
Consortium 1994 ), the rat Tsc2 gene has been localised adjacent to the PKD I gene in a 
tail-to-tail orientation (Kobayashi et al. 1995 ). The intergenic distance between these two 
genes is very small (approximately 60bp) and highly conserved between human and 
rodents (Ollson et al.). This indicates that the genetic distance between Prill] and the rat 
homologue of PKD I equals the 3,9 cM distance between Pr", I and Eker. 
Our results suggest incomplete penetrance of PKD in young pups of our crosses. In 10 
affected litters we observed renal cystic disease in only 51 of 127 pups. This is less than 
the 50% predicted by a Mendelian pattern of inheritence, suggesting that not all mutants 
express the cystic phenotype at this age. Incomplete penetrance indicates heterogeneity of 
disease expression and suggests the involvement of genetic or environmental factors 
modifying the expression of disease in addition to the primary genetic defect. Whether this 
pattern of incomplete penetrance matches a similar pattern of disease expression in the 
original Han:SPRD-Pkd mutants can not be established since no systematic studies of 
heterozygous baby Han:SPRD-Pkd rats have been reported. We note that a variable 
expression of disease would not affect the outcome of the current linkage analysis because 
this analysis was restricted to phenotypically proven heterozygotes only. 
In contrast to reports on Han:SPRD-Pkd rats, our study of the BB x Han:SPRD-Pkd 
cross did not reveal a gender effect. Young male and female animals from the crossbreed 
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were equally affected. In adult Han:SPRD-Pkd rats, however, cystic males develop renal 
failure, while female animals with renal cysts maintain a normal renal function. Studies of 
a gender effect in baby Han:SPRD-Pkd rats have not yet been reported. TIle lack of a sex 
effect in our rats may reflect the prepubertal stage of the animals studied. At this age 
sexual endocriue differentiation has not yet been completed. In addition, any possible 
phenotypical difference between our crossbreed and Han:SPRD-Pkd may be explained by 
differences in genetic background. It is likely, that disease modifying genetic factors are 
different between the iubred BB strain used for this study and the SPRD strain in which the 
mutation originally arose. Such strain associated genetic modfying factors have also been 
reported for other animal models ofPKD (Guay-Woodford et a1. 1996). 
Our observation questions the value of the Han:SPRD-Pkd strain as a model of human 
disease. The affected gene in these rats is different from the gene affected in most human 
patients with ADPKD: the PKDl gene. Nevertheless we still consider the Han:SPRD-Pkd 
rat a valuable model of inherited renal cyst formation, because this model may still serve 
the study of genetical, pathophysiological as well as clinical aspects of human cystic 
disease states. 
Han:SPRD-Pkd may still be considered a candidate for the genetic homologue of one 
of the non-PKD1 types of human renal cystic diseases (Welling et a1. 1996). These include 
ADPKD type 2 localised on chromosome 4 (Kimberling et a1. 1993, Peters et a1. 1993 ), 
autosomal recessive polycystic kidney disease localised on chromosome 6p21 (Zenes et a1. 
1994), medullary cystic disease and nephronophthisis localised on chromosome 2p 
(Antignac et a1. 1993). Linkage analysis of the rat model with loci thought to be involved 
in these human diseases awaits the definition of appropriate genetic markers in the rat. 
In addition Han:SPRD-Pkd rat is still considered one of the best animal models 
available for physiological, nutritional and biomedical research of PKD. Its phenotypical 
similarities with human disease states made it the subject of a number of clinical, 
experimental and pathophysiological studies. Such studies suggest that different forms of 
human and experimental renal cysts share conunon pathways regarding both 
pathophysiology and clinical expression. Pathophysiological phenomena observed iu both 
human PKD and Han:SPRD-Pkd iuclude the involvement of all nephronsegments, the 
proliferation of cyst lining epithelial cells (Grantham et a1. 1987, Kaspareit-Rittinghausen 
et a1. 1991) - associated with increased proto-oncogen expression as was shown in the rat 
model (Cowley et a1. 1993), thickened and multilaminated basement membrane 
abnOlmalities in areas of cellular immaturity (Cowley et a1. 1993,Wilson et a1. 1991) and 
sex-dependent differences in clinical and histological severity of the disease indicating that 
other factors can alter the expression of the primary genetic defect in polycystic kidney 
disease (Cowley et a1. 1993). Clinical similarities of human ADPKD and Han:SPRD-Pkd 
include (Kaspareit-Rittinghausen et a1. 1991) the mode of inheritance, the slow progression 
to end stage renal failure iu heterozygotes, the presence of proteinuria and hypertension 
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during the progression of disease, as ,veIl as the phenomena associated with renal failure 
inclnding anaemia, renal osteodystrophy and hypercholesterolaemia. 
We conclude that the Han:SPRD-Pkd rat is not a genetic model of ADPKD type 1. 
Nevertheless this rat strain is still considered to be a valuable animal model of human PKD 
and chronic renal failure. 
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A new rat model that phenotypically resembles autosomal 
recessive polycystic kidney disease. 
Abstt'act 
Numerous murine models of polycystic kidney disease (PKD) have been described. While 
mouse models are particularly well-suited for investigating the molecular pathogenesis of 
PKD, the rat is well-established as an experimental model of renal physiology. The 
Han:SPRD CJ' rat has been proposed as a model for human autosomal dominant PKD. We 
have now identified a nev.' spontaneous rat mutatioll, designated wpk. The mutant 
phenotype resembles human autosomal recessive PKD (ARPKD). The current study was 
designed to characterize the clinical and histopathologic features of wpklwpk mutants and 
to map the wpk locus. Homozygous mutants developed llephromegaly, hypertension, 
proteinuria, impaired urinary concentrating capacity, and uremia, resulting in death at 4 
weeks of age. Early cysts were present in the nephrogenic zone, at embryonic day 19. 
These were localized by specific staining and electron microscopy to differentiated 
proximal tubules, thick linlbs, distal tubules and collecting ducts. In later stages the cysts 
were largely confmed to collecting ducts. While the renal histopathology is strikingly 
similar to human ARPKD, wpklwpk mutants had no evidence of biliary tract abnOlnlalities. 
The wpk locus maps just proximal to the cy locus on rat Chromosome 5, and 
complementation studies have demonstrated these loci are not allelic. 
We conclude that the clinical and histopathologic phenotype of this new rat model strongly 
resembles human ARPKD. While homology mapping indicates that rat wpk and human 
ARPKD involve distinct genes, this new rat mutation provides an excellent experimental 
model to study the molecular pathogenesis as well as the renal pathophysiology of 
recessive PKD. 
Introduction 
Renal cystogenesis occurs with a number of inherited, developmental, and acquired 
diseases (I). A COnmlOI1 feature among this otherwise heterogeneous set of disorders is the 
development of epithelial-lined cysts arising from various nephron segments and the 
collecting ducts. 
Of these conditions, the inherited renal cystic diseases have been most extensively 
investigated. These disorders} which are transmitted as single Mendelian traits, include: 
1). autosomal dominant polycystic kidney disease (ADPKD), 2). autosomal recessive 
polycystic kidney disease (ARPKD), 3). juvenile nephronophthisis-medullary cystic 
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disease complex (IN-MCD), 4). tuberous sclerosis complex (TSC), 5). von Rippel-Lindau 
(VHL) disease, and 6). several multiple malfoilllation syndromes (reviewed in (2,3)). 
These disorders cause significant morbidity and mortality in both adults and children. For 
example, ADPKD causes 6-8% of adult end stage renal disease (ESRD) (2). In ARPKD, 
30-50% of affected neonates die in the perinatal period. Surviving ARPKD patients, 
coupled with children who have IN, comprise 6-14% of all pediatric ESRD patients (4,5). 
Recent genetic studies have identified the principal genes involved in ADPKD (PKD 1 
and PKD2), IN (NPHPI), TSC (TSCI and TSC2) and VRL (VHL) (6-15). In addition, 
linkage studies have defmed the predominant, if not exclusive locus for ARPKD 
(PKHDI), as well as distinct loci for several of the malfOlmation syndromes (16-18). 
While many of these disorders are inherited as dominant traits, multiple lines of evidence 
suggest that a second, somatic mutation in these disorders is necessary for disease 
expression (19-27). TIlliS, like ARPKD and IN, ADPKD, TSC, and VHL are thought to 
involve recessive mechanisms at the cellular level. In addition, recent evidence indicates 
that some of these genes interact, either directly at tile protein level or in the pathogenesis 
of cystic disease (28-30). Together, these data suggest that inherited human cystic disease 
is initiated by cellular recessive mechanisms and conmlOll molecular pathways may be 
involved in different cystic diseases. However, the molecular pathogenic events involved 
in the initiation and progression of renal cystic diseases remain largely unknown. 
In addition to these human renal cystic disease genes, numerous murine (mouse and 
rat) models of polycystic kidney disease (PKD) have been described. Most models involve 
dismption of a single gene and the mutant phenotypes closely resemble human PKD with 
regard to morphology, cyst localization and disease progression. Several models are the 
result of spontaneous mutations (31-42), while others were engineered either through 
chemical mutagenesis (43) or transgenic technologies (44-59). In addition, experimental 
models of PKD have been induced by chemical cystogens, primarily in rats (reviewed in 
(60)). 
Investigations of the murine model systems have identified several common 
pathogenic features) that are common to both murine PKD models and human disease. 
These include: (1) dysregulated epithelial cell proliferation and differentiation; (2) 
alterations of tubular basement membrane constihtents and the associated extracellular 
matrix; (3) abnormalities of epithelial cell polarity with apical mislocalization of key 
receptors and enzymes; and (4) abnormalities in transepithelial fluid transport. 
In addition, gender and genetic background also appear to modify the disease course 
in both murine and human PKD (2,61-63). Recent investigations suggest that a modifying 
gene) Jckm2, 011 distal chromosome 1 may influence the disease phenotype of the mouse 
jck, bpk, and kat models (64-66) while a locus on proximal chromosome 4 appears to 
modify the disease severity in the cpk, pc)" and bpk models (65,67,68). 
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Therefore, a multigenic pathway appears to be involved in renal cystogenesis in both 
human PKD and murine models. In both human disease and these animal models, the 
disease-susceptibility genes appear to act by cellular recessive mechanisms. While the 
numerous mouse PKD mutations provide powerful models to characterize the genetic 
factors that regulate renal cyst initiation and disease progression, these models have 
limited utility with regard to renal physiologic investigations. In contrast, the rat is a well-
established model system for investigating renal physiologic parameters such as renal 
blood flow, glomemlar filtration rate, renal tubular transport and blood pressure regulation. 
Among the genetically-determined and chemically-induced rat PKD models, only the Han 
SPRD: cy rat has been well characterized (62). This rat mutant has been proposed as a 
model of human ADPKD. 
In this report, we describe a new rat PKD model. Affected homozygotes develop 
rapidly progressive PKD that clinically and histologically resembles human ARPKD. This 
mutation occurred spontaneously in an outbred Wistar strain. We therefore have 
designated the mutant locus, wpk (wistar polycystic kidneys). We have localized wpk to 
Chromosome 5. This locus is distinct from the rat Han SPRD: cy locus, and its mouse and 
human orthologs are not allelic with any previously described mouse PKD model or 
human PKD gene. However, based on its phenotypic similarities with human ARPKD, the 
wpk rat provides a new experimental model for investigating the pathogenesis of recessive 
PKD. Given that renal physiology has been well-studied in the rat, the wpk rat should 
provide the first model system to evaluate the abnormalities in renal tubular transport and 
systemic blood pressure regulation associated with recessive PKD. 
Materials and Methods 
Rats 
The wpk mutation was fust recognized in 1994 in a colony of outbred Wistar rats, U: WU 
(Cpb), at Utrecht University, The Netherlands. This breeding colony was initiated in 1989 
from 10 ancestral breeding pairs obtained from the 'National Institute of Public Health and 
the environment (RIVM)", Bilthoven, The Netherlands. No new rats were introduced to 
the colony from 1989 to the present. In 1996, a breeding pair of test-proven heterozygotes 
were trallsfelTed to the University of Rotterdam, TIle Netherlands, and a new subcolony 
was initiated. This colony has been maintained by brother x sister matings for over 5 
generations. Individuals heterozygous for the mutant allele were identified in each 
generation by test-crossing phenotypically normal offspring from known heterozygotes. 
The Han:SPRD-cy rat model of PKD (40) was used for complementation experiments 
and as a phenotypic reference for our evaluation of the homozygous wpk/wpk rats. In this 
model, +/cy heterozygotes develop slowly progressive PKD that leads to renal failure in 
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males only, at .:::: six months of age, whereas cy/cy homozygotes develop a severe fann of 
PKD within the fIrst few weeks of life. Heterozygous Han:SPRD +ley breeding pairs were 
kindly provided in 1994 by F. Deerberg (Central Institute for LaboratOlY Animal Breeding, 
Hannover, Gellnany) and a breeding colony was established at the University of 
Rotterdam. BB-DP rats, an inbred strain (F30) derived from the biobreeding-diabetic prone 
rat were kindly provided by H.A. Drexhage (Dept ofimmunology, Erasmus University). 
To map the II'pk locus, Wistar-+lwpk heterozygotes of both sexes were bred to BB-DP 
rats, and Fl progeny heterozygous for the wpk mutation were intercrossed to generate F2 
rats. Affected homozygotes could be identifIed by abdominal palpation at postnatal day 12. 
All animals were fed standard rat chow containing 24% protein and had free access to 
acidifIed tap water. All experinlents were conducted in accordance with the Dutch 
guidelines for the care and use of laboratory aninmls. 
Clillical pal'flmeteJ's 
Kidney weight, body weight, blood pressure, and urine and blood chemistries were 
assessed in groups of 6-8 rats at the age of 3-4 weeks. Affected wpklwpk rats were 
compared to phenotypically unaffected Iittelmates. Affected cyley rats were compared to 
+1+ Iittemmtes. In contrast to +/IIJlk heterozygotes, +ley rats could be identifIed 
histologically and these pups were excluded from further analysis. 
The weights of the left and right kidneys of wpklll'pk homozygotes did not differ. The 
kidney weights were thus combined and expressed as percentage of body weight. Data 
from male and female pups were pooled, since gender effects were never obsen/cd in 
prepubertal animals. 
Bloodpressure was measured in 6 pairs of 3-4 weeks old rats anesthetized with 
ketamine and thiopental, using an indwelling catheter in the femoral artery. Blood was 
obtained by cardiac punchlfe in six pairs of IIJlMIJlk homozygotes and unaffected 
littennates. Plasma urea nitrogen, creatinine and total bilimbin were measured in the 
plasma using Kodak Ektachem 700 spectrophotometry. Urine was collected after 2 hours 
of fasting in 4 weeks old affected and unaffected wpk rats. Urinary creatinine was 
measured by the Jaffe method and urinary protein by absOlption spectroscopy. 
In older animals, urinary protein excretion, blood pressure and blood chemistries were 
compared between test proven heterozygous +/lIJlk rats and wild-type controls at the age 
of 1.5 years for females and 1 year for males. Urine specimens were collected over 24 
hours using a metabolic cage. Blood pressure was determined by tail plethysmography. 
The aninlals were trained for this procedure prior to the measurements (69). Blood was 
obtained by aortic puncture under ether anesthesia. 
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For histological analysis, kidneys were obtained from wpk!wpk and conti·o! animals on 
embryonic day 19 and on postnatal days 0, 7, 14 and 21. The cystic phenotype was 
established by histology. A multiple~organ autopsy, including healt, lung, liver, pancreas, 
spleen, brain and intestine, was performed on 21 day old homozygous mutants and on 
adult heterozygotes. Heterozygous females were studied at the age of 1.5 years and males 
at the age of 1 year. 
For light microscopy and immunohistochemistry, the kidneys and livers were fixed in 
4% parafolmaldehyde in phosphate buffered saline (PBS), pH 7.4 and embedded in 
paraffin. For liver histology, the left ventral lobe was dissected, fixed in 4% 
parafonnaldehyde in PBS, and embedded in paraffin with the convexity to the surface of 
the block. 
For electron microscopy (EM) representative samples of the kidneys were fixed in 
2.5% glutaraldehyde, postfixed in 1 % osmiumtetraoxide, and dehydrated in graded alcohol 
series. For scanning EM (SEM) the samples were then critical point dried, mounted on 
stubs, coated with goldlpaladium and examined in a JEOL JSM 25 scanning electron 
microscope. For transmission EM (TEM) the fixed and dehydrated samples were 
embedded in epon. Thin sections were stained with uranyl acetate and lead citrate and 
examined in a Philips CIOO electron microscope. 
Human kidney from a neonate with ARPKD and end stage renal failure was used as a 
comparative reference for the SEM analysis of wpklwpk kidneys. 
El'flillatioll oJlfle biliOlJ' ,llIelfl/ p/flfes 
In addition to the renal cystic lesion, the intrahepatic morphology was evaluated in six 
affected lIpklll'pk homozygotes and six phenotypically unaffected animals, aged 21 days. 
The depth and angle of liver sections was standardized for histological and morphometric 
analysis as previously described (35). Bile ductules and recognizable portal areas were 
systematically examined in each section by one blinded observer. A recognizable portal 
area was defined as a venule accompanied by one or more bile ducndes. 
Immlillollislocltem iSIIJ' 
The localization of the renal cysts was evaluated by inmmrlodetection of nephron segment-
specific proteins and lectin binding sites at postnatal days 0, 7, 14 and 21. Based on 
preliminary studies, the following reagents were selected. As a rat proximal tubular 
marker, we used polyclonal goat anti-rat dipeptidyl peptidase 4 (dpp4) (kindly provided by 
E. de Heer, Leiden) (70) at dilutions of 1:500. As a marker of the thin limb of Henle's loop 
(medulla) and proximal tubules (cortex) we used polyclonal rabbit anti-rat aquaporin I 
(Aqp 1) at 1:100 (generous gift ofP. Deen, University of Nijmegen, The Netherlands). As 
a marker of the thick ascending limb we used polyclonal rabbit anti-human Talllin Horsfall 
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glycoprotein (TH) at I :200 (Biomedical Technologies, Stoughton, MA, USA). As a 
marker of the cortical and medullary collecting tubules we used polyclonal rabbit anti rat 
aquaporin 2 (Aqp2) at 1:100 (generous gift of P. Deen, University of Nijmegen, TIle 
Netherlands). All antibodies were diluted in PBS, 0.5% dried milk, 0.15% glycine. 
Schafer et a1. have reported increased expression of collagen type IV and laminin in 
the renal cysts of 2 month old Han:SPRD +/cy rats (40). Therefore, for comparative 
pmposes, kidney sections from 21 days old Wi star wpklwpk rats, 21 day old Han:SPRD 
cy/cy rats and 2 month old +/cy rats, were analyzed with Jones' silver stain as ,yell as with 
a polyclonal rabbit anti-mouse collagen IV antibody at I :200 (Collaborative Medical 
Products; (71» and polyclonal rabbit anti-mouse laminin antibody at 1:50 
(Eurodiagnostica, Al11hem, The Netherlands; (72». 
The tissue sections were pretreated with pronase 0.1 % in PBS for 5-10 minutes prior 
to the incubations with anti-TH, anti-dpp4 and anti-Col IV and with 0.2% SDS in PBS for 
5 minutes prior to the incubations with anti-Aqp2. Anti laminill and anti aqp 1 were used 
without such pretreatment of the tissue sections. Primary rabbit antibodies were detected 
using swine anti-rabbit peroxidase conjugate at I: 100 (DAKO). Goat anti-dpp4 was 
detected using rabbit anti-goat peroxidase conjugate at 1:100 (DAKO). The sections were 
stained with 0.05% diaminobenzidine, 0.01% hydrogen peroxide and counterstained with 
hematoxylin. 
Slatistics 
Clinical data are expressed as means and standard deviations (SD). Differences 
between wpk and control animals were analysed by t-test. 
peR-based gellotypillg 
To type progeny for inheritance of alleles of anonymous DNA microsatellite markers, 
spleen genomic DNA was prepared according to standard protocols. Initial mapping was 
performed using interval haplotype analysis (73). For d,ese studies, we selected 
microsatellite markers whose Wistar and BB-DP alleles differed in size by at least 6 base 
pairs (bp) and which mapped within -10 centimorgan (cM) of proximal and distal ends of 
each chromosome. Once a chromosomal localization ,vas determined, fmiher mapping 
was performed using markers spaced at 20-cM intervals spaced along Chr 5 (Iow-
resolution linkage mapping Shldy) and then within 4 cM of D5Rat73 (high-resolution 
linkage mapping Shldy). All markers were chosen from the on-line WhiteheadIMIT 
database (accessible at http://www-genome.wi.mit.edu/; described by Szpirer et a1. (74». 
peR primer pairs for these markers were purchased from Research Genetics, Inc, 
(Huntsville, AL). 
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Forward primers were end-labeled with 32P-adenosine triphosphate, and peR 
amplification was perfonned as described by (75). Amplified fragments were analyzed on 
denaturing 6% polyacrylamide gels. 
Allalysis of genetic data 
Genotype data obtained by analyzing 35 affected F2 progeny for microsatellite markers 
known to map to the ends of each autosome were subjected to interval haplotype analysis 
exactly as described by Neuhaus and Beier (73». To constmct low- and high-resolution 
linkage maps, individual chromosomal haplotypes were inferred from F2 genotypic data as 
described previously (75) and markers were ordered so as to minimize the numbers of 
crossover events needed to account for the inferred haplotypes. 
Results 
Wistar-lI'pklll'pk phellotype 
OUf Wistar-+lwpk colony breeding has been maintained for over 5 generations using a 
scheme of brother-sister matings. Heterozygotes had a normal phenotype and bred as 
productively as wild-type Wistar rats. A typical litter contained 9 to 14 pups. As expected 
for an autosomal trait, approximately 1:4 offspring of test-proven heterozygotes expressed 
polycystic kidney disease (PKD) and males and females were affected in equal numbers 
(23.5% and 24.2%, respectively). Of note, approximately 10% of the Fl pups died within 
the first 2 weeks of posolatallife of as yet undetennined causes. 
Table. 1 Comparative clinical features at 3-4 weeks of age. 
Wistar Han SPRD: cy 
wpklll'pk Unaffected cy/cy +1+ 
Body weight (BW) 43.3 ± 6.8 48.2 ± 7.2 34.3 ± 3.5 38.1 ± 5.8 
KidneyweightIBWxl00 10.9±0.6* 1.1±0.1 21.8±1.4 * 1.0±0.5 
Blood pressure (mean) 139 ± 26 • 90 ± 10 NO NO 
Plasma urea 29.3 ± 2.8' 8.9 ± 0.7 51.2 ± 8.8 * 13.2 ± 1.7 
Urinary protein excretion 580 ± 307 * 33 ± 26 NO NO 
Urinary osmol. 394 ± 87 * 961 ± 584 NO NO 
Clinical features of homozygous mutants and unaffected littemmtes. Body weight (grams), kidney 
weight (% of body weight (% ofB\V) and plasma urea (nunollL) were studied in 3 week old rats; 
Proteinuria (mg/mmol creatinin), urine osmolality (mosmlkg) and mean blood pressure (nmlHg) in 
3-4 week old rats. Numbers are given as means ± SD. ND-not done, * p < 0.0 I VS, controls, 
The phenotype in homozygous mutants was characterized by progressive 
nephromegaly and abdominal distension. Nephromegaly was first palpable at posolatal day 
12. By 4 weeks of age, homozygous mutants were mnted and had large, palpable kidneys. 
Affected rats died at 4-6 weeks of age. The total kidney weight to body weight (KW IBW) 
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ratio at 4 weeks was greater than 10% (Table I). In comparison, the KW/BW was 1% in 
unaffected littennates and 20% in Han:SPRD cy/cy mutants at the same age. At tln·ee 
weeks of age, l1Ipklwpk hOlllozygotes had elevated plasma urea levels, proteinuria and a 
low urine osmolality after 2 hours fasting, relative to unaffected littennates. The mean 
arterial blood pressure assessed by direct measurement in the femoral artery was markedly 
elevated (Table I). The weight of the liver relative to kidney free-body weight and the 
plasma bilirubin levels were not significantly different in homozygous mutants versus 
unaffected littermates. 
Test-proven heterozygotes were clinically unaffected. There ,vas no significant 
difference between l8-month old female +/lI'pk heterozygotes and age-matched, wild-type 
controls with respect to body weight (345 ± 24 vs. 344 ± 29 grams); systolic blood 
pressure (135 ± 9 vs. 128 ± 7 nilll Hg); plasma creatinine (4l ± 4 vs. 46 ± 5 frmoVL) and 
(20 ± 13 vs. 27 ± 18 mg/dayllOO grams bodyweight). Similarly, one-year old males +/lIpk 
heterozygotes did not differ from age-matched controls with respect to BW (547 ± 31 vs. 
517 ± 25 grams); systolic blood pressure (130 ± 7 vs. 127 ± 8 nilll Hg); plasma creatinine 
(47 ± 5 vs. 49 ± 7 pmoVL) and urinary protein excretion rate ( 40 ± 26 vs. 38 ± 21 
mg/day/1 00 grams bodyweight). 
Pathology ofllpk/llpk kidl/eys 
At a gross level, neonatal wpklwpk kidneys had a normal architechue including normal 
lobulation, medullary rays, and a well defrned corticomedullary demarcation. In affected 
pups, the kidneys progressively enlarged but maintained a reniform shape, despite the 
progressive cystic changes in the parenchyma. The capsular surface was smooth. The 
renal pelvis and calices were not enlarged and maintained a normal relation to the 
parenchyma (fig. I). The ureters weIe present and non~di1ated. 111is pattent is VClY similar 
to that observed in the kidneys of 1mman ARPKD neonates. 
The histopathology was characterized by progressive cystic dilatation of renal hlbules. 
Early cysts were noted at 19 days of embryonic development (Fig. 2A,"). At this stage, as 
well as in neonatal kidneys, the lesions were predominantly localized to the renal cortex. 
The cysts were round or oval-shaped and lined by either a single layer of cuboidal cells or 
flattened epithelia (Fig. 2c). Some of the cysts were lined by a bmsh-border bearing cell 
type, suggestive of proximal tubular epithelia. The cell density of the epithelial lining is 
high in most, but not in all cysts. Glomcl1llar cysts were not observed. 
With subsequent disease progression, cysts developed throughout the entire kidney 
(fig. 2D) with cortical cysts arrayed in a radial orientation, while medullalY cysts were 
generally round in shape and of variable size. In kidneys with advanced cystic disease, 
there was an apparent reduction in the number of glomemli and non-dilated tubules and 
those remaining appeared to be compressed between imlUmerable tubular cysts. Interstitial 
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Fig. 1. Normal and cystic kidneys at 3 weeks of age ( x 2.3). The affected kidney has a well 
maintained renifonn shape, a smooth capsular surface and radially oriented cysts. The renal 
pelvis and ureters are undilated. 
fibrosis was not observed and the renal vasculature was unremarkable. In contrast to the 
early cystic kidneys, the cysts in more advanced disease were lined with a relatively 
homogenous cell type. Within individual cysts the cell density varied considerably. 
Interestingly, areas of high cell density were often juxtaposed to similar areas in 
neighbouring cysts (Fig. 2E). This observation suggests that focal epithelial cell 
proliferation within cysts may be detennined by the local biological environment. 
However, tTIle epithelial hyperplasia with associated polyps or microadenomas, as noted in 
human ADPKD (76), in eyley rats (40), and in the c-myc overexpression model of PKD 
(77), was never observed. 
1m IIlUIl 0"; sf ocll e Ill; sf I)' 
Cysts in neonatal kidneys stained either anti-dpp4, anti Tamm Horsfall protein, or (from 
day I onwards) anti-Aqp2 antibody, indicating cellular characteristics typical for proxiroal 
tubules, thick ascending limb or collecting tubules, respectively. Staining of medullary 
cysts with anti-Aqpl indicating a thin loop-derived cell type was rarely seen. Cortical cysts 
occasionally stained with anti-Aqp I in a weak pattel1l. These cysts were lined by a 
bl1lshborder baring cell type and also stained with anti-dpp4, indicative of proximal 
tubules. Each individual cyst was typically lined with only one cell type and overlapping 
staining patterns, other then Aqp I in proximal tubules, were not observed. By two weeks 
of age, the vast majority of cysts appeared to derive from collecting ducts, as the majority 
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Fig. 2. Lightmicroscopy of kidneys at different age. (A,B): Normal and cystic kidney at 
embryonic day 19. Clusters of cysts in the cortex suggest that adjacent cysts are dilations 
of tubular loops of the same nephron. Medullary cysts are markedly smaller ( Hematoxilin 
x 30). (C): Neonatal kidney with cortical cysts lined by various types of epithelium 
(Methylene blue x 120 (D): Cortical area of an end stage cystic kidney exhibiting large 
epithelial cysts. Glomerular cysts were not observed. The few glomemli and undilated 
tubules appear to be compressed between ilmumerable cysts (Hematoxilin x 30) (E) . TIle 
cell density varied considerably within individual cysts. Areas of high cell density were 
often juxtaposed to similar areas ill neighbouring cysts (methylene blue x 80 ). (F). 
Aquaporin-2 staining of the vast majority of cysts in a 3 weeks old cystic kidney 
(Diaminobenzidin, Hematoxilil1 x 100 ). 
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of cysts stained with anti-Aqp2. At three weeks of age, over 90% of the cysts expressed 
aqnaporin 2 (Fig. 2F). In comparison, renal cysts in 3-week old cylcy homozygotes 
appeared to arise from all nephron segments (data not shown). 
In wpklwpk homozygotes, the renal tubular basement membrane (TBM) morphology, as 
assessed by Jones' silver staining, was not significantly different between cystic tubules 
and normal tubules in either early or advanced disease. Moreover, there ,vas no difference 
in the expression of the TBM constituents, collagen type IV and laminin, when cystic and 
nOl1~cystic tubules were compared. In contrast, coHagen type IV and laminin were 
overexpressed in the TBM associated with some, but not all renal tubular cysts in SRPD-
+/cy and SRPD-cy/cy kidneys (not shown; (40)). 
Electroll microscopy 
Scanning elech'on nlicroscopy was consistent with the light microscopic observatiOl' that 
early and late cysts have different epithelial linings (Fig. 3). The cell surface 
characteristics in early cystic hlbules varied considerably between individual cysts. Some 
had a homogeneous brush border, charactistic of proximal tubules (fig. 3A). Others had 
more distal tubule or collecting duct characteristics, including less microvilli and a more 
smooth apical surface. Some had the typical characterisics of collecting ducts expressing a 
prominent single cilium, as illustrated for 3 weeks old tissue (fig. 3E). 
Cysts in kidneys with advanced disease were radially oriented. In contrast to early 
cysts, these cysts were unifOlnlly lined by a homogenous cobblestone cell-type, indicative 
of collecting duct origin (fig. 3B-D). These cells had the typical phenotype of principal cells, 
including a relatively smooth apical surface and a well-differentiated, conspicious single 
cilium (fig. 3E). TIlese cilia were prominently evident in the vast majority of cortical cysts 
and less prominent or absent in medullary cysts. In addition, the epithelial lining of most 
cysts contained a small number of rough-surfaced cells with characteristics previously 
described for rat type B intercalated cells (fig. 3F) (78). This mixed patten! of principal 
and intercalated cells is characteristic of cortical and outer medullary collecting ducts in 
the rat and is very similar to the patten! obselved in the vast majority of the cysts in our 
human ARPKD reference sample (fig. 30 .11) (78). 
Transmission electron microscopy was consistent with both the light microscopic and 
SEM fmdings. Early renal cysts in wpk/wpk rats were lined by well-differentiated cells 
with the phenotypic characteristics of either proximal tubules, thick ascending limbs, distal 
tubules, or collecting ducts (Fig. 4). Microvilli were well-fonned, cell junctions and basal 
lamina were intact, and the cell organelles were nonnally distributed. At 3 weeks of age, 
the vast majority of cortical as well as medullary cysts were lined by a homogeneous layer 
of cells that had the characteristic phenotype of collecting duct cells (79). Abnolmalities 
evident in human ADPKD and in the Han:SPRD cy/cy model, e.g. basement membrane 
thickening, intercellular vacuoles, or intratubular micropolyps were not observed (76). 
The basal laminae were intact with nOIDlal architecture and thickness. 
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Fig. 3. Scanning electron microscopy (SEM) of renal cysts on neonatal (A) and 3 weeks 
old (B-F) affected wpk/wpk rats and of an end stage human ARPKD kidney (O-H). (A): A 
neonatal wpk/wpk cyst lined by a bmshborder baring celltype, suggestive of a proximal 
tubular celltype. (B): A 3 weeks old wpk/wpk kidney. At low magnification radially 
alligned fusifonn cysts can be observed in the cortex and more rounded cysts in the 
medulla. (C): At this stage the cysts are densily packed and the epithelia of adjacent cysts 
lay often juxtaposed, with little interstitial tissue in between. Nomlal renal stmctures can 
hardly been identified. To be continued 011 next page. 
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Fig. 3. (Continued from previous page) (D): The vast majority of cysts are lined by a 
homogeneous cobblestone-like cell pattem. (E): Most cells have the typical characteristics 
of principle cells including a relatively smooth, rounded surface and a single cilium. (F): 
Other cells have the characteristics of intercalated cells, including a relatively rough and 
angular surface and no cilium. The microprojections are moderate in both size and number, 
as described for type B intercalated cells (78) (G): Human ARPKD cyst typically lined by 
a homogenous cobblestone-like cell pattem and (H) a mix of principle and intercalated 
cells. Magnification A x 6.500, B x 10, C x 100, D x 450, E x 6.500, F x 2.000, G x 650, H 
x 2.000. 
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Fig. 4. Transmission electron microscopy of renal lesions in neonatal (A,B) and 3 week 
old (C,D) wpkJwpk rats. A: Neonatal cyst lined by proximal tubular epithelium. The cells 
are characterized by a well differentiated bmshborder, an apical endosomal-lysosomal 
apparatus, a dense network of microtubules, normal intracellular organelles incJuding 
peroxisomes and many mitochondria which are short and randomly distributed. The basal 
lamina are regular and intact (x 4.000). B: Cortical cyst lined by collecting tubular cells 
featuring a relatively smooth cell surface, apical tubulovesicular profiles and a regular 
basement membrane of normal thickness (x 3.000). C: Cyst-lining cells of a 3 weeks old 
affected rat. Characteristics of principle cells include a fairly smooth apical surface, few 
and short microvilli, basolateral folds, a tight cytoplasmic network of tubulovesicular 
profiles below the apical membrane and sparse mitochondria. The basal lamina are intact 
and regular ( x 5.000). D: The intercellular junctions of these cells are relatively deep and 
tight and the cells have nalTOW folds of cytoplasm that interlock with countelparts of 
adjacent cells (x 25.000). 
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NOllrellal (issues 
Multi-organ autopsy of 3-week old Wistar-lIpkll,pk pups as well as of adult Wistar-+/lIpk 
heterozygotes did not reveal any nOll-renal stmctural abnomlalities. Of particular note, no 
evidence ductal plate malfonnation or biliary cysts was evident by light microscopy in 
multiple liver sections from six 3-week old lIpk/lIpk rats. Morphometric analysis of 
standardized liver sections revealed no evidence of portal triad abnonnalities or bile 
ductule proliferation in lIpk/wpk homozygotes as compared to unaffected controls (Table 
2). Similarly pancreatic tissue had nonnal ducts and nomral endocrine and exocrine 
stmctures in both mutant animals and controls (data not shown). 
Table 2. Intrahepatic biliary profiles 
Wistar lIpk / wpk Wistar + / + 
Portal area's /100 veins 16.6 ± 2.7 14.9 ± 2.2 
Bile ductules / portal area 1.27 ± 0.13 1.19 ± 0.07 
Intrahepatic biliary profiles in 3 week old wpk/wpk rats, The development of the biliary system is 
expressed as the percentage of recognizable portal arcas relative to the total number of vein 
profiles. Bile ductules per portal area is a measure of biliary proliferation. Numbers are given as 
means ± SD. The differences are statistically not significant. 
(Wislar-+lwpk X BB-DP)Fl wpk/+ illlerCl"oss 
In our (Wistar-lIpk/+ X BB-DP)FI intercross, FI +/wpk hybrids were identified by 
progeny testing. Evaluation of aged FI male and female rats revealed no manifestations of 
renal cystic disease and both F 1 males and females bred in a robust fashion. 
Of the 225 F2 progeny generated to date, 55 (24.4%) have recessive PKD. The 
number of F2 "pk/llpk pups is consistent with that expected for the Mendelian inheritance 
of a single recessive trait. Detailed histologic analysis of F2 mutants was not performed. 
Ge/lelic mappi/lg ofwpk 
To test whether lIpk is allelic with the cy locus on rat Chr 5, we crossed test-proven 
Wistar-+/llpk and SPRD-+/Cy heterozygotes. None of the 35 FI pups manifest the severe, 
early-onset phenotype evident in either lIpk/wpk or cy/cy rats. As expected, 17 of the 35 
(48.5%), expressed a phenotype consistent with that described in SPRD-+/cy 
heterozygotes. These data exclude allelism between the lIpk and cy loci. 
We then perfo11lled a whole genome scan using interval haplotype analysis as 
described by Neuhaus and Beier (73). In effect, by typing markers at the ends of each 
chromosome, we generated a series of 20 chromosomal intervals for the 35 affected F2 
progeny of the (Wistar-+/lIpk X BB-DP)FI intercross. 
Among the progeny of an intercross, a proportion of the F2 pups will inherit 
chromosomes that are apparently non-recombinant (NR), that is, the alleles of markers 
along these chromosomes will correspond to a single parental strain, in this case either 
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Wistar or BB-DP. In the analysis of a recessive mutation like wpk, a rapid genome scan 
can be perfOlmed by analyzing each chromosome for the distribution ofNR intervals. TIle 
fewer the number of NR chromosomes which cOlTespond to the unaffected parental strain 
(BB-DP), the less likely it is that the loci along that chromosome are randomly distributed. 
Accordingly, this chromosome interval is more likely to catTy the mutation. 
TIle distribution of chromosomal intervals is evaluated by Chi-square analysis. The 
maximum inferred Chi-square is calculated for each chromosomal interval and expressed 
as a percentage of the maximum possible Chi-square (%max Chi-square). Previous 
modeling experiments have established a % max Chi-square value> 0.75 as the threshold 
for linkage (73). Therefore, this strategy provides an efficient method to identify a 
candidate chromosome for more detailed analysis using standard recombinational mapping 
techniques. 
D. 
A. 
DSRatl2S 
D5Ratl25 III 0 0 III DSRal210 
DSRat210 III III 0 III 41108 ~ 3.7 ± 1.8 DSRat7J, wpk 
wpk III III III III 8/108 ~ 7.4 ± 2.5 
D5Rat7J III III III III DSRatl31 
D5RatIJI III III III 0 
94 2 4 8 
DSRat71 
DSRal41 
Fig.S Genetic localization of the wpk locus on Chromosome 5. (A) Haplotype distribution 
among 108 test chromosomes from the (Wistar- +/wpk x BB-DP) FI intercross. For each 
locus, black boxes represent the inheritance of Wistar-derived alleles and white boxes 
represent the inheritance of BB-DP-derived alleles. The number of chromosomes for each 
haplotype is shown below the columns. (D) The markers, D5Rat125 and D5Rat41, used in 
the initial interval haplotype are indicated. The map distances, in centimorgans (eM), were 
calculated from the recombination frequencies obselved for each interval and are 
expressed with the standard errors. 
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Table 3. Haplotype analysis 
Single point Haplotype analysis 
analysis 
Chr. Markers MaxP expM % max Nrof 
n Chi-sq Chi-sq Chi-sq Chi-sq H-types 
1 D IRat8-DlRat84 35 4.8-0.5 70 14.6 20 19 
2 D2Ratl-D2Rat103 35 3.9-0.5 70 27.6 39 13 
3 D3Rat3-D3Rat7 35 2.3-6.9 70 44.8 64 7 
4 D4Rat149-D4Rat67 34 0.3-1.2 68 28.4 41 12 
5 D5Rat125-D5Rat41 34 66-1.4 68 60.2 88 2 
6 D6Ratl05-D6Ratl 34 3.8-2.2 68 28.4 41 12 
7 D7mit20-D7RatlI5 32 1.5-2.1 64 30.2 47 10 
8 D8Rat56-D8Rat12 35 4.7-2.8 68 46.1 67 6 
9 D9Rat43-D9Ratl 35 2.8-0 70 22.8 32 15 
10 DlORat2-DlORat47 35 2.8-0 70 22.8 32 15 
11 D IIRat52-DlIRat37 29 7.6-11.6 58 39.7 68 5 
12 D12Rat2-Dl2Rat22 34 3.3-0.7 68 23.5 34 14 
13 D 13Rat4-Dl3Rat157 35 4.8-8 70 30.2 43 12 
14 Dl4Rat5-Dl4Rat51 35 1.4-2.3 70 22.8 32 15 
15 D15Rat5-Dl5Rat29 35 2.3-1.9 70 22.8 32 15 
16 D16Rat16-D16Rat21 35 8.3-1.6 70 35.7 51 10 
17 Dl7Rat6-Dl7Rat51 35 1.6-0.2 70 38.6 55 9 
18 Dl8Rat29-D 18Rat13 35 1.6-1.2 70 30.2 43 12 
19 D19Rat28-D 19Rat2 34 4.7-1.4 68 46.1 67 6 
20 D20Rat21-D20Rat29 35 1.6-3.5 70 20.6 29 16 
Table 3: Haplotype analysis. A whole genome scan was perfonned with 20 chromosomal 
intervals flanked by a proximal and distal marker, c.g. DIRat8 and DIRat84, respectively. N is 
the number of animals in the dataset. Chi-square values for each marker are indicated. Max P 
Chi-sq is the maximum possible Chi-square for the indicated n; exp M Chi-sq is the maximum 
inferred experimental Chi-square; %.max Chi-sq is the percentage of the maximum possible Chi-
square; NR haplotypes is the number of non-recombinant hapJotypes inherited from the 
unaffected parental strain. 
Analysis of our dataset revealed a %max Chi-square value = 88% for Chr 5 and % max 
Chi-square value < 75% for all other chromosome intervals (Table 3). These data provided 
presumptive evidence for linkage to Chr 5. We typed the initial cohort of 35 affected F2 
pups \vith a series of anonymous DNA microsatellite markers spaced at -20 eM intervals 
along this chromosome. These pups and an additional 19 F2 pups (total 54 pups/l 08 
meioses) were typed with markers within 4 cM of D5Rat73. These data, summarized in 
Figure 5, position wpk within a 11.1 cM interval centered on D5Rat73. 
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Discussion 
Similarities behl'eell tlte rat wpk/wjJk phellotype alUillllmaJl ARPKD 
The rat wpk model and human ARPKD share numerous similarities in their clinical 
phenotype and renal histopathology. In wpklll'pk homozygotes, renal cysts develop ill utero 
and enlarged kidneys are palpable within the first few weeks of life. Disease progression is 
associated with continued renal enlargement, systemic hype11cnsion, significant reduction 
in urinary concentrating capacity, progressive renal insufficiency, and death by 4-6 weeks 
ofage. 
hI comparison, the majority of hum all ARPKD patients are identified either illlltero or 
at birth. The most severely affected fetuses have enlarged echogenic kidneys and 
oligohydranmios dne to poor fetal renal output. At birth, these neonates often have a 
critical degree of pulmonary hypoplasia that is incompatible with survival. Renal function, 
though frequently compromised, is rarely a cause of neonatal death. For those infants who 
survive the perinatal period, systemic hypertension, and progressive renal failure usually 
evolve (5). In addition, ARPKD patients have defects in both urinary diluting capacity and 
concentrating capacity. There is often hyponatremia, presumably resulting from defects in 
free water excretion (5). 
In both the rat wpk model and human ARPKD, renal cysts develop in both proximal 
and distal nephron segments (80). With disease progression, the cystic lesion in both the 
rat model and human ARPKD predominantly involves the cortical and medullary 
collecting ducts. 
Systemic hyputellsioll 
Hypertension is a COl1ll110n finding among human PKD patients and contributes to both 
morbidity and mortality. Longitudinal obsenrations indicate that hypertension is a major 
contributant to disease progression in ADPKD (81). Among affected children, 
hypertension occurs in both dominant and recessive PKD, but tends to be more severe in 
ARPKD (63,82-85). 
Stimulation of the renal-angiotensill-aldosterone axis (RAAS) appears to be a major 
mechanism causing hypertension in ADPKD (81). Whether and to what degree increased 
activity of the RAAS contributes to hypertension in ARPKD remains unclear. The lintited 
available data are conflicting. On the one hand, histopathologic observations indicate that 
with progressive disease, the glomemli are compressed in the septae between expanding 
collecting duct cysts. Mechanical compression of the glomemli and the inh'arenal 
vasculature CQuld, at least theoretically, stimulate RAAS activity. However, clinical data 
from affected neonates indicate that ARPKD is achlally a low renin state with expansion of 
total body volume and occasional hyponatrentia (61). 
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Given the extensive body of work regarding blood pressure regulation in the rat and 
the strikiug phenotypic similarities between the rat wpk model and human ARPKD, we 
propose that the wpk rat may provide a new, powerful model system to investigate the 
physiologic and genetic mechanisms that contribute to hypertension in recessive PKD. 
Absellce o[ biliUlJ' abllol'lIIalities 
In this study, we found no evidence for biliary histopathology in Wistar-wpklwpk 
homozygotes. Since we did not examine the liver histology ofF2 wpklwpk homozygotes of 
the \Visatr x BB-DP intercross, we can not comment as to whether genetic background 
affects the expression of a biliary lesion in the wpk model. However, we note a possible 
precedence with the mouse cpk mutation, another murine model of ARPKD. In the 
C57BLl6J mouse strain, cpk/cpk homozygotes do not have biliary disease. However, when 
the cpk mutation is outcrossed to several different strains, e.g. AKR, BALB/c, DBAI2J, 
and CASTlEi strains, cpk/cpk homozygotes express a biliary lesion which varies in 
severity and closely resembles the ductal plate malformation evident in human ARPKD 
(86-87). 
CellulaI' 1II001lhoiogy o[wpk/wpk I'ellal cysts 
Characterization of the cystic epithelia in the wpk model has yielded a number of 
interesting insights. First, the initial cysts appear to be derived from fUllctioning, nOll-
obstmcted nephrons and the cystic epithelia maintain their segment-specific phenotype. 
These observations are consistent with data from the mouse bpk and cpk models and 
suggest that the disease-susceptibility genes in these models do not dismpt the early stages 
of nephrogenesis, e.g. induction of mesenchymal-ta-epithelial transfonnatioll, acquisition 
of stem-cell character, fate determination, epitheliogenesis, and polarization (88). 
In more advanced disease, cysts in the Wistar-wpklwpk kidneys are lined by well-
differentiated collecting duct cells, as evidenced by segment-specific marker profiling and 
electron microscopy. Although the cystic epithelia appear to have escaped the nomlal 
mechanisms controlling tubular diameter, they retain specific epithelial phenotypes with a 
heterogeneous popUlation of principal cells and intercalated cells and maintain their 
organization as a monolayer. Interestingly, the cyst epithelium is not unifOlTIlly 
proliferative, with focal areas of increased proliferation in contiguous areas of adjacent 
cysts. This observation suggests that cell proliferation is influenced by local 
environmental factors as well as by the defective gene. 
Interestingly, no abnonualities of the extracellular matrix or the basal lamina were 
associated with the renal cyst initiation Of progression in wpklwpk kidneys. 
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The wpk as II lIew 1II0dei of recessive PKD 
The mutant phenotype of the rat wpk model closely resembles human ARPKD and the 
mouse cpk, bpk, and OIpk models. However, the wpk model is genetically distinct from all 
other previously described PKD loci. The wpk locus maps to proximal Chr 5. While the 
rat cy locus also maps to Chr 5 (37), we have demonstrated that wpk and cy are not allelic. 
Based on homology mapping, the human wpk orthologue maps to chr 8q II 
(http://,,,,'w.llcbi.1I11ll.lIih.gov/Holllology). TI,ese data exclude the wpk locus as a candidate 
for the human ARPKD gene, PKHDl, which maps to human ChI' 6p21-p12 (89). 
Similarly, the mouse wpk orthologue maps to proximal mouse chromosome 4 and thus is 
genetically distinct from mouse bpk on Chr 10 (75), cpk on Chr 12 (90), or OIpk on Chr 14 
(91). It is interesting to note, however, that a principal modifyiug gene for both the mouse 
cpk and pcy models also maps to proximal Chr 4 (67-68). TIus observation raises the 
provocative possibility that the mouse "1Jk orthologue may be a candidate PKD modifying 
gene. 
Couclusioll: 
We have characterized the clinical and histopathologic phenotype ofa new rat PKD model. 
Like the mouse models, cpk and bpk, the rat "1Jk model strongly resembles human 
ARPKD. Homology mapping indicates that the rat wpk gene is distinct from the human 
ARPKD gene, PKHDl, as well as the mouse cpk and bpk genes. In addition to identifying 
a new gene involved in the pathogenesis of recessive PKD, this new rat mutation provides 
the first experimental model to study the renal pathophysiology associated with recessive 
PKD. 
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Deregulation of cell survival in cystic and dysplastic renal 
development 
Abstract 
Various aberrations of cell biology have been reported in polycystic kidney diseases and 
in cystic renal dysplasias. A common theme in these disorders is failure of maturation of 
renal cells which superficially resemble embryonic tissue. Apoptosis is afeature of normal 
murine nephrogenesis, where it has been implicated in morphogenesis, and fulminant 
apoptosis occurs in small cystic kidneys which develop in mice with null mutations of 
bcl-2. TIlerefore we examined the location and extent of apoptosis in pre- and postuatal 
samples of human polycystic and dysplastic kidneys using propidium iodide staining, in 
situ end-labeling and electron microscopy. In dysplastic kidneys cell death was prominent 
in undifferentiated cells around dysplastic tubules and was occasionally found in cystic 
epithelia. The incidence of apoptosis was significantly greater than in nomlal controls of 
comparable age both pre- and postnatally. In the polycystic kidneys there was widespread 
apoptosis in the interstitium around undilated tubules distant from cysts, in undilated 
tubules between cysts and in cystic epithelia. The level of apoptosis compared to controls 
was significantly increased postnatally. A similar increase of cell death was also noted in 
the early and late stages of renal disease in the polycystic cpk/cpk mouse model. We 
speculate that deregulation of cell survival in these kidneys may reflect incomplete tissue 
maturation, and may contribute to the progressive destruction of functional kidney tissue 
in polycystic kidneys and the spontaneous involution reported in cystic dysplastic 
kidneys. 
Introduction 
Organogenesis involves an increase in cell numbers, cell differentiation and 
morphogenesis. In normal development the increase in cell number is determined by the 
balance between proliferation and death, which in this context has been called 
'programmed cell death'. This term is often used interchangably with 'apoptosis', first 
used by Kerr ef al. [1) to describe death in a variety of normal and pathological contexts 
when accompanied by nuclear condensation and fragmentation with cell shrinkage. These 
changes are striking on electron microscopy but can also be detected by light microscopy 
as pyknotic nuclei [2). A common biochemical correlate of apoptosis is DNA digestion 
by endonucleases into nucleosome sized fragments which can be visualised as a 'ladder' 
on electrophoresis [3) and detected in situ by end-labeling [4]. Exceptionally some 
133 
Chapter 3.1 
programmed cell death during development is not accompanied by these morphological 
events [5] and DNA laddering is not always detected in cells dying by morphological 
criteria of apoptosis since the DNA is sometimes cleaved into larger fragments (50-300 
kbp) [6]. In the wonn CaeJlorhabditis elegalls apoptosis is developmentally regulated by 
the expression of specific genes and some of their mammalian homologues have been 
defined [7]. 'Growth factors' can not only conh'ol proliferation and differentiation but can 
also enhance apoptosis [8] or act as survival factors [9]. In contrast to apoptosis, cells 
dying by necrosis swell with deshllction of organelles and loss of integrity of cell 
membranes [10]. DNA laddering does not occur in necrosis, although some models show 
single-strand DNA breaks [6]. 
In nephrogenesis cell proliferation, differentiation and morphogenesis occur during 
the branching of the ureteric bud and in nephron fomlation [11-13]. Apoptosis has been 
demonstrated during normal murine renal development in the nephrogenic zone and also 
in the papilla; cell death can be reduced by epidemlal growth factor (EGF) [2]. Koseki 
and colleagues showed that the uninduced renal mesenchyme died by apoptosis when 
isolated from the ureteric bud, and that tItis process was ameliorated by EGF [14]. 
Sintilarly, hepatocyte growth factor (HGF) has been implicated in survival of renal 
mesenchymal cells in se111m-free organ culture [15]. 
The pathogenesis of some human kidney diseases can be understood in the context of 
aberrant development. In polycystic kidney diseases (PKD) there is evidence of enhanced 
epithelial proliferation [16] and altered polarity [17-18] leading some authors to suggest 
that the epithelial cells are "locked" in an immature, dedifferentiated state [19]. Similarly, 
in dysplastic kidneys there is a failure of differentiation of renal mesenchyme into 
nephrons and decreased branching of the ureteric bud [II, 20, 21]. We therefore 
considered it pertinent to examine the location and quantity of apoptosis in 110nnal human 
nephrogenesis and in kidney diseases which can be viewed as aberrations of 1l0lTI1al 
nephrogenesis. In this study we demonstrate that the distribution and incidence of renal 
programmed cell death is increased in children with polycystic and dysplastic kidneys. 
Methods 
Experilllell/(li Strategy 
The ainl of the study was to define the tissue location and quantify the extent of apoptosis 
during nOlmal kidney development and in fetal and childhood polycystic and dysplastic 
kidneys. The methodologies we used included both histological and molecular techniques 
together with quantitative statistical analysis. 
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This research was approved by the hospitals' research ethics conmlittees. During human 
development the metanephros can fIrst be identifIed in the sixth week after fertilisation 
and sequential layers of nephrons are formed until 36 weeks after fertilisation [II]. We 
therefore arbitrarily divided our specimens into experimental prenatal groups before 40 
weeks gestation and postnatal groups after 40 weeks as follows: 
i) Nonnal prenatal kidneys (n ~ 6). 
ii) Polycystic prenatal kidneys (n ~ 4). 
iii) Dysplastic prenatal kidneys (n ~ 6). 
iv) NOlmal postnatal kidneys (n ~ 6). 
v) Polycystic postnatal kidneys (n ~ 4). 
vi) Dysplastic postnatal kidneys (n ~ 4). 
Details of these patients and specimens are listed in Tables I and 2, including their sex, 
the gestational or chronological age, associated abnormalities in other organ systems, 
indications for tennination of pregnancy or for removal of a kidney, plus the side affected 
by renal disease and the plasma creatinine in the childhood samples. There is no 
signifIcant difference in age and sex distribution. within the prenatal and postnatal groups. 
Kidney pathology was classifIed by gross morphology, routine histopathology and, in the 
cases of polycystic kidneys, by liver histology and family history. All of the polycystic 
kidneys were classifIed as autosomal recessive polycystic kidney disease (ARPKD) apart 
from one postnatal sample \vhich had histology consistent with dominant disease 
(ADPKD), although ultrasound scans of the parents (aged 21 and 23) were normal. Two 
children with ARPKD had elevated plasma creatinines. The dysplastic samples all had 
classical histological criteria of this disorder, namely dysplastic tubules, "undifferentiated 
mesenchymal" tissue and metaplastic cartilage. 
Colleclioll of Specill/ells 
For the normal prenatal kidney group we studied both spontaneous miscarriages and 
phenotypically nomml kidneys from abortions perfomlcd for severe abnormalities in 
other organ systems which would have compromised the survival of the fehls or infant. 
These samples were compared with the polycystic and dysplastic kidneys which were 
collected under similar conditions. In these three groups the parents ,,,ere given time to 
mourn the loss of the child. Then the fetus was stored at 40 C until autopsy when organs 
were fIxed in 10% formalin. All specimens were processed within 24 hours. 
The postnatal polycystic and dysplastic samples were harvested surgically. Therefore, 
as a comparable nOlTIml surgical group ,ve used kidney tissue adjacent to, but unaffected 
by, Wilms' tumors. These kidneys were chosen to control for any potential changes in 
tissue morphology which may have been induced by general anaesthesia or surgery. Since 
both WTl mutations and chemotherapy may cause apoptosis [6,22], we excluded children 
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Table 1. Prenatal kidneys 
Gestational Renal and associated pathology 
age 
weeks 
NOlnml 
17 
19 
20 
20 
21 
22 
Polycystic 
20 
34 
35 
35 
Dysplastic 
17 
19 
20 
22 
24 
34 
Sex 
M 
M 
F 
F 
M 
F 
M 
F 
F 
M 
M 
F 
M 
M 
F 
M 
Abortion for neural tube defect 
Spontaneous miscarriage 
Abortion for trisomy 21 with atrial septum defect 
Spontaneous miscarriage 
Abortion for cephalocoele 
Abortion for major skeletal malfOlTIlations 
Abortion for ARPKD 
Spontaneous premature labor, ARPKD 
Spontaneous premature labor, ARPKD and liver fibrosis 
Spontaneous premature labor, ARPKD and liver fibrosis 
Abortion for multicystic dysplastic kidney with contralateral 
renal agenesis 
Abortion for multi cystic dysplastic kidney with contralateral 
renal agenesis 
Abortion for bilateral renal cystic dysplasia 
Abortion for bilateral renal cystic dysplasia, bladder dilated 
without anatomical urethral obstruction, atrial septum defect 
Abortion for bilateral renal cystic dysplasia 
Spontaneous premature labor, kidneys dysplastic, bladder 
dilated with partial urethral obstmction 
*' Children born at 34 to 35 weeks died within hours because of respiratory failure due to 
hypoplastic lungs. Chromosomes were nonnal in all fetuses assessed except for the case 
of trisomy 21. Parents were normal by history in all cases. 
who had received chemotherapy, and none of our patients had mutations in the WTl gene 
(Personal communication - Dr. Richard Gmndy, Dept. of Haematology and Oncology, 
Hospital for Sick Children, Great Onnond Street, London, U.K.). Surgical specimens were 
placed on ice, examined by a pathologist and immediately fixed in 10% fonnalin for 
histology. A limited number of dysplastic samples (n~3) were snap frozen in liquid 
nitrogen for DNA extraction and fixed in glutaraldehyde for electron microscopy. 
Deteetiolt of apoptosis by propidilllll iodide stailtiltg 
All chemicals were supplied by Sigma (Poole, Dorset, UK.) unless otherwise stated. 
Propidium iodide is a fluorescent dye which intercalates with nucleic acids. Apoptotic 
cells can be identified in tissue sections by their small, fragmented (pyknotic) nuclei 
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Table 2. Postnatal kidneys 
Age Creat. 
months Side Sex umollL Renal Pathology 
Normal 
5 R F 60 Wilms tumor before chemotherapy 
8 R M 65 Wilms tnmor before chemotherapy 
28 L M 35 Wilms tumor before chemotherapy 
30 R M 48 Wilms tumor before chemotherapy 
38 R M 34 Wilms tumor before chemotherapy 
72 L F 38 Wilms tumor before chemotherapy 
Polycystic 
10 R F 98 Diagnostic open surgical biopsy, ARPKD 
11 L M 14 Diagnostic open surgical biopsy, 
histologically ADPKD 
48 R M 322 Nephrectomy at transplantation; ARPKD 
72 R M 50 Surgical biopsy for infections, ARPKD 
Dysplastic 
8 R F 50 Cystic dysplastic upper pole with 
obstrnction of the pelvi-ureteric junction 
15 R M 33 Non-functioning multicystic dysplasia 
16 R M 32 Non-functioning multicystic dysplasia 
60 L F 38 Upilateral duplex ureters with non-
functioning dysplastic upper pole 
Plasma creatinine is the immediate preoperative plasma value. Two children in the 
polycystic group had elevated creatinine values, but this not appear to correlate with the 
pyknotic index in these specimens (data not shown), No kidney disease was reported in 
any of the parents including the histologically defmed ADPKD. 
which stain brightly when they are visualised under fluorescence miscoscopy. We used 
the technique of Coles ef al. [2] with minor modifications. Five micrometer paraffm 
sections were dewaxed through Histo-Clear (National Diagnostics, Atlanta, USA.) twice 
for 10 minutes, followed by dehydration through 100% alcohol (Hayman Ltd., Witham, 
Essex, UK.) twice for 5 minutes and then stepwise through 95%, 90%, 75%, 50% and 
30% alcohol for 3 minutes each. After washing in phosphate buffered saline (PBS, pH 
7.4) for 5 minutes they were incubated in propidium iodide (4 mg/I) with RNase A (100 
mgll; Unipath, Basingstoke, Hampshire, UK.) in PBS at 370 C for 30 minutes. After one 
further wash in PBS they were mounted in Citifluor™ (Chemical Labs, University of 
Kent, Canterbury, Kent, UK.). Specimens were examined under fluorescence (wavelength 
568mn) on a Zeiss AXiophot microscope (Carl Zeiss, 7082 Oberkochen, Germany) and on 
a Leica confocal laser scanning microscope (CLSM Aristoplan-Leica, Heidleberg, 
Gemlany). The precise tissue location of apoptosis was determined in ARPKD samples 
137 
Chapter 3.1 
Figure 1. Location oj apoplosis ill propidium iodide stained sectiolls of I/ormal alld polycystic 
kidlleys. A) Nephrogenic zone from normal developing kidney, 20 weeks gestation. Note 
apoptotic nuclei in comma shaped bodies, which are primitive nephrons. B) Glomerulus and C) 
proximal tubule from normal mature kidney • aged 30 months. Note absence of apoptosis, 
although nuclei in the glomerulus appear generally brighter. A fibroblast is seen adjacent to the 
tubule epithelium in (e). It has a bright elongated nucleus but should not be confused with the 
smaller irregular pyknotic nuclei. 0) Undilated tubule from polycystic kidney harvested at 34 
weeks of gestation surrounded by numerous apoptotic nuclei in interstitial tissue. E) is from a 
child with ARPKD and shows a group of apoptotic nuclei in the interstitium between cysts. F) 
is from an infant with dominant disease showing two apoptotic nuclei in the epithelium of a cyst 
close to a multilayered region of epithelium suggestive of hyperproliferation. Key: comma 
shaped body (c), cyst (cy), glomerulus (g), undifferentiated renal mesenchyme (m), tubule (t) 
and ureteric bud (u). Arrowheads indicate apoptotic nuclei, open arrow in A) indicates a mitotic 
figure and closed arrows in C) indicates a fibroblast and closed arrows in F) point to 
multilayered epithelium. Bar is 20 micrometer. 
by counterstaining with FITe conjugated Tetl'agoll%bus lotus or Arachis /zypogaea 
lee tins. These bind to proximal tubules and distal segments (distal tubule and collecting 
ducts) respectively [23,24]. After the propidium iodide staining the lee tins were applied to 
the sections at 1 :50 dilution in PBS at room temperahlre for 4 hours, mounted in 
Citifluor™ and examined under fluorescence (wavelength 488 nm). Apoptotic nuclei 
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detected by the propidium iodide method were quantified by generating a pyknotic index 
as described and by calculating the percentage of pycnotic nuclei as described below. 
Detectioll of apoptosis by in situ elld-lrlbelillg 
During apoptosis the nuclear DNA is digested by endonucleases leaving free 3' ends. 
These ends can be tagged using tenninal deoxytransferase to add labeled nucleotides 
which can be visualised on tissue section using secondary detection systems. \Ve 
modified the technique of GavrelIi el al. [4] by using an Apoptag ™ kit (Oncor, 
Gaithersburg, Malyland, USA.). ParaffIn sections were dewaxed and rehydrated, treated 
with proteinase K (20 mgtl) for 15 minutes and washed in PBS. Slides were then covered 
with equilibration buffer for 30 seconds, followed by terminal deoxytransferase and 
digoxigenin conjugated UTP from the Apoptag ™ kit as reconmlended by the 
manufacturer. The reaction was terminated using the Apoptag ™ stop buffer. Labeled 
nuclei were detected either i) by light microscopy after incubation with a peroxidase 
conjugated anti digoxigenin antibody and diamino benzidine (these sections were 
quenched with 3% hydrogen peroxide for 15 minutes at room temperature as an initial 
step) or ii) by fluorescent microscopy (wavelength 568 nm) after applying an anti-
digoxigenin antibody conjugated with rhodamine (Boehringer Mannheim, Lewes, East 
Sussex, UK.). 
Qualllitalioll of apoptosis ill 1111111111/ kitilleys 
Preliminary experiments with both propidium iodide and in situ elldwlabeled specimens 
showed that the number of apoptotic cells could vary between different areas of the same 
section, although there was good correlation between the two techniques. Therefore, in 
order to integrate the quantity of apoptosis in each specimen we photographed 10 random 
fields from throughout each sample stained with propidium iodide at 20 x magnification 
on a Zeiss Axiophot microscope. The number of pyknotic nuclei was then counted by 3 
'blinded' observers and we derived the pyknotic index for each specimen by taking the 
mean number of pyknotic nuclei per 10 fIelds. Results from each observer were also 
compared to ensure that there was no observer bias [25]. In this study we have also 
expressed the quantity of apoptosis as a percentage of the total number of nuclei. Since 
the pyknotic indices and the percentage of apoptotic cells in each experimental group 
were not nonnally distributed we transformed the data by conve11ing to 10gIO values, thus 
allowing analysis by Stident's t-test. A probability value of {<O.05 was considered to be 
statistically significant. 
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Fig. 3. Location of apoptotic nuclei assessed by propidillm iodide Gild lectin staining ill 
polycystic kidl/eys. All sections stained with propidium iodide (red) and FITC-conjugated lectin 
(green) are from ARPKD. (A and B) (higher power): Area of undilated distal tubules stained 
with Arachis hypogaea lectin with several adjacent pyknotic nuclei. (C and D): Tetragonolobus 
lotus lectin staining shows proximal tuhules. (C) Undilated proximal tuhule next to distal tubule 
with adjacent pyknotic cells and hyperproliferative epithelium. Two apoptotic cells also seen in 
the lumen of the distal tubule. (D): Dilated proximal tubule on the left and dilated distal 
segment on the right. TItree proximal tubules between cysts. One of these (right) contains a 
single apoptotic cell within its epithelium whereas the degenerating central tubule contains 
many apoptotic cells. Key: distal segment (d). hyperproliferative area (*), and proximal tubule 
(p). Arrowheads indicate apoptotic nuclei. Bar is 20 micrometer. 
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Figure 2. (previous page) Location of apoptotic lIuclei assessed by in situ end labeling in 
sections of normal and polycystic kidlleys. A), C), E) and G) are control sections in which the 
terminal deoxytransferase enzyme was omitted. Note that labeled nuclei, which appear brown, 
are absent. B), D), F) and H) are adjoining sections which have been subjected to the complete 
end labeling procedure using digoxigenin UTP as described in the Methods. All sections 
counterstained with methyl green. A) and B): Normal mature kidney showing apoptotic nuclei 
in tubular epithelial cells. This section together with Figure I C. demonstrates the range of 
apoptosis in normal postnatal kidneys. C) to F) show sections from patients with ARPKD 
harvested before 36 weeks of gestation. There is a wide distribution of apoptotic nuclei in the 
cyst epithelium and interstitial cells in D) and in the epithelial cells of relatively undilated 
tubules adjacent to a large cyst in F). Note that in F) the nuclei of the flattened epithelial cells 
lining the large cyst are not apoptotic, demonstrating the specificity of the technique. G) and H): 
Glomerulus from a child with dominant disease showing a cyst of Bowman's space with 
apoptotic nuclei in both the cyst wall and the glomerulus. Key: cyst (cy), glomerulus (G) and 
tubule (I). Arrowheads indicate apoptotic nuclei which appear brown. Bar is 40 micrometer. 
Detection of apoptosis by electl'oJl miCl'oscoPY 
Apoptotic cells have a characteristic appearance on electron microscopy with 
nuclear condensation around the periphelY of the nucleus, cell shrinkage and 
budding off of both the nuclear and cell membranes. Samples of 3 dysplastic 
kidneys were fixed initially in 2% glutaraldehyde in 0.05M cacodylate buffer, then 
in 1% Osmium tetroxide and finally embedded in epoxy resin. Ultrathin sections 
contrasted with uranyl acetate and lead citrate were examined with a Joel 100 CX 
transmission electron microscope. 
Detectioll of apoptosis by DNA electl'op/rol'esis 
During apoptosis the endonuclease DNA digestion produces nucleotide fragments which 
are multiples of 180 - 200 bases (180, 360, 540, 720 etc.) [3]. These can be visualised as a 
ladder on agarose gel electrophoresis. Fresh surgical specimens of 3 dysplastic kidneys 
were thawed to room temperature (after storage at -70°C), homogenised in a lysis buffer 
(10 mM Tris HCI (pH 8.0), 10 nllVl EDTA, 0.1% SDS, 100 ug/ml proteinase K) and 
incubated overnight at 520 C. DNA was then extracted using the phenol/chloroform 
technique [26].13riefly, equal volumes of phenol (equilibrated pH 8.0) and chloroform are 
added to the specimen which was then centrifuged at 5,000 x g. The aqueous layer is 
separated and the process is repeated. DNA was then precipitated with an equal volume of 
ice cold 100% alcohol, washed in 70% ethanol and resuspended in TE buffer (0.1 M Tris-
HCI, pH 8.0, 10 nllVl EDT A). Two micrograms of DNA was subjected to electrophoresis 
through a 1.5% agarose gel containing ethidium bromide and visualised under UV 
illumination. This extraction technique should be specific for DNA but any potential 
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RNA contamination was eliminated by incubating the samples with I uglul of RNAse A 
for 30 minutes before electrophoresis. 
Detectioll of apoptosis ill mice lVitil polycystic kidlleys 
Human ARPKD is a relatively heterogeneous condition. TIlcrefore, we examined 
apoptosis in cpklcpk mice which phenotypically res semble human ARPKD, but in which 
the kidney histology is more homogeneous and the progressive course of the disease is 
highly predictable [18,27,28]. Homozygous cpklcpk mice (Jackson Laboratory, USA) 
were sacrificed at birth when there is mild dilatation of the proximal tubules and at day 14 
when there is gross cystic changes in the collecting ducts. TIle extent of apoptosis was 
compared with phenotypically nomml !ittemlates (cpkl+ and +1+) as discussed in the 
Quantitation section above. 
Effects of storage 011 apoptosis ill fetal mice kidlleys 
To assess the possible effects of storage on the quantity of renal apoptosis we performed 
the following experiment. Pregnant CD I mice (Charles River UK Ltd.)) were sacrificed 
by cervical dislocation at the 16th day of gestation; a stage when the fetal kidney contains 
a spectmm of nephrogenesis broadly equivalent to our human prenatal samples. Embryos 
were killed by cervical dislocation. In one group kidneys were immediately removed and 
fixed in 4% PFA, whilst in the other group the whole fetus was left at 40 C for 24 hours 
before removing and processing the kidneys. Subsequently, apoptosis was quantitated on 
histological sections. 
Effects of allaestllesia allli rellal aftelY c1ampillg 011 "poptosis ill mice 
We assessed the potential effects of anaesthesia and renal artery clamping on apoptosis by 
perfomring these procedures on mice. Adult CD 1 mice (25g) were anaesthatized with 
nitrous oxide I halothane and underwent laparotomy. The renal vessels were identified 
using a dissecting microscope and the renal arteries were clamped for 15 minutes. Mice 
were then sacrificed. Control mice underwent cervical dislocation with immediate 
dissection and processing of the kidneys. Apoptosis was quantitated as above. 
Results 
LOC(ltioll of (Ipoptosis ill 1101'111(111111111(111 kidneys 
In prenatal kidneys apoptosis was detected in nephron precursors in the nephrogenic 
cortex, typically in conmla shaped bodies (Figure lA) and in interstitial cells in the 
medulla (not shown). Apoptosis was not found in either tlre undifferentiated mesenchyme 
(Figure lA) or in more mature nephrons towards the center of the organ. In the postnatal 
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Figure 4. Location of apopfotic Iluclei ill dysplastic kidneys. A) Low power view of dysplastic 
kidney from a 16 month old child counterstain cd with toluidine blue to show dysplastic tubules 
inunediately surrounded by fibromuscular collarettes and adjacent areas of undifferentiated 
cells of mesenchymal appearance. B) Propidium iodide labeling showing pyknotic nuclei in the 
interstitium between cysts. C) to E) are in situ end labeled sections using an anti digoxigenin 
antibody conjugated to rhodamine. C) Large dysplastic tubule with surrounding collarette 
containing one apoptotic nucleus. D) Numerous apoptotic nuclei in area of undifferentiated 
cells. similar to the area in B). E) Small dysplastic tubule with many adjacent apoptotic nuclei. 
Key: collarette (ct), dysplastic tubule (dt) and undifferentiated mesenchyme-like cells (m), 
Arrowheads indicate apoptotic cells. Bar is 40 micrometer in A and Band 20 micrometer in all 
other sections. 
samples rare apoptotic nuclei were detected in the epithelial cells of proximal tubules 
(Figure 2B) but were never noted in glomemli (Figures IB and 2B), interstitial cells 
(Figures I C and 2B) or loops of Henle, 
Locatioll of apoptosis ill polycystic hllmall kidlleys 
The distribution of apoptosis within the kidney was similar in both pre- and postnatal 
samples, In ARPKD apoptosis was detected (i) in the interstitium around undilated 
proximal and distal tubules (Figs, lD, 3A-C); (ii) within the epithelial lining of cysts, 
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Figure 5. Electroll microscopy of dysplastic I.:idlleys A) Cyst wall showing apoptotic cell with 
condensed pyknotic nucleus surrounded by normal epithelial cells. The apoptotic cell appears to 
he shrinking. B) Poorly differentiated mesenchyme showing both nonnal cells and one cell 
undergoing apoptosis with nuclear condensation. Key: apoptotic cells (a), collagen (c), cyst 
(cy), epithelial cells (E), fibroblast (F). Arrows indicate the tight junctions between epithelial 
cells, arrowheads indicate pyknotic nuclei. Bars are lnun, 
145 
Chapter 3.1 
720 bp-7 
540 bp-7 
360 bp-7 
180 bp-7 
A B c D E F 
Figure 6. DNA ladderillg ill dysplastic kidlleys. DNA was extracted from dysplastic kidneys 
from infants and children, then electrophoresed through a 1.5 % agarose gel as described in the 
Methods. Lane A and lane B: Dysplastic kidney showing laddering. Lane C: Dysplastic kidney 
with no detectable ladder. Lanes D,E and F: Samples from the same kidney as A, Band C 
treated with RNAse A rule out RNA contamination. 
often adjacent to areas of epithelial hypercellularity (Figs. IE, IF, 2D, 3C); (iii) and in the 
epithelium of undilated proximal tubules between large cysts (Fig 3D). In the ADPKD 
sample apoptosis was additionally observed within glomemli with cystic dilatation of 
Bowman's capsule (Fig 2H). 
Location of apoptosis ill dysplastic IIumall kidneys 
A similar histological pattel11 of cell death was seen in prenatal and postnatal specimens. 
Apoptosis was prominent in areas of undifferentiated cells (Figure 4B, 4D and 5B) but 
was also, on occasion, observed in close proximity to dysplastic tubules (Figure 4C and 
4E). In the multicystic dysplastic kidneys apoptosis was rarely detected in cystic epithelia 
and areas of cartilage did not contain apoptotic cells (data not shown). These sites of 
apoptosis were confnmed on electron microscopy: Figure SA shows an electron 
micrograph of an apoptotic cell adjacent to normal epithelial cells in the wall of a cyst. 
Figure 5B shows an apoptotic cell in an undifferentiated area which ressembles 
uninduced mesenchyme. We found DNA laddering in two out of the three dysplastic 
samples (Figure 6) although histology revealed apoptotic nuclei in all samples; this might 
be explained by the finding that DNA is sometimes broken down into large fragments 
during apoptosis which cannot be visualised by the laddering technique [6]. 
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Figure 7. Quaflfitatioll of apoptosis. Apoptosis was quantified in tissue sections using the 
propidium iodide method described in the text and expressed as (A) Pyknotic Index 
corresponding to the mean number of apoptotic cells per 10 microscope fields from throughout 
the tissue and (B) Percentage of pyknotic nuclei. Groups were: nannal prenatal kidneys, 
polycystic prenatal kidneys, dysplastic prenatal kidneys, normal postnatal kidneys, polycystic 
postnatal kidneys and dysplastic postnatal kidneys, Mean and SEM is shown, Significant 
differences were: a - nonnal prenatal versus nonnal postnatal (p < 0.0 I), P - dysplastic 
prenatal versus nonnal prenatal (p < 0.001), y - polycystic postnatal versus normal postnatal (p 
< 0.00 I) and 8 - dysplastic postnatal versus normal postnatal (p < 0,002) and E - dysplastic 
prenatal versus dysplastic postnatal (p<0.002), 
Qualltificatioll of apoptosis ill /111111(111 kifilleys 
Apoptotic ells were rare in nomlal postnatal kidneys, but significantly more death was 
seen in normal prenatal organs (Fig. 7; p<O.OI). This difference provided the rationale for 
analyzing the quantity of apoptosis in dysplastic and polycystic patient samples in 
separate prenatal and postnatal groups. Dysplastic kidneys had more apoptosis than 
nonnal kidneys of a comparable age (Fig.7; prenatally P<O.OOI; postnataaly P<O.002), 
and the absolute levels of apoptosis fell significantly between the prenatal and postnatal 
period (Fig.7; P<O.005). In prenatal polycystic kidneys, apoptosis was not significantly 
greater than in the normal group. In the postnatal period, however, a high level of cell 
death was maintained, and this value was significantly higher than nannal controls (Fig. 
7; P<O.OOI). All postnatal polycystic kidneys contained high levels of apoptosis 
irrespective of the level of plasma creatinine (Table 2). 
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Apoptosis ill animal experiments 
Cpk/cpk mice had significantly more apoptosis than their phenotypically nomlal 
littemlates both on the first day of life, when there was only mild dilation of the proximal 
tubules (Table 3; P<O.OI), and at posolatal day 14 when the kidneys were grossly distende 
by distal cysts (Table 3; P<O.OI). 111e location of apoptosis was similar to that seen in the 
human samples (data not shown). There was no significant difference in the level of 
apoptosis between mouse fetal kidneys which were either processed inmlcdiately or left 
in situ for 24 hours at 4'C before removal and fixation (Table 3). Similarly, no 
significance in the quantity of apoptosis was observed in mice kidneys which had been 
subjected to anaestesia and renal artery clamping versus organs which were lllIDlediately 
removed and processed (Table 3). 
Table 3. Pyknotic index and percentage pyknotic nuclei in kidneys from 
animal experiments outlined in the text 
Experiroental group 
A 
Nannal newborn 
Polycystic newbom 
Nonnal day 14 
Polycystic day 14 
B 
Control fetal mice 
Storage for 24 hours 
C 
Number 
4 
4 
4 
4 
10 
5 
Pyknotic index 
mean (sd) 
0.16 (0.10) 
1.58 (0.14) 
0.41 (0.29) 
1.37 (0.26) 
1.04 (0.76) 
1.12 (0.84) 
% Pyknotic nuclei 
mean (sd) 
0.02 (0.004) 
0.07 (0.007) 
0.02 (0.008) 
0.08 (0.008) 
0.09 (0.06) 
0.10 (0.07) 
Control adult mice 6 0.44 (0.25) 0.04 (0.02) 
Operative group 8 1.08 (0.79) 0.09 (0.07) 
Group A: Significantly more apoptosis in both cpk/cpk polycystic groups compared 
to age matched controls (P<O.OOJ). Group B: No significant difference between 
fetal kidneys processed immediately or stored in situ for 24 hours. Group C: No 
significant difference in renal apoptosis between controladult mice and the 
operative group, which underwent anaestesia and renal artery clamping. 
Discussion 
In the adult kidney apoptosis has been described in animal models of glomemlonephritis 
[29] and in experimental reperfusion injlllY [30]. The results from the cunent study 
suggest that apoptosis also occurs in dysplastic renal malfomlations and childhood 
polycystic kidney diseases. 
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In normal human fetal kidneys apoptosis was detected in the nephrogenic cortex and the 
medulla. In view of the high level of apoptosis in conmIa-shaped bodies (Fig. IA) we 
speculate that it my be involved in both nephron morphogenesis and controlling the 
number of cells within a nephron, Apoptosis also occurs between branches of the 
collecting ducts [2], an area where Potter described regression of the first generations of 
nephrons [II]. It could be argued that a delay of processing human specimens may have 
altered the degree of apoptosis, but we did not find any difference in the level of cell 
death in embryonic mice kidneys after prolonged storage at 4'C (Table 3). In addition, the 
distribution of apoptosis was similar to that described in a study in rats where developing 
kidneys were perfusion fixed immediately before harvesting [2]. We found a low level of 
apoptosis in proximal tubules of normal postnatal specimens (Figs. 2 and 7), but apoptosis 
was never observed in glomemli, Henle loops or interstitial cells (Figs. I and 2). 
Conflicting studies have suggested that hypoxia / ischaemia causes apoptosis in renal 
epithelia in ex vivo experiments [31], but has no effect in cell culture [32]. In the current 
study, however, we found that anaestesia and surgelY did not increase apoptosis in an 
animal model (Table 3). Other workers have also shown that apoptosis ill vivo is only 
enhanced in the reperfusion phase after renal artelY clamping [30,33]. We therefore 
suggest that there is balanced eell turnover in the mature human kidney with lost cells 
either dying by apoptosis or shed into the urine [34], and these are replaced by a low level 
of epithelial proliferation [35]. 
Del'eglllatioll of apoptosis ill polycystic kifllleys 
\Ve have made a number of original observations regarding apoptosis in polycystic 
kidneys obtained predominantly from patients with ARPKD. Firstly, in the postnatal 
period, pyknotic nuclei were observed in the interstitial tissue around undilated proximal 
and distal tnbules (Figs. I to 3), but we never observed apoptosis in this location in 
nomIaI postnatal kidneys. Secondly, apoptosis occurred in hyperproliferative epithelium 
of distal cysts (Figs. I and 3), and we also found undilated proximal tubules dying by 
apoptosis between cysts (Fig. 3). Lastly, the incidence of apoptosis was raised in postnatal 
polycystic kidneys (Table 3 and Fig. 7). Next we sought evidence of apoptosis in the 
cpklcpk mouse ; here the kidney phenotypically resembles human ARPKD, but the 
histology is more homogeneous and the disease progression is highly predictable [18,27]. 
We found that apoptosis was increased, compared to phenotypically nonnallittellnates, in 
both an early and a late stage of renal disease (Table 3). TI,e animal data support our 
findings in human ARPKD and are also in accord with a study reporting apoptosis in 
human ADPKD [36]. Thus, enhanced apoptosis is found in different types of polycystic 
kidney disease, It is unknown how apoptosis relates to the genetic defects in human 
polycystic kidney diseases [37-40]. Evidence for a primary genetic demlation of renal 
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survival is, however, provided by mice with bcl-2 Hull mutations which develop cystic 
kidneys [41,42]. Moreover, transgenic mice which overexpress c-myc develop renal 
cysts [43], and enhanced expression of this cellular protooncogene occurs in cpk!cpk mice 
[44,45]. C-IIIYc cuses proliferation or apoptosis depending on the concentrations of 
ambient growth factors [46], and thus the imbalance of EGF [47,48] and HGF [49] 
reported in polycystic kidney diseases may affect cell survival. We speculate that 
proliferation and fluid secretion in polycystic kidney epithelia [16,19,50] outweigh the 
high levels of cell death reported in this study, hence causing incresed size of the kidneys 
with concomitant desh11ction of fUllctional renal tissue. 
Dereglliatioll of apoptosis ill dysplastic kidlleys 
Most apoptosis in dysplastic kidneys occUlTed in cells located around dysplastic tubules. 
Cells in this area superficially remble undifferentiated mesenchyme which, in the normal 
metanephros, will differentiate into nephrons [11-13]. We suggest that enhanced 
apoptosis in dystplastic organs may prevent the differentiation of these precursors. 
Moreover, we hypothesize that enhanced cell death may contribute to U,e well recognized 
phenomenon of of spontaneous involution of dysplastic kidneys [51-53]. During nOlmal 
nephrogenesis, bcl-2 is highly expressed in nephron precursors [54,55], and this protein 
may be required to prevent the death of cells during the mesenchymal to epithelial 
transition. Preliminary data from our laboratory [54] suggest that bcl-2 is highly 
expressed in dysplastic tubules where apoptosis is rare, but is only weakly expressed in 
undifferentiated cells ,,,here apoptosis is found. In humans, renal dysplasias may occur in 
conjunction with renal obstmctioll (such as posterior urethral valves) and some, but not 
all, animal studies suggest that prenatal obstl1lction causes dysplasia [56-58]. Increased 
apoptosis is seen in experimental urinary obstmction in the postnatal period [59,60] and is 
associated with increased renal TGF-fl [61], a molecule implicated in epithelial apoptosis 
[8]. However, only a minority of our patients had obstl1lcted kidneys (Tables I and 2). 
Renalmalfonnations occur in mice with null mutations for ret [62], \l'lIt-4 [63] and RARs 
[64], but apoptosis has not been studied in these models, and none of them faithfully 
mimic human multi cystic renal dysplasia. 
Conclusions 
In smmnary, we have found that apoptosis occurs during normal human kidney 
development in locations similar to those reported in animals, and continues at a very low 
level after birth. More importantly, apoptosis occurs at a high level in ARPKD and 
dysplastic kidneys, ,vhich are important causes of end-stage renal failure in infancy and 
childhood [21]. The fact that apoptosis can be reduced by various molecular means both 
ill vitro and ill vivo [2,14,65] may suggest novel therapeutic strategies for these diseases. 
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Abstract 
Polycystin-l is the protein product of the PKD I gene. Mutations in this gene are 
responsible for most cases of polycystic kidney disease, but little is known about how 
these mutations lead to the development of cysts. Indeed, even less is known about the 
normal role of polycystin-I in the kidney. TIle cellular localisation of polycystin-I has 
been the subject of intense investigation by many groups, including ours. In this report we 
describe our results and compare our data with those of others. We generated 14 different 
polyclonal antisera against fragments of the predicted 462 kD polycystin-I molecule to 
enable us to investigate the expression of polycystin-I in cells and tissues by 
inullullocytochemishy, WestC111 blotting and inullulloprecipitation. OUf antibodies readily 
recognised a 134 kD polycystin-I fragment overexpressed in COS cells and stained the 
epithelial cells of fetal, adult and cystic kidney sections with the same pattent as reported 
by others. However, further investigations revealed that this pattem was' not specific for 
polycystin-l. We could not unequivocally detect polycystin-l in vivo, either by 
immunoblotting or immunocytochemistry. Therefore OlIr studies do not support the 
reported pattent of polycystin-I expression in the kidney. 
Introduction 
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
inherited diseases, affecting approximately I in 1000 individuals. Cystic destmction of 
the kidneys causes renal failure in approximately half of the patients, usually by the age 
of 50 (Welling and Grantham 1996). In most cases cysts are also formed in the biliary 
tract and, less frequently, in the pancreas, spleen, ovalY and testis. In addition to lesions in 
epithelial tissue, ADPKD is also associated with connective tissue abnormalities 
including colonic diverticula, arterial aneurysms and dysfunctional cardiac valves. 
Mutations in the PKDI gene are responsible for approximately 85% of cases (Welling 
and Grantham 1996), while most of the remaining cases result from mutations to the 
PKD2 gene (Mochizuki et a1. 1996). 
PKDI encodes polycystin-I, a 4302 amino acid (462kD) protein. Polycystin-I is most 
likely a membrane-spamling glycoprotein, feahrring multiple extracellular domains that 
may be involved in cell-cell or cell-matrix interactions and several intracellular 
phosphorylation sites that could be involved in signal transduction (Hughes et a1. 1995; 
Sandford et a1. 1997; TI,e International PKD Consortium 1995). At least three other 
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transcripts that are approximately 97% identical to PKD I, are expressed from multiple 
copies of the genomic region containing PKD I exons 1 - 31. It is not known whether 
these transcripts code for protein. 
We have developed and tested a large number of antibodies against polycystin-1. Here 
we show that our antisera recognise specifically a large fragment of polycystin-l when 
this is over-expressed in COS cells. The renal epithelial staining obtained with our 
antisera is in good agreement with published reports (Aguiari et al. 1997; Geng et al. 
1996; Geng et al. 1997; Griffm et al. 1996; Griffin et al. 1997a; Griffin et al. 1997b; 
Ibraghhnov-Beskrovnaya et al. 1997; Ong et al. 1999a; Ong et al. 1999b; Palsson et al. 
1996; Peters et al. 1996; Peters et al. 1999; Van Adelsberg et al. 1997; Ward et al. 1996; 
Weston et al. 1997; Wilson 1997; Wilson and Burrow 1999). However, we have been 
unable to demonstrate that this staining pattern is polycystill-l specific. In view of our 
experience we propose that additional ,York is required before polycystill-1 can be 
reliably detected by immunocytochemistry . 
Methods 
Animals alld tissues 
Tlnee month old New Zealand White rabbits were obtained from a conunercial breeder 
(Charles River, Someren, The Netherlands). The animals ,vere selected for immunization 
based on Imv immunoreactivity of their preinmmne sera against either adult or fetal 
human renal tissue, when tested on Westem blots and/or tissue sections. Sera from 
chicken, goat, guinea pig and mice were obtained from the same breeder. 
Nonnal renal tissue was obtained from tumor nephrectomy specimens and from a 
donor kidney that could not be used for transplantation (a kind gift from Eurotransplant, 
Leiden). Fetal renal tissue was obtained at 14-16 weeks. Cystic kidneys were surgically 
obtained from three ADPKD patients with end stage renal disease. 
COllstrllcts, peptides fllld proteills 
Sequences of pep tides and fusion proteins used during the course of this work are given in 
Table I. Figure 1 shows their relative positions in the putative polycystin-I molecule. 
Two peptides conesponding to the aminoacid sequence of polycystin-l were produced 
using solid phase peptide synthesis in a continuolls flmv manner, using Fmoc strategy on 
a Novasyn-Clystal automated peptide synthesizer (Erickson 1976), conjugated to 
Keyhole-Linlpet Hemocyanin (KLH) and purified by reverse phase high performance 
liquid chromatography. Purity ,vas confinned by amino acid sequencing. 
cDNA clones AH4, 3A3 and AH3 (The European PKD Consortium 1994) were 
trhlllUed to smaller fragments by restriction enzyme digestion and cloned into either the 
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pGEX (GST) or the pQE30 (HIS) expression vectors. GST and HIS-tagged fusion 
proteins were expressed in E.Coli (XL-I blue). HIS3A3-protein (aminoacids (aa): 3725-
3871) was purified on a Ni-NTA colunm according to the manufacturers instmctons 
(Diagen in Hilden, Germany). GSTAH4-protein (aa: 4275-4302) was purified on a 
glutathione sepharose 4B colunm (Phalmacia) as recommended by the manufacturer. 
GSTAH4-protein (aa: 4095-4302), GSTAH3-protein (aa: 3133-3322) and HISAH3-
protein (aa: 3133-3322) were purified on SDS-PAGE preparative gels. 
The AH8-cDNA encodes the C-terminal 1225 aminoacids of polycystin-I, including 
all the epitopes recognised by our antisera. AH8-cDNA, cloned into the pcDNA3 
expression vector was a kind gift ofP.C.Harris and C.J.Ward, Oxford. 
AntiserulIl productioll 
Rabbits were immunized using 100-250 Ilgram of protein in PBS, mixed as a I: I 
emulsion with Freund's complete adjuvant. Booster emulsions in Freund's incomplete 
adjuvant were injected at 3 weeks and then at 6 weeks. Sera were obtained 9-14 days 
following injection. The inuuune reactivity of the antisera was tested against the 
corresponding innnunogen, using either ELISA (anti-peptide sera) or Western blot 
analysis (anti-fusion protein sera). The antisera were affinity purified, using the antigens 
GSTAH4 (aa: 4275-4302 and aa: 4095-4302 ), GSTAH3 (aa: 3133-3322), HIS3A3 (aa: 
3725-3871) and GST alone, either spotted on blotting paper or coupled to a CNBR-
activated sepharose 4B colunm (Pharrnacia). TIre unbound and purified fractions were 
subsequently tested against the corresponding antigens (dot blots) and on AH8 transfected 
COS cells. 
Expressioll of AH8 
AH8-cDNA was transcribed and translated in vitro in the presence of "S-methionine, 
according to the manufacturers instructions (TNT kit, Promega, USA). This constmct was 
also used to transfect COS cells, using Lipofectamine™ according to manufacturers 
instructions (Life Technologies, Gaithersburg, MD, USA). Transfected cells were grown 
for 2 days and then used for immunocytochemistry or inmlUnoblotting experiments. 
JVestenr blotting alld illllllllllopl'ecipitatioJl 
AH8 transfected COS cells were sonicated in PBS in the presence of protease inhibitors, 
electrophoresed through a 8% SDS/polyacrylamide gel, and blotted onto Inunobilon-P 
(Millipore). Homogenates from renal tissues in 50mM Tris-EDTA and cultured cells in 
either PBS, Tris or RlPA buffer (150mM Nael, 1% NP-40, 0.5% deoxycholate, 0.1% 
SDS, 50ruM Tris) were similarly sonicated in the presence of protease inhibitors, 
including leupeptin (leN), pepstatinA (leN), antipain (Sigma) and Pefabloc 
(Boehringer). 
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Membrane fractions were obtained according to Geng (Geng et al. 1997). For the 
detection of polycystin-I, the extracts were electrophoresed in 5% gels or 5-15% gradient 
gels and blotted. Antisera were diluted 1:1.000-1:5.000. Binding of antibody was 
visualized by enhanced chemiluminescence (ECL, Amersham), using horseradish 
peroxidase conjugated swine-anti-rabbit IgG as a secondary antibody (DAKO). 
For immulloprecipitation protein extracts from in vitro translation products and 
detergent lysates of AH8 transfected cos cells were incubated with antibodies and with 
protein A sepharose beads. TI,e precipitates were washed extensively in RIP A buffer and 
incubated in SDS sample buffer, prior to electrophoresis. After electrophoresis, gels 
containing 3SS methionine labeled proteins were fixed and immersed in Amplify 
(Amersham) for 15 minutes, dried and exposed to X-ray film for several days. Gels 
containing precipitates of unlabeled protein were in1lllunoblotted as before. 
ImJIIlI1I ocyl OC" e 111 i sIr), 
Tissue for immunocytochemistry was fixed in paraformaldehyde (4%) prior to embedding 
in paraffin. Sections were incubated in 1 % H20 2 to block endogenous peroxidase activity 
and aspecific binding was blocked with Protifar (0.5%) (Nutricia, The Netherlands), 
glycine (0.15%). For the identification of polycystin-l we explored a number of antigen 
Ullllasking methods, including incubation in 0.1 % pronase for 5 minutes, or in 0.2% SDS 
for 5 minutes, or in 0.1% or 1.0% Triton X-IOO for 5 minutes, or in a microwave for 3 
minutes in 10mM citrate. Antigen unmasking had no significant effect on the staining. 
TIle sections were subsequently immUllostained using an indirect inununoperoxidase 
protocol including primary antibodies (dilution I: 100-500), horseradish peroxidase 
conjugated swine-anti-rabbit immunoglobulin as a secolldaty antibody at 1: 100 (DAKO) 
and 3,3'diaminobenzidine.HCl as substrate. Affinity purified antibodies were used at 
concentrations four times higher than used for the conesponding cmde sera. Controls 
included replacement of the primary antisennll by both the corresponding preimmune 
se11lm and by PBS. [nmulllocytochemistry with affinity purified sera was additionally 
controled using the unbound fraction as a primary step. 
Cultured cells and fresh frozen tissue sections were fixed in either 4% 
parafoffilaldehyde for 10 minutes, followed by methanol for 20 minutes and 1 % H20" or 
with methanol for 5 minutes at -20'C, or with acetone at -20'C for either 2 seconds or 2 
minutes. Since the results with these protocols were not significantly different, we used 
the first protocol as a standard. Blocking aspecific binding and subsequent 
inmlUnostaining was as described for paraffin embedded sections. 
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Figure.1 Schematic representation of the intracellular and membrane spanning domains of 
polycystin-I based on amino acid sequence and domain analysis (Sandford et al. 1997> Hughes 
et al. 1995). This region corresponds to the AH8 encoded polycystin-1 fragment (aa 3078-4302) 
used to test the antisera. Also indicated arc the polycystin-I fragments corresponding to the 
fusion proteins (interrupted lines) and peptides (solid bars) used to generate domain specific 
antisera. AH3 includes amino acids 3133-3322, 3A3 includes aa 3725-3871 and AH4 includes 
aa 4095-4302. 
Results 
CharacterisatioJl of (llIti-po[ycystill-l antiSel'll 
Polyclonal antibodies against pep tides and 11Ision proteins derived from different parts of 
the C-tenninal domain of polycystin-I were raised in 14 New Zealand White rabbits 
(Figure I, Table I.). The inmlUnoreactivity of each senllll was tested against the 
corresponding immunogen and against AH8, a 134kDa protein containing the entire C-
tem1inal domain of poly cyst in-I (Ward et af. 1996). The best results were obtained with 
antisenun 2226. 111is was raised against AH4, a GST fusion protein containing the 208 
most C-terminal amino acids of polycystin-1. Senllll 2226 was affinity purified using the 
same fusion protein. 
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Table 1. Inll~1Unoreactivity of 14 antisera tested against AH8 
ARB ARB 
In vitro 
translation COS transfeetion 
Anti Raised against Iuulluno Western IIllIllUIlO 
Epitopes • precipitation blot Cytoehem. serum : 
1633 3232-3255 ± + 
1805 3133-3322-GST fusion nd nd 
1932 3133-3322-RIS filsion + + ± 
2225 " nd + + 
1635 3847-3865 nd nd 
1923 3725-387 I-HIS filSion ++ + + 
1931 " ++ + ± 
1818 4275-4302-GST fusion + +++ + 
2118 " nd +++ + 
2224 " nd +++ + 
1815 4095-4302-GST fusion + ++ nd 
1930 " ++ +++ + 
2226 " + +++ ++ 
1630 '1590-1614' b nd 
a Polycystin-l fragments used for immunization. Aminoacid sequence numbers 
correspond to reference: Hughes 1995, b Sequence corresponds to amino acids 1590-1614 
of the initially reported PKD I sequence ( The Eur PKD Cons 1994 ), later shown not to 
be part of the PKD 1 coding region (Hughes 1995 ). nd: not done. 
In vitro translation of an expression const11lct encoding the C-tenninal domain of 
polycystin-l gave the expected 134kDa AH8 protein produc!. This protein was 
immunoprecipitated by the 2226 antisemm, but not by the conesponding preimmune 
SenlI1l. Next, COS cells were transfected with the AR8 expression constmc!. Again, 2226 
detected a single protein band of the expected size (134kDa), both by 
imnllllloprecipitation and directly on a Westem blot (Figure 2.). Inmmnocytochemical 
analysis of the transfected COS cells with 2226 clearly indicated strong expression of the 
AH8 protein. The staining was localised to the intracellular compartment and had a 
meshwork like pattem (Figure 4A.). 2226 did not react with untransfected COS cells nor 
with cells over-expressing other, unrelated proteins. TIle reactivity of the affinity purified 
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Figure.2. Western blot of AR8 transfected COS cell homogenates stained with serum 2226 and 
with the corresponding preimmune serum (P2226). No proteins other than AH8 were 
recognised. 
preparation was comparable with the crude 2226 immune serum, while the 2226 
preimmune serum and the unbound fraction after affmity purification were negative 
(Figure 4.). 
In addition to 2226 several other antisera (Table \.) were also strongly 
immunoreactive to AH8. However, unlike 2226, these antisera not only recognised 
additional protein bands on Western blots of transfected and untransfected COS cells but 
also weakly stained untransfected cells in the inununocytochemical experiments (not 
shown). None of the additional (non-AH8) protein bands were recognised on Western 
blots by more than one antiserum. In each case the corresponding preimmune serum was 
less reactive. That is, it recognised fewer protein bands on Westem blots (or none at all) 
and did not stain untransfected COS cells in immunocytochemichal experiments. 
Since we could show that 2226 was specific for polycystin-I, we perfonned Westem 
blot analysis of nornlal human kidney tissue and human fibroblast and ureteric bud cells 
in culh.re with the crude 2226 inunune serum (Figure 3.). We were unable to detect a 
protein band corresponding to polycystin-1, suggesting that the protein is either not 
expressed at detectable levels, or lost during sample preparation. Interestingly, we noticed 
that the AH8 proteiu was unstable, when over-expressed in COS cells. n,is 130 kD 
polycystin fragment was not easy to detect unless the Iysates were analysed immediately 
after preparation. 
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Figure. 3. Western blots of homogenatcs of normal adult renal tissue and of Hannal human 
fibroblasts, stained with three different antisera and with the corresponding preimmune sera, 
(P)2226, (P)1931 and (P)1815. Serum 2226 did not recognise any protein. The 2 other antisera 
illustrate the induction of immunoreativity during the immunisation procedure. However, the 
stained protein bands most likely did not represent polycystin M I or polycystin M 1 breakdown 
products since they were either not recognised by more than one antiserum or also recognised 
by one or more preinmmne sera. Moreover these bands were usually not of the expected 
molecular weight. 
The same analysis was carried out using the other antisera raised against polycystin-l. 
Several different protein bands were detected by the different antisera (Figure 3). 
However, in addition to not being recognised by 2226, these bands were either not of the 
expected size, not recognised by more than one antisemm or were also recognised by one 
or more preinnnune sera. It is therefore unlikely that they represent polycystin-l or 
polycystin-l breakdown products. 
Immullocytochemical allalysis o/llIIlIIall renal tissues using 2226 
Innnunocytochemical analysis of adult, fetal and cystic kidneys with the clUde 2226 
innnune selUm revealed specific staining of renal tubular epithelia (Figure 4.). In fetal 
kidneys robust staining of the ureteric bud and medullaIY collecting tubules was observed. 
This staining was either cytoplasmic or confined to basal cell surfaces. Moderate staining 
was seen in some of the cortical tubules and occasionally in the parietal epithelium of 
Bowman's capsule. In adult kidneys a weak cytoplasmic staining of all tubular segments, 
but not of Bowman's capsule, was noted. In end stage kidneys from three ADPKD 
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patients many cysts were stained. The staining intensity varied between cysts and cellular 
distribution was cytoplasmic. No immunoreactivity was detected against glomcmli or 
interstitium. Cultured human fibroblasts or human renal epithelial cells were not stained 
by 2226. 
Although the 2226 preimmune senun did not stain adult or cystic kidneys, it stained 
the fetal ureteric bud and collecting tubules even more intensely than the cmde 2226 
immune SCnIm did. 
Affmity purification of 2226 abolished completely the reactivity against both fetal 
and adult tissue. The unbound fraction, however, stained the ureteric bud and collecting 
tubules similar to the cmde 2226 immune senun. Taken together, these results indicate 
that the observed staining of the fetal uteric bud and collecting tubules is very unlikely to 
represent polycystin-I. 
Immullocytochemical allalysis of Ituman rellal tissues usillg otlrer antisera agaiJlst 
po/ycystill-l 
In addition to 2226, we generated 13 other polyclonal antisera against polycystin-l 
(see above). In contrast to their conesponding preinunune sera which were unreactive, 
most antisera stained renal hlbular epithelia similar to 2226. In each case, the staining was 
cytoplasmic or confined to basal cell surfaces. TIle fetal ureteric bud and branches were 
stained by all antisera and by one preinmmne semm (preimmune 2225). In addition, some 
antisera stained more proximal fetal hlbular segments and, occasionally, the parietal cells 
of Bow mall's capsule. Adult kidneys were stained by some, but not all antisera. If present, 
this staining was either confined to distal tubules and collecting ducts or localised to all 
tubular epithelia. Kidney sections from patients with ADPKD also stained positive with a 
number of antisera. This consisted of intracellular staining of nonnal tubules and of 
approximately 70-90% of the cy.:;ts. Some of the immunoreactive cysts were more 
robustly stained than the unaffected tubules. 
Flgure.4. (next page) lnununocytochemistry of AHS transfected COS celis (COS-AHS), a 14 week 
old human fetal kidney, a normal adult kidney and an end stage cystic kidney from one of the 
patients with ADPKD. Staining with antiserum 2226 (A-D), affinity purified serum 2226 (E-H), the 
unbound fraction of this purification (J-L), the corresponding preinunune serum P2226 (M-P) and a 
polycystin-l-unrelated antiserum (1630), raised against a nonsense peptide (Q-T). The efficiency of 
the affinity purification is demonstrated by the COS-AHS experiments. Purified 2226 did not stain 
any renal structures in either normal, fetal or cystic kidneys. Note that most other serum samples 
gave considerable polyeystin-I-unrelated background staining of human renal epithelia. The 
unrelated antiserum 1630 gave a similar staining pattern as 2226 on fetal and cystic kidneys. In 
adult kidneys relative intense staining with 1630 was noted in distal tubules and collecting ducts, 
when compared to proximal tubules (panel S). Interestingly, serum from a later bleeding of the 
same rabbit (1630) stained adult kidney (not shown) more like 2226 (panel C), manifesting the 
same intensity in all tubular elements. The preinmmne serum p 1630 was unreactive (not shown). 
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A number of antisera raised against non-polycystin-l epitopes also stained tubular 
epithelia of fetal, adult and cystic kidneys, in a pattem similar to the one described for our 
anti-polycystin-l sera. In these cases the cOlTesponding preimnume sera were unreactive 
(unpublished results). One of these antisera (#1630) was raised against a peptide from the 
polycystin-I C-terminal as originally described (The European PKD Consortium 1994), 
(Table 1; Figure 4Q-T). This peptide was subsequently found to correspond to non-coding 
sequences in the 3 'UTR of the PKD 1 gene and is therefore not translated (Hughes et a!. 
1995). 
Further, the same staining pattern was observed in either fetal or adult kidneys using 
sera from 15 out of 26 unimmunised rabbits and also with sera from chicken, goat, guinea 
pig and mouse, confmnil1g that non-specific staining can be a significant obstacle to the 
detection of polycystin-l in renal epithelial structures. 
Discussion 
Reporled expressioll ofpolyc)'slill-1 ill rellallissues 
Expression of the PKD 1 transcript in human and murine tissues and whole organ 
homogenates has been described (Geng et a!. 1997; Griffin et a!. 1997a; The European 
PKD Consortium 1994; Ward et a!. 1996). These studies indicate that mRNA is expressed 
in all tissues examined. 
Many reports describe the cellular localisation of the PKD 1 protein, polycystin-l 
(Aguiari et a!. 1997; Geng et a!. 1996; Geng et a!. 1997; Griffin et a!. 1996; Griffin et a!. 
1997a; Griffin et a!. 1997b; Ibraghimov-Beskrovnaya et a!. 1997; Ong et a!. 1999a; Ong 
et a!. 1999b; Palsson et a!. 1996; Peters et a!. 1996; Peters et al. 1999; Van Adelsberg et 
al. 1997; Ward et a!. 1996; Weston et a!. 1997; Wilson 1997; Wilson and Burrow 1999). 
The antisera used in these studies were raised against over 25 different peptides and 
fusion proteins, all derived from the predicted polycystin-I amino acid sequence. In each 
report the renal expression of polycystin-I was localized predominantly to tubular 
epithelia of adult, fetal and cystic kidneys. The most intense staining was usually 
observed in the ureteric bud of fetal kidneys and in cyst-lining epithelia from ADPKD 
patients. However, despite this broad agreement, the exact pattern of polycystin-l 
expression is not the same in all cases. While a tubular segment specific distribution has 
been reported by many authors, no tmifornl pattern has yet emerged. Some studies 
indicate renal tubular expression in proximal and distal convoluted tubules and to a lesser 
extent in collecting ducts (Weston et a!. 1997), while others localised polycystin-l 
exclusively to collecting tubules (Palsson et a!. 1996; Wilson 1997). Glomerular 
expression other than in Bmvman's capsule is absent according to most studies. However 
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significant staining of glomerular visceral epithelia ,vas observed by some investigators 
(Pals son et al. -1996; Peters et al. 1996; Weston et al. 1997). The renal vasculature and 
endothelium were unstained inmost, but not all studies (Ibraghimov et al. 1997; Peters et 
al. 1996). TIle intracellular distribution is similarly unclear. Most authors report a 
cytoplasmic distribution in most structures. Additional plasma membrane expression has 
been observed in some studies (Aguiari et al. 1997; Geng et al. 1996; Ibraghimov et al. 
1997; Palsson et al. 1997; Van Adelsberg et al. 1997), but not in others. This plasma 
membrane staining has been either unpolarised (Ibraghimov et al. 1997; Van Adelsberg et 
al. 1997) or polarised to the apical cell membrane (Geng et al. 1996; Palsson et al. 1996). 
TIle intracellular distribution of polycystin-I has also been studied in cultured human 
renal epithelial cells. Using the same cell lines, two groups made different observations, 
localising polycystin-I to either the peripheral cytoplasm (Griffm et al. 1996) or to the 
cell membrane of human renal proximal tubular epithelial cells (Ibraghimov et al. 1997). 
It is as yet unclear which of these reports describe the tme expression pattem. 
The expression of polycystin-I in renal cysts from patients with ADPKD has also 
been studied. The mechanism by which a mutation of the PKD I gene leads to the 
fonnation of these cysts is not clear. Recent evidence indicates that cysts are lined by 
cells where a second hit mutation of the wild type PKD I allele has occurred, suggesting 
that cyst fOlmation is caused by the absence of functional polycystin-I. Loss of 
heterozygosity (LOH) in cyst-lining epithelia was demonstrated for PKD I as well as for 
PKD2, and in both renal and hepatic cysts (Brasier et al. 1997; Koptides et al. 1999; Qian 
et al. 1996; Watnick et al. 1998; Wu et al. 1998). However, in conflict with this concept is 
the robust staining of most cysts by anti-polycystin-I antisera, described by most authors. 
Absence of staining in cyst-lining cells, as predicted by tire LOH hypothesis, has been 
demonstrated for PKD2 in a murine model, but not for PKDI (Wu et al. 1998). 
Characterisation of tile allti-polycystin-l autisera 
We raised 14 different polyclonal antisera against human polycystin- I. To thoroughly test 
and characterise the specificity of the immune sera we used a transfection-based system 
whereby we could over-express a 134kDa protein, consisting of the unique C-tenninal 
domain of polycystin-I, in cultured man1ll1alian cells. We called this protein AH8. Using 
this approach, we could perform a range of different immunological assays with our 
antisera. 
We demonstrated that most of our antisera could detect AH8 by 
inmmnocytochemistry, inmmI1oprecipitation and \Vestern blot analysis. One antisenun 
(1630), raised against the same epitopes described by Van Adelsberg, did not recognise 
AH8 (Van Adelsberg and Frank 1995). Re-analysis of the PKD I transcript has shown that 
these epitopes are in fact not pari of the translated polycystin-I molecule (Hughes et al. 
1995; The intemational PKD Consortium 1995). 
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With the exception of sennn 2226 (detailed below) we noted that on Western blots our 
antisera recognised other proteins, in addition to AH8. These proteins were detected in 
both untransfected COS cells and in cells trausfected with AH8 and were generally not 
detected by the conesponding preimmune sera. This indicates that the reactivity may have 
been caused by the immunisation procedure itself, perhaps by either a general 
enhancement of the overall immune response or by the extended exposure of inmmnised 
rabbits to Illnnan (epithelial) antigens. Alternatively, the extra bands may represent 
polycystin-l homologues. Examples of human proteins with homology to the domain 
recognised by our antisera include the PKD2 protein (Mochizuki et al. 1996) and the 
PKDREJ protein (Hughes et al. 1999). 
SenllTI 2226, was superior to the other antisera raised against polycystin-l since there 
were no appreciable background signals. No additional protein species were recognised 
by this serum on Westem blots or by immunoprecipitation, and untransfected COS cells 
were not stained. 
ImlllllllocytOc/lelllical delectioll of polycyslill-l ill hUIII(l1I rellal tissues Ilsillg Ollr 
antisera 
Our initial obsenrations suggested that all our antisera recognised polycystin-l in renal 
tissue sections. The observed pattem of immune staining was the same for antisera raised 
against different polycystin-l epitopes and ,vas not observed with most of the 
corresponding pre immune sera. OUf data were also in broad agreement with the other 
published reports, as described above. However, since we subsequently discovered that 
this epithelial staining pattenl was also seen when using polycystin-l unrelated sera, we 
could not be certain that the observed staining was due to polycystin-l. This view was 
sUPP0l1ed by our observations that sera from unimmunised rabbits and from rabbits 
inllllunised with antigens unrelated to polycystin-l, including semm 1630, had a similar 
pattern of inllTIunoreactivity against human renal epithelia. Further, many of our antisera, 
but not antisemm 2226, recognised additional proteins on Western blots of COS cells 
transfected with AH8, suggesting that these antisera were not absolutely specific for 
poJycystin-1. Supporting this conclusion was the background staining of untransfected 
COS cells by most antisera, but not 2226, in immunocytochemical experiments. 
The strongest evidence that the observed epithelial expression pattern was unlikely to 
be specific for polycystin-l came from our experiments with semm 2226. In each of our 
test assays using the over-expressed AH8 protein, 2226 produced the strongest signal with 
the least background. Immunocytochemical analysis of adult and fetal kidney sections 
with the cmde 2226 immune semm revealed the characteristic epithelial staining pattem, 
similar to our other antisera. However, affinity purification of 2226 completely abolished 
this staining, while the avidity for AH8 was unaffected. Conversely, the non~binding 
fraction from this purification procedure did not recognise AH8, but did stain renal 
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epithelium. Therefore, on the basis of these results, we conclude that the epithelial 
staining observed by us, and possibly others, was not specific for polycystin-I and that we 
could not detect polycystin-I in either paraffm-embedded or frozen renal tissue sections. 
Supporting this conclusion, with (cmde or affmity purified) 2226 we were also unable to 
detect any protein band on vVestem blots of either human renal tissue or cells. Several of 
our other antisera did detect proteins in the expected size range (400 - 700kDa). However, 
no single band was detected by more than one antisemm, indicating that these protein 
bands were unlikely to represent polycystill-l. Since the antisera were raised against the 
same polycystin-I domain, these additional bands are also unlikely to represent 
polycystin-I breakdown products. 
There are several possible explanations for our results. Firstly, polycystin-I may not 
be expressed, or expressed at vanishingly low levels in the tissues examined. 
Alternatively, it may not survive the sample preparation procedures for either Westenl 
blotting or the inununocytochemical analysis of tissue sections. This conclusion is 
supported by our observation that the over-expressed AH8 protein was also unstable. 
Further, the epitopes recognised by our antibodies may be obscured by their immediate 
environment, such as the plasma membrane where polycystin-l is thought to reside, 
and/or the binding of other renal proteins. It is also possible that confonnational changes 
during sample preparation may destroy or obscure the polycystin-I epitopes recognised 
by our antibodies. 
III slImmm)' 
We have generated a large number of poly clonal antisera against human polycystin-I and 
characterised these as far as possible in transfected cells over-expressing the C-tclTIlinal 
domain of this important protein. OUf antibodies show a similar epithelial expression 
pattern as described by others. However, we have strong evidence that the pattern we 
found is aspecific and results from unrelated immunoreactivity. Our data suggest that 
endogenously expressed polycystin-I is velY difficult to detect, either because it is 
masked by its immediate enviromnent and/or extremely labile, or because it is expressed 
at very low levels in adult and fetal human kidney. The value of the cunently available 
data on the cellular and tissue distribution of polycystin-I may be considerably enhanced 
by exchange of antisera between independent research groups, as well as by the use of 
tme negative control tissue to rigorously test the specificity of all the different antisera 
described to date. Such control tissue may potentially be derived from PKD I-knockout 
animal models (Lu 99), as well as from human PKD I cysts in which loss of 
heterozygosity has directly been demonstrated. Until these resources become available, 
the rcnallocalisation of polycystin-l may remain uncertain. 
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General discussion and future perspectives 
Ultimate goals of medical research are the cure and prevention of disease. The 
development of new treatment strategies is often triggered by novel insight in specific 
biological events that underlie the disease process. Here, we will summarize the current 
knowledge OIl PKD and discuss options for further investigations in view of the 
development of new treatment strategies. Then, we will suggest how experimental models 
may contribute to these investigations. 
Genetic defects in PKD 
The genes of the predominant fomls of ADPKD (PKDl and PKD2) and the gene 
associated with one of the mouse models of ARPKD (Tg737) have recently been cloned 
and sequenced (TIle European Consortium '94, Mocllizuki '96). Many other genes, 
including the human ARPKD gene (PKHD 1) and a number of genes involved in murine 
PKD have also been localized, but not yet characterized. In addition, several genetic loci 
were associated with disease severity in murine PKD, suggesting that genetic factors 
(,modifying genes') other than the primarily affected PKD-gene, modulate disease 
expression in PKD. 
The mutational mechanism underlying PKD 1 is controversial. Evidence is 
accumulating that germline PKD I mutations are probably inactivating. The relatively few 
mutations described to date are mainly predicted to terminate the protein prematurely 
(Peral '96, '97, Roelfsema '97). The observation that large deletions, dismpting PKDl and 
the adjacent TSC2 gene, are associated with severe early onset PKD indicates that a PKD I 
null allele can result in cyst formation (Sampson '97). Moreover, the severe cystic 
phenotype of fetal homozygous pkd I-knockout mice indicates that the complete absence 
of poly cyst in-I is associated with cyst formation (Lu '97). 
Additional insight into the mutational mechanism of PKD 1 comes from the 
observation that epithelial cells from ADPKD cysts are clonal in origin (Qian '96) and 
that approximately 20% of cysts exhibit loss of heterozygosity (LOH) at PKD I, 
apparently due to a mutation of the wild type allele (Qian '96, Brasier '97). A 'two-hit' 
model is an attractive explanation for the focal nature of cyst fOlmation and for the 
variability of cystic disease in PKD I. It is however unclear why LOH was demonstrated 
in only a minority of the cysts. It is possible that this reflects a limited ability to detect 
mutations, rather than a lack of somatic mutations. An altemative explanation may be that 
second-hit mutations are not required for cyst fonnation. 
Further exploration of the mechanism by which the initial germline mutation leads to 
the focal development of cysts in ADPKD may guide the development of treatment 
strategies. If, as an example, ADPKD is based on 'loss of function' of polycystin-I or 
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polycystin-2, targeted gene complementation might be an option to intemlpt the cystic 
process (Moullier '94). 
The gene-products of the PKDI (polycystin-I), PKD2 (polycystin-2) and Tg737 genes 
have been predicted from the DNA sequences and the respective protein functions are the 
focus of intense investigations. Polycystin-I is thought to be a membrane glycoprotein 
involved in cell adhesions (Hughes '95 TIle Intemational Consortium '95), whereas 
polycystin-2 has homology to a family of voltage gated sodium/calcium channels 
(Mochizuki '96). The two proteins can interact in experimental systems, suggesting 
cooperation in vivo (Qian '97, Tsiakas '97), consistent with the phenotypic similarities of 
PKD 1 and PKD2. Further in vitro studies indicate that polycystin-l may also co-associate 
and potentially interact with other proteins including Tg737, G-proteins and cell adhesion 
molecules, suggesting that polycystin-l plays a role in multiprotein cell-cell and cell-
matrix interactions (Wilson '99b, '99c). Such interactions may regulate different cellular 
programs such as proliferation, differentiation and apoptosis through the activation of 
specific transcription factors (Arnauld '99). 
It is likely that further investigations will reveal even more proteins involved in the 
normal cellular functions of the polycystins and disclose whether the observations in 
experimental systems reflect the situation in vivo. Understanding the nOlTIlal fUllction of 
these proteins may contribute to the understanding of the pathophysiology of 
cystfonnation. 
It is to be expected that many more genes involved in renal cystic diseases, other than 
PKD 1 and PKD2, will be identified and characterized within the near future. These 
include the ARPKD gene, the PKD3 gene, the nephronophthisis and medullary cystic 
disease genes and a number of genes responsible for spontaneous animal models of PKD, 
including primaty disease genes and disease modifying genes. It is tempting to speculate 
that some or all of these genes are involved in a conmlon cystogenic pathway and that 
their characterization may provide extra opportunities to study the complex processes of 
cyst fmulation and cyst expansion. Such studies may also reveal the mechanisms that 
detelmine the high variability of disease expression, associated with both ADPKD and 
ARPKD. 
The cellular phenotype of PKD epithelia 
potential targets for treatment 
Celll/la/' pathophysiology 
Cyst lining epithelia have been studied extensively by many investigators. These 
shldies revealed a vast number of cellular abnonnalities, as reviewed by many authors 
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(Wilson '96) as well as in Chapter I of this thesis. The causal relationship of these 
abnomlalities with the underlying genetic defects of PKD is unclear and mandates further 
investigations. Irrespective of the complete understanding of their pathophysiology, 
cellular phenomena may serve as targets for the treatment ofPKD. 
Following an early stage of nonnalnephrogenesis, PKD cysts develop as dilations of 
normally developed renal tubules. The initiation of cyst fOlmation is highly variable 
among patients as well as among individual nephrons. It has become evident that the focal 
loss of control on tubular diameter and the subsequent fommtion of cysts is associated with 
abnomlal epithelial cell proliferation and cell survival, altered transtubular fluid transport 
and abnormal composition and accumulation of extracellular matrix constituents. 
In addition to these abnoIDlal cell functions, a large number of abnormalities of the 
structure and composition of the cystic cell have been described. These include 
ablloIDmlities of the cytoskeleton, the Golgi complex, the plasmamembrane composition, 
the basement membranes, and many different proteins including growth factor receptors 
and transcription factors. Particularly interesting has been the observation in human 
ADPKD and ARPKD, as well as in some of the murine models of PKD, that cyst lining 
epithelia manifest abnormal cell polarity with regard to a number of proteins, including the 
EGF receptor and Na-K ATPase. Abnomlal cellular distribution of these proteins may 
theoretically playa role in both the proliferation and abnomlal trans tubular fluid transport 
of cystic epithelia. It should be noted however, that most of these data are derived from 
either end stage ADPKD kidneys or from murine models of PKD. Whether they also 
reflect the situation in early cystogenesis in human disease is unclear. 
It also remains to be determined how the various ceBular abnormalities of the cystic 
phenotype relate to each other and contribute to either the fonnation of cysts and/or to the 
subsequent progression of the lesions. 
Tile cellular pllellotype as a target for treatlllellt 
The current knowledge of the cellular phenotype of cystic epithelia may present new 
opportunities for treatment. To target therapies to the abnonnal extracellular matrix 
composition and matrix metabolism or to the altered tubular fluid transport will be difficult 
until more is known about the pathophysiology of these processes. The most appealing 
target for therapeutic interventions at present appears to be the abnomlal cell proliferation 
in cyst-lining epithelia. 
Cumulative data indicate that epithelial cell proliferation plays a primary role in cyst 
development and cyst growth. Epithelial hyperplasia is present in all human renal cystic 
diseases and appears to precede the fonnation of cysts (Gab ow '91, Nadasdy '95). At the 
molecular level, PKD has been associated with increased expression of a number of ProtOM 
oncogenes. Moreover, overexpressioll of protoMoncogenes and growth factors in 
experimental animals has resulted in renal cyst formation. 
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A particular role in the proliferation of cystic epithelia appears to be played by the 
EGF-EGFR axis. EGF is one of the most potent stimulators of epithelial cells, has been 
detected in mitogenic concentrations in ADPKD cystfluid and is capable of inducing cysts 
in organ culture models. Moreover, functionally active EGF-receptor was found to be 
overexpressed and mislocated to the luminal cell membranes of ADPKD cysts, as opposed 
to the basolateral distribution in normal renal tubules. Similar results were obtained with 
tissues from three genetically different mouse models of ARPKD (Sweeney '98). Taken 
together, these data suggest that an abnonnal autocrine or paracrine EGF loop may be a 
common cystogenic pathway, downstream from a number of different primary gene 
mutations. Two recent shldies indicate that interference with this pathway may ameliorate 
the cystic process. Richards et a!. reported that mice homozygous for the OIpk mutation 
have less cystic lesions and a longer life span when intercrossed with EGF-receptor 
mutants (Richards '98). Sweeney et a!. demonstrated that phalmacological inhibition of 
EGF receptor activity can reduce progression of cystic lesions in a murine organ culture 
model of ARPKD (Sweeney '99). From these studies it can be hypothesized that inhibition 
of the EGF-EGFR axis in human PKD may reduce the cystic damage. Such treatments will 
only be applicable to human patients if specific targeting to the cells of interest can be 
guaranteed, in order to avoid serious side effects. 
It is of interest in this regard, that succesful targeting of vectors to tubular-segment 
specific sites, has recently been reported. Moullier et a1. demonstrated in mice that vectors 
brought into the renal arterial circulation ,vould target proximal tubules, while retrograde 
introduction from the renal pelvis would target collecting tubules (Moullier '94, Lai '98). 
This is particularly relevant in ARPKD where cysts arise predominantly in collecting 
tubules. In addition, Zhu et a!. reported that genes can also be transferred succesfully into 
nonnal as well as cystic rat kidneys (Zhu '96). Selective targeting may be enhanced by 
taking advantage of the apically expressed EGFR in cystic epithelia. Methods to target 
delivery through receptor mediated endocytosis of foreign genes, coupled to ligands such 
as EGF, have already been reported (Wu '89). 
An altel1lative approach to target cystic epithelia and inhibit cell proliferation 
specifically in collecting tubular cysts has been proposed by Gattone et a!. (Gattone '99). 
Collecting tubules are the predominant site of cyst development in human ARPKD as well 
as in most recessive mouse models. One of the biological systems specifically localized to 
collecting tubules is the vasopressin-aquaporin axis. It was hypothesized that this axis 
might be involved in the progression of PKD. This was based on the observations that the 
vasopressin type-2 receptor (V,R) was overexpressed in cystic kidneys of cpk mice and 
that activation ofV2R is known to stimulate the production of cAMP, a substance capable 
to promote cyst enlargement in vitro. Gattone et a!. found that inhibition of the 
vasopressin-aquaporin system, using a relatively specific V2R antagonist, was associated 
with a marked reduction of cyst enlargement and with delay of renal failure. This approach 
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may be an attractive option for human ARPKD patients, if a similar effect can be 
demonstrated. V,R antagonist have already been used succesfully in human cardiac 
patients participating in clinical trials (Martin '99). 
We conclude that the cellular phenotype of PKD presents targets for therapeutic 
interventions. TIle various options need to be explored in more detail. Further 
understanding of the cellular pathophysiology of PKD may identify even more and better 
potential targets for h·eatment. 
The clinical phenotype of PKD 
potential targets for treatment 
This discussion deals with renal aspects of PKD. Non-renal manifestations of PKD, 
including severe complications such as cardiovascular disease, cerebral aneurysms and 
hepatobiliary disease, are beyond the scope of this discussion and have been reviewed 
elsewhere (Welling 96). 11,e clinically most serious renal symptoms are hypertension and 
renal failure. 
Hypertellsioll 
Hypertension is a conUllon complication of PKD and contributes to its morbidity and 
mortality. Longitudinal observations indicate that hypertension is a major contributant to 
disease progression in ADPKD (Chapman '97, see also the following section 'renal 
failure'). Among affected children, hypertension occurs in both ADPKD and ARPKD, but 
tends to be more severe in A RPKD. 
The mechanisms causing hypertension in PKD are unclear. Expansion of the 
intravascular volume is thought to play an important role in both recessive and dominant 
PKD (Kaplan '89, d'Angelo '75). Activation of the renin-angiotensin-aldosteron system 
(RAAS) appears to play an additional role in ADPKD and has been associated with 
increased renal vascular resistence, increased sensitivity to angiotensin II, renal sodium 
retention and volume expansion (Watson '92, \Vang '97). Whether activation of RAAS is 
also present in ARPKD is unclear because the reported data are controversial. It is thought 
that increased activity of RAAS may result from il1trarenal angiotensin II production, due 
to local ischaemic conditions and may directly contribute to the obsented vascular damage 
and renal interstitial fibrosis. Such vascular lesions, including glomerular sclerosis, are a 
prominent finding in ADPKD. Zeier et a1. described that, in advanced ADPKD, arteriolar 
sclerosis was much more marked in the kidney than in other viscera (Zeier '91). Although 
the progression of renal damage in PKD is clearly multifactorial, extrapolation from other 
progressive renal disorders such as diabetic nephropathy, in association with the observed 
increased activity of RAAS, indicates that glomenllar hypertension may be an important 
factor. 
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In view of these considerations, angiotensin converting enzyme (ace) inhibitors have 
been advocated as dmg of choice in ADPKD induced hypertension (Watson '92). In 
addition to lowering systemic blood pressure (Ecder '99), these dmgs are thought to reduce 
glomemlar hypertension and thus may reduce the progression of renal damage in PKD. 
ReJ/al [ailllre 
Although convincing hypotheses have been advanced to explain the development of 
cysts, the mechanisms leading to renal failure in cystic kidneys are less understood. It is 
noted that even in advanced cases of ADPKD, cysts develop in only a minority of the total 
nephron population. Most nephrons appear to be lost without fonning a cyst, either as a 
consequence or in parallel with, cystfoffimtion elsewhere. Histological features associated 
with end stage renal failure (ESRF) in ADPKD include advanced renal vascular sclerosis, 
marked interstitial fibrosis and focal tubular atrophy (Zeier '91). Vascular changes are 
assumed not to be just the consequence of hypertension since these are also present in 
normotensive patients. Moreover vascular changes in ADPKD are kidney specific and 
more severe than in patients with comparable renal dysfuIlction who suffered from 
glomentlar disease. Severe interstitial fibrosis was associated with scarce infiltrates of 
Iymfocytes and macrophages. Pathophysiologic mechanisms that might explain the loss of 
functioning nephrons include glomemlar hyperfiltration, vascular sclerosis and mechanical 
compression by cysts and / or interstitial fibrosis. FUIiher studies on these mechanisms are 
hampered by the lack of human tissues from early disease states. 
End stage renal failure (ESRF) complicates the disease course in all patients with 
ARPKD and about half the patients with ADPKD. However, the rate of progression to 
ESRF is highly variable, even among family members, who are affected by the same 
genetic defect. In ADPKD, a number of factors have been associated with progression, 
including genotype, gender, ethnicity, hypertension, age at clinical presentation, 
pregnancies and urinary tract infections. TIle pathophysiologic mechanisms underlying 
these associations are poorly understood. Similar data on ARPKD patients are not 
available. 
The effect of genetic heterogeneity on the cystic phenotype has been well recognized in 
ADPKD. Although the clinical and histopathological manifestations of PKD I and PKD2 
are indistinguishable in individual patients, these are markedly different when comparing 
groups of patients. Patients with PKD I have on average a more severe disease, including 
more hypertension and the development of renal failure at a higher frequency and at 
younger age than patients with PKD2. Genetic heterogeneity also contributes to clinical 
variations within the subgroups of PKD 1 and PKD2 patients. It has, for example, been 
recognized that patients with large deletions, overlapping the neighbouring TSC gene, 
manifest very severe early onset disease, in comparison to patients with smaller mutations. 
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Additional clinical variatiability may, in theOlY, result from somatic mutations of the cystic 
genes. If, as has been suggested, somatic 'second hit' mutations of the wild type allele are 
either required or contributive to the formation of ADPKD cysts, such mutability is likely 
to be variable among individual patients and may further explain the variability of disease 
expression. It will be clear that further analysis of ADPKD mutations and of the 
corresponding protein defects will be needed to understand these genotype-phenotype 
relations in more detail. 
Most gender studies demonstrate that ADPKD is a more severe disease in men than in 
women. One of the factors predisposing males to an adverse renal prognosis might be the 
higher prevalence and severity of hypertension in males. Theoretically, increased 
transcription of renin under the influence of androgens could also playa role (Wagner '90). 
It is of interest that a worse prognosis for males has also been noted in the cy rat model of 
ADPKD and it was found that orchidectomy reduced the cystic damage in affected 
animals. Testosterone abrogated this effect in male rats and aggravated the disease course 
in female rats (Cowley '97). Better understanding of the endocrine and cellular 
mechanisms underlying this gender effect may reveal targets for therapeutic intervention. 
Ethnicity has also been associated with renal outcome (Yium '94). Black American 
patients have earlier onset of ESRF than do white patients, indicating the presence of yet 
unidentified genetic, environmental and/or socio~economic factors that need to be 
explored. 
Hypertension is present in the majority of patients with either ADPKD or ARPKD and 
multivariate analysis of ADPKD data indicated that hypertension is an independant risk 
factor for the development of renal failure. In addition, Ritz et al. observed that the age at 
onset of ESRF in ADPKD was lower in the offspring of families with prinmy 
hypertension (Gebel1h '95). It is now generally assumed that hypertension contributes to 
the development of renal failure. TI,is may be further supported by histological data from 
ADPKD tissues, suggesting particular susceptibility of renal vessels to blood pressure 
induced injury, as compared to arterioles in other viscera (Zeier '91). It has been 
hypothesized that antihypertensive treatment, especially with ace-inhibitors, may delay the 
development of renal failure. Such an effect has indeed been demonstrated in the CJ' rat 
model of PKD, using ace-inhibitors (Ogbol1l '95'). However, direct evidence of a renal 
protection by treatment with ace-inhibitors in either hypertensive or nonl1otensive human 
PKD patients, has not yet been reported. 
The cumulative data strongly suggest that hypertension is deleterious for renal 
prognosis in PKD, as it is in other renal disease, for example in glomemlonephritis or 
diabetic nephropathy. A lot more work is clearly needed to understand the mechanisms and 
therapeutic options of hypertension and of its damaging effect on cystic kidneys in both 
ADPKD and ARPKD. These investigations will include clinical trials in patients andlor 
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animal models as well as experimental studies on haemodynamic, endocrine and cellular 
factors involved in the pathophysiology of hypertension-induced renal damage in PKD. 
Treatment of PKD in experimental models 
Several therapeutic options have recently been tested in experimental PKD models. 
Some of these yielded a significant reduction of the cystic lesions and I or a delay of the 
development of renal failure. Although most are not (yet) ready for clinical use, these 
observations will ulldoubtly direct further investigations. 
A number of different genetic manipulations were succesfully applied to ameliorate the 
manifestations of murine pkd: I). Supplementation of the pkd inducing mutation with wild 
type gene can significantly reduce the expression of disease in the OJpk mouse model 
(Yoder '96); 2). A change of the overall genetic background can drastically reduce the 
cystic phenotype in a number of animal models (Fry '85, Nagao '91, Moyer '94, Upadhya 
'99 ); 3). Genetic inhibition of the EGFR has been associated with reduced disease 
manifestations in murine PKD (Richards '98 ). 
Promising results have also been obtained using specific inhibitors of biological 
processes thought to be part of the pathophysiology of cyst fonnation: I). Inhibition of the 
renin-angiotensin axis (thought to be involved in disease progression) reduces cystic 
damage and prolongs renal survival in pkd of the c)' rat model (Ogborn '95'). This 
protective effect could not (yet) be established in human ADPKD patients with renal 
failure (Ecder '99, Wang '97). However, systematic studies in early ADPKD and in 
patients with ARPKD have not yet been reported. 2). Inhibition of the vasopressin V-2 
receptor (thought to playa role in collecting tubular cyst progression) was found to reduce 
cyst enlargement in arpkd of tile cpk mouse model (Gattone '99, Martin '99). 3). Inhibition 
of the EGFR signaling pathway or of the tubular sodium pump (Na-K ATPase), can block 
experimental cyst induction in metanephric organ cultures (Avner '85, '87b, Pugh '95). 
An interesting observation by Woo et al. indicated that paclitaxel (Taxol) can 
dramatically reduce the cystic damage to the kidneys and prolong lifespan in affected cpk 
mice (Woo '94). This observation was later suggested to result from the ability of 
paclitaxel and related taxanes to stabilize microtubules and promote microtubule assembly 
(Woo '97'). These promising results were later confll1lled by others (Martinez '97). 
Hmvever, while paclitaxel had a positive effect in cpk mutant mice, this effect was not 
applicable to three other murine models of PKD (Martinez '97, Sommerdahl '97). 
Moreover, paclitaxel exhibits considerable toxicity. More experimental studies of both 
efficacy and toxicity would be needed to further explore the therapeutic potential of 
microtubule specific agents. 
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Discussion 
Several dietary interventions were reported to have a renal protective effect in murine 
pkd models. These include protein restriction (Cowley '96, Ogborn '95a, Aukema '92c), 
soy as a protein source (Aukema '99, Ogborn '98) and enrichment of standard chow with 
10% flaxseed (Ogbom '99). Recent clinical evidence indicates that patients with advanced 
ADPKD may benefit from dietary protein restriction (Klahr '97). However, more and 
longer systematic prospective stndies, also involving early cases of ADPKD and patients 
with ARPKD, are clearly needed to resolve these issues. If similar protective effects can 
also be demonstrated in humans with PKD, dietary measures will be a relatively simple 
way to reduce morbidity and delay renal failure in these patients. 
The cumulative data suggest that PKD may be ameliorated also in human patients and 
provide a basis for further exploration of the therapeutic options in this severe disorder. 
Conclusions 
PKD research made remarkable progress during the last two decades. New insights 
were obtained from different research fields. Genes hosting the primary mutations have 
been localized (ARPKD) and characterized (ADPKD). In addition, several murine genes 
that either host a primary PKD mutation or encode disease modifying factors, have been 
identified and localized. At the cellular level, a multitude of structural and functional 
phenomena were specifically associated with the cystic phenotype. Taken together, these 
phenomena indicate that abnomlal epithelial cell proliferation, altered fluid transport and 
abnormal regulation of extracellular matrix constituents are all part of the cellular 
pathophysiology of PKD. Clinical and epidemiological studies demonstrate that disease 
manifestations of ADPKD and ARPKD are highly variable, both between and within 
affected families. This variability indicates that genetic and envirOllllental factors, other 
than the primary mutation, are critical determinants of disease severity in PKD. 
Direct treatment is not available to PKD patients. However, a number of promising 
treatment options have been succesfully applied in aninlal models of PKD. More 
fundamental as well as treatment oriented research is clearly needed to further explore 
these options. A particular challenge to fuhlre researchers is to understand the functional 
relationship between the multitude of PKD abnormalities observed in different fields of 
research: genetics, cellular pathophysiology and clinical observations. Especially fruitful 
may also be the exploration of factors that determine the highly variable expression of 
disease manifestations in PKD. 
As in the past, experinlental models of cyst fOlmation provide helpful tools for such 
investigations. Genetically detemrined animal models can be nsed to investigate, in a 
systematic way and at different stages of disease, the genetical, cell biological and clinical 
aspects of renal cyst formation. The models described in this thesis provide unique 
opportunities for snch studies. The bpk mntation expressed in Balblc Mice is a good 
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model of ARPKD (Chapter 2.1). Although genetically distinct from its human counterpart, 
affected bpk mice express a clinical and histological phenotype much like human ARPKD 
patients, including hyperplastic lesions of the intra- and extrahepatic biliary tract. The 
succesful isolation and culture of the biliary epithelial cells from affected bpk mice, 
enables the investigation of key pathophysiologic features of ARPKD epithelia (Chapter 
2.2). 11le Han:SPRD-cy model is not a genetic model of PKDl (Chapter 2.3). 
Nevertheless, we consider Han:SPRD-cy a valuable model of PKD. Its phenotypic 
similarities with human ADPKD makes cy more appropriate as a model to Shldy specific 
aspects of the PKD 1 phenotype, when compared to the pkd I knockout mouse, which 
expresses only mild cystic lesions and at old age only. The lI'pk rat model, described in 
Chapter 2.4, manifests a renal phenotype resembling human ARPKD, including a 
collecting tubular nature of the cysts, proteinuria and severe systemic hypertension. 
Although genetically distinct from human ARPKD, we consider lI'pk of particular valne to 
study the cellular pathophysiology and therapeutic options of collecting tubular cyst 
formation. Wpk may additionally be used to explore the cause and potential treatment of 
systemic hypertension in ARPKD, as well as to study the contribution of hypertension to 
the development of renal failure in PKD. The long history of hemodynamic and 
physiologic studies in rats makes lvpk morc suitable for such studies than the existing 
mouse models of ARPKD. 
We found that 'programmed cell death' (apoptosis) occurs during nonnal human 
kidney development and continues at a velY low level after birth. More importantly, 
apoptosis occurs at an increased level in human ARPKD and dysplastic kidneys as well as 
in mouse ARPKD (Chapter 3.1). These data parallel the finding of increased apoptosis in 
human ADPKD by Woo et aJ. (Woo '95), suggesting that apoptosis is part of a conmlon 
cystogenic pathway. "'hether apoptosis is either the cause or the consequence of cyst 
formation remains to be detennined. In vih'O studies suggest that apoptosis may be an 
essential part of the fomlation of cysts. Lin et aJ. demonstrated that the fOlIDation of cysts 
by canine kidney cells (MDCK) in three dimensional cultures can be prevented by 
inhibiting apoptosis (Lin '99). Apoptosis was inhibited in this system using overexpression 
of the anti-apoptoticproto-oncogene bcl-2. The fact that apoptosis can be reduced by 
various molecular means both in vivo and in vitro suggests potential for novel therapeutic 
strategies (Coles '92, Kelllledy '97, Lin '99). However, such therapies may have 
unintended side effects because apoptosis can also be viewed as a last line of defense 
against neoplastic transf0l1llation of the hypelproliferative epithelia in PKD. Elucidation of 
the mechanisms responsible for the coupled stimultion of apoptosis and proliferation in 
PKD may provide opportunities for interventions that avoid the potential risk of selectively 
inhibiting apoptosis alone. 
In Chapter 3.2 we report our efforts in vain to identify polycystin-l in human renal 
tissues, using inununological detection methods. This is in contrast to reports by other 
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investigators. We conclude that the renal localization ofpolycystin-I is not yet certain. The 
issue is clearly controversial and may be elucidated when reagents are exchanged between 
illdependant research groups and when adequate control tissue, lacking polycystin-l 
expression, becomes available to test the available antisera. 
PKD is an inevitable disorder in those who inherit the genetic defect. The main 
objective of further research will be to reduce the progression of the cystic lesions and to 
delay the development of renal failure. The experimental models presented in this thesis 
provide new opportunities to study the pathophysiology underlying these processes. 
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Summary 
In this thesis we report experimental data regarding the pathophysiology of polycystic 
kidney disease, PKD. PKD is the most frequent inherited cause of renal failure in humans 
and is characterized by the progressive replacement of nonnal renal tissues by fluid filled 
cavities (cysts). A direct treatment of the cystic process is not available. The development 
of such a treatment will require a proper understanding of the biological mechanisms 
involved in the pathophysiology of cyst formation. 
In chapter 1 we review the PKD literature. This review presents the clinical entities of 
PKD, as well as a summary of the CUlTent understanding of cyst fOllllation. Specifically, 
we focus on the contribution of experimental models ofPKD to cunent knowledge. 
PKD includes autosomal dominant polycystic kidney disease (ADPKD) and autosomal 
recessive polycystic kidney disease (ARPKD). This classification parallels differences in 
clinical, genetic and histopathological features. ADPKD affects I in 1.000 individuals and 
leads to renal failure in half the patients, usually after the third decade of life. The disease 
results from the progressive fonnation of cysts, often complicated by hypertension and 
sometimes by renal infections. Many patients have additional cysts in the liver. Other 
manifestations include cerebral aneurysms, cardiac valve abUOlnmlities and cysts in other 
excretory organs. In contrast, ARPKD affects only 1 in 40.000, but is a more severe 
disease than ADPKD, leading to renal failure either at birth or during childhood in all 
patients. The renal lesions are associated with severe hypertension, biliary hyperplasia and 
hepatic fibrosis. 
Genetic analysis has revealed a number of causative gene defects. The gene involved in 
ARPKD has been localised to chromosome 6p21.1-pI2, but has not yet been cloned. 
ADPKD results from a mutation to any of at least three distinct genes. Two of these 
genes, PKD I and PKD2, have been cloned and sequenced. The proteins PKD 1 and PKD2 
gene products, polycystin-l and polycystin-2, are predicted to be transmembrane proteins 
involved in ceH-ceH and cell-matrix interactions. At present, many different research 
groups are attempting to defIne the normal functions of these proteins and to investigate 
how their absence and/or disfunction leads to renal cyst fOlmation. 
Histopathological and cell biological analysis indicates that cysts develop as dilations 
of histologically normal nephrons. Interestingly, this process does not affect all nephrons, 
suggesting that factors other than the genetic defect are involved in the initiation of cyst 
fOllllation. It has been proposed that the formation and subsequent expansion of cysts 
requires at least three key pathologic features: epithelial cell proliferation, altered 
transepithelial fluid transport and abnormal regulation of the extracellular matrix. These 
features have been studied extensively, using both human tissues and experimental models 
ofPKD. 
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In order to better understand the factors involved in renal cystogenesis and in the 
progression towards renal failure, many investigators have focussed on either animal 
models, whole organ models or cell models of renal cyst formation. In this first chapter we 
present a summary of the currently available models and assess their contribution to the 
understanding of the pathophysiology of renal cystic disease. 
In chaptel' 2 we report the exploration of a number of experimental PKD models. 
In chapter 2.1 we describe the characteristics of a new spontaneous mouse model of 
ARPKD, bpk. Affected bpk mice manifest severe renal cystic disease in association with 
biliary abnonnalities, much like human ARPKD. Homozygotes typically die before 
reaching maturity, due to renal failure with enlarged kidneys. Renal cysts shift from 
proximal tubules at birth to collecting tubules 20 days later. TIle epithelium lining these 
cysts is clearly overRproliferative, as indicated by the increased amount of mitosis in these 
cells compared to nOlmal epithelium. In addition, epithelial hyperplasia was found in the 
intra- and extrahepatic biliary tract of affected mice, including nonobstl.1lctive hyperplastic 
dilatation of the extrahepatic biliary tract. The hyperplastic renal and biliary lesions make 
the bpk mouse strain a good model for the dual organ cellular pathophysiology of PKD. 
We isolated, cultured and characterized bilialY tract epithelium from common bile duct 
explants of bpk mice in order to explore the cellular basis of this hypelplasia (chapter 2.2). 
Primary cultures resulted in dense colonies of contact-inhibited epithelial cells with a 
homogenous growth pattern. Colony grmvth in semmRfree basal medium of bpk-derived 
cells was not different from controls, as assessed by thymidine uptake and colony size 
increments. Supplementation of the medium with epidermal growth factor (EGF) however, 
induced a proliferative response in the bpk colonies that was significantly increased over 
controls, as assessed by thymidine uptake and colony size increments. This increased 
response was not observed using other growth factors. We concluded that primary cultures 
of bpk biliary epithelium may provide a useful in vitro model for the study of the cellular 
pathophysiology of ARPKD. 
While mouse models are particularly well suited for investigating the molecular 
pathogenesis of PKD, the rat is well-established as an experimental model of renal 
physiology. The Han:SPRD-cy rat has been proposed as a model for ADPKD. The study 
described in chap tel' 2.3 explores the genetic basis of the Han:SPRD-cy rat model of 
ADPKD. We investigated whether the disease in these rats is linked to the rat homologue 
of the PKD 1 gene. PKD 1 carries the disease-causing mutation in most patients with 
ADPKD. We used the protamine gene (p/'II/J) as a polymorphic marker for the PKDl 
region in the rat. Mating Han:SPRD-cy rats with the inbred BB strain and backcrossing the 
offspring with BB rats yielded animals infoffimtive for linkage analysis. This analysis 
indicated that PKD in the Han:SPRD-cy rat is not caused by a mutation in the PKD 1 gene. 
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We have now identified a new spontaneous rat mutation, designated wpk. In chapter 
2.4 we describe the characterization of the wpk phenotype as well as the mapping of the 
wpk locus. The phenotype of homozygous mutants resembles human ARPKD, including 
nephromegaly, hypertension, proteinuria, uremia and death before reaching maturity. The 
renal cysts shift from both proximal and distal nephron segments at birth to collecting 
tubules during neonatal development. Affected rats show no evidence of biliary tract 
abnonllalities. The wpk locus was mapped just proximal of cy, the locus involved in the 
Han:SPRD-cy rat model, on chromosome 5 and complementation testing has demonstrated 
that these two loci are not allelic. While homology mapping indicates that rat wpk and 
human ARPKD involve distinct genes, this new mutation provides an excellent 
experimental model to study the molecular pathogenesis as well as the renal 
pathophysiology of ARPKD. 
Organogenesis involves an increase in cell numbers, cell differentiation and 
morphogenesis. The increase of cell number results from both proliferation and death. 
'Programmed cell death' is a well defined cellular phenomenon and thought to be playa 
role innonnal differentiation and morphogenesis. We report in chapter 3.1 that apoptosis 
occurs during normal renal development and continues at a very low level after birth. 
Moreover, we noted that apoptosis occurs at an increased incidence in pre- and postnatal 
human ARPKD and dysplastic kidneys, when compared to age matched controls. In 
ARPKD kidneys we found widespread apoptosis in the interstitium around undiluted 
tubules, in undilated tubules between cysts and in the cyst lining epithelia. We speculate 
that deregulation of cell survival may reflect incomplete tissue maturation and may 
contribute to the progressive destmction of functional kidney tissue. 
Mutations in the PKD I gene are responsible for most cases of polycystic kidney 
disease, but little is known about how these mutations lead to the development of cysts. 
Even less is known about the nomml role of polycystin-I, the PKD I gene product. 1n 
chapter 3.2 we describe our studies on the cellular localization of polycystin-l. We 
generated 14 different pOlyclonal antisera against fragments of the predicted 462 kD 
polycystin-I protein to enable us to investigate the expression of polycystin-l in cells and 
tissues by inllllunocytochemistry, Westenl blotting and immulloprecipitation. These 
antibodies readily recognized a 134 kD polycystin-I fragment overexpressed in COS cells 
and stained the epithelial' cells of fetal, adult and cystic kidney sections with the same 
pattem as reported by others. However, further investigations revealed that this pattem was 
not specific for polycystin-l. We could not unequivocally detect polycystin-I in vivo, 
either by innnunocytochemistry or inununoblotting. Our studies do not support the 
reported pattem of polycystin-I expression in the kidney and we therefore conclude that 
the renal localization of polycystin-I remains uncertain. 
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In chapter 4 we discuss the fuhlIe perspectives of PKD research. PKD is an inevitable 
disease for those inheriting the genetic defect. The ultimate goals of biomedical research 
into PKD are to reduce the cystic process and to delay the development of renal failure. 
The current understanding of these processes comes from clinical, genetical and cell 
biological observations. However, little is known about the relationship between these 
three different sets of observations. A major challenge of future PKD research is to 
integrate these three different fields of research in order to understand how gene defects 
disrupt the nonnal functions of cells, leading to the fonnation of cysts and ultimately to 
renal failure. 
Particularly fruitful may be to elucidate the heterogeneity of the PKD phenotype. 
Remarkable heterogeneity is present at the cellular level, where the cystic process affects 
only a minority of the nephrons. Heterogeneity at the clinical level has been well 
documented, both between and within PKD families. Understanding the mechanisms that 
determine whether a particular nephron and a particular patient will be more affected than 
others, may provide important insights for the development of effective therapeutic 
strategies. 
Experinlental models of PKD have contributed significantly to the current 
understanding of PKD. Genetic studies have revealed a number of genes and gene products 
that are involved in the fonnation of renal cysts and/or in subsequent renal failure. In 
addition, experimental models allow the systematic study of specific cellular processes 
involved in PKD, during different stages of development of nomlal and cystic kidneys. 
Moreover, animal models have been succesfully used to explore a large number of 
potential treatment strategies. It is therefore to be expected that these experinlental models 
may also guide investigations in the future and contribute to the understanding of the 
pathophysiology and therapeutic options of human PKD. 
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Samenvatting 
In dit proefschrift beschrijven we resultaten van experimenteel onderzoek van 
polyeysteuze nierziekten (Qolycystic kidney gisease, PKD). Deze groep ziekten wordt 
gekenmerkt door de vonning van cystell in beide niercn en door cen hoge mate van 
erfelijkheid. Cysten zijn met voeht gevulde blaasjes die, behalve in de nieren, ook in 
andere organen kmmen voorkomen. Naar het erfelijkheidspatroon wordt onderscheid 
gemaakt tussen autosomaal recessieve PKD (ARPKD) en autosomal dominante PKD 
(ADPKD). Naast PKD bestaan er nog andere vormen van cystenieren, die in dit 
proefschrift buiten beschouwing blijven. 
Ondanks intensief onderzoek bestaat er nog geen gerichte behandeling voor patienten 
met PKD. Voor het ontwikkelen van een dergelijke behandeling is meer begrip nodig van 
het biologisch mechanisme van cystevonning. Naar dit mechanisme is in de laatste twee 
decennia veel onderzoek gedaau, waarbij enerzijds gebmik is gemaakt van materiaal 
afkomstig van patienten met PKD en anderzijds van verschillende diennodellen van PKD. 
Het huidige inzicht is vooral afkomstig uit drie verschillende onderzoeksgebieden: 
Klinische observaties van de ziekteverschijnselen, celbiologische observaties betreffende 
abnOlIDale eigenschappen van de cellen die betrokken zijn bij het cysteuze proees en 
genetische observaties betreffende de defecten in het erfelijk materiaal dat ten grondslag 
ligt aan de verschillende vomlen van PKD. 
In hoofdstuk 1 wordt een overzicht gegeven van de beschikbare literatuur gegevens 
over PKD. We belichten hierin naast ziekteverschijnselen vooral de huidige inzichten in de 
ontstaanswijze van cysten. Als inleiding op de eigen onderzoekingen wordt daarbij met 
name aandacht gegeven aan de bijdrage die de versehillende experinlentele modellen van 
PKD tot op heden hebben geleverd. 
PKD is de meest frequente erfelijke oorzaak van nierfunctie verlies bij de mens. De 
ernstigste vonnen van de ziekte worden op de kinderleeftijd gezien, maar de meest 
frequente VOrmen komen meestal pas op volwassen leeftijd tot uiting. Op grond van het 
erfelijkheidspatroon wordt PKD onderscheiden in ADPKD (overerving naar 50% van de 
nakomelingen) en ARPKD (25% van de nakomelingen). Dit onderscheid is tevens van 
belang in verband met verschillen in klinisch beloop en prognose. De verschillen in 
erfelijkheidspatroon weerspiegelen verschillende genetische defecten en gaan gepaard met 
specifieke veranderingen in de betrokken weefsels en cellen. 
ADPKD komt relatief frequent voor (1:1000 mensen) en leidt bij de helft van de 
patienten tot nierfalen en dus tot afhankelijkheid van dialyse en lof niertransplantatie. De 
ziekte leidt in het algemeen pas op middelbare leeftijd tot emstige problemen. In 
uitzonderlijke gevallen komt ADPKD op de kinderleeftijd tot uiting en soms al voor de 
geboorte. De belangrijkste gevolgen van de nieraandoening zijn nierfalen en hoge 
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bloeddruk. Daamaast onstaan in de loop van de tijd bij veel patienten cysten in de lever en 
soms in andere organen. Een zeldzame en onbegrepeu, maar bijzonder ernstige 
manifestatie van ADPKD is het optreden van cerebrale aneurysmata, die tot 
hersenbloedingen aanleiding knmlCn geven. 
ARPKD komt minder frequent voor (l :40.000) en leidt bij vrijwel alle patienten al op 
de kinderleeftijd tot nierfalen en diajyse behoefte. Een deel van de patienten overlijdt al bij 
de geboorte aan ademhalingsproblemen die indirect het gevolg zijn van onvoldoende 
nierfunctie tijdens de embryonale ontwikkeling. ARPKD gaat in vrijwel alle gevallen 
gepaard met afwijkingen aan de galwegen, die kunnen leiden tot leverfalen en portale 
hypertensie. 
Het maken van onderscheid tussen ADPKD en ARPKD kan op de kinderleeftijd 
moeilijk zijn. In moeilijke gevallen wordt het onderscheid gemaakt op grond van familie 
geschiedenis, ziekte beloop, beeldvonnend onderzoek van niercn en lever en zonodig 
weefselonderzoek (biopsie). Wellicht zal dit in de toekomst kUl1llen worden aangevnld met 
moleculaire analyse van de betrokken genen. 
Het huidige begrip van de vorming van cysten in de nier is vooral gebaseerd op 
genetisch en celbiologisch onderzoek. 
Genetisch onderzoek heeft de erfelijke basis van PKD geidentificeerd en specifieke 
gendefecten (mutaties) aangetoond. ADPKD wordt veroorzaakt door een mutatie in een 
van tenminste drie verschillende genen. Kennelijk is de (onbekende) functie van ieder van 
deze genen voor de nier onmisbaar. Twee van de genen (PKD 1 en PKD2), die samen 
veralltwoordelijk zijn voor de overgrote meerderheid van de patienten, werden geisoleerd 
en ontrafeld. Op grond van de hierbij gevonden genetische code kan de samenstelling 
worden voorspeld van de eiwitten waar deze genen voor coderen. Voorlopige gegevens 
suggereren dat deze twee eiwitten, polycystine-l en polycystine-2, zijn gelocaliseerd in de 
celwalld, waar ze gezamenlijk een funetie uitoefenen die te maken heeft met het contact 
tussell de eel en zijn omgeving. Verder onderzoek is er op gericht deze functie veIder in 
kaart te brengen en te begrijpen hoe een dysfunctioneren van deze eiwitten bij PKD kan 
leiden tot de vomling van cysten. Van ARPKD werd de genetische basis gelocaliseerd op 
het zesde chromosoom. Over de aard van het gemuteerde gen is nog niets bekend. 
Celbiologisch en histopathologisch onderzoek llCeft geleerd dat cysten onstaan als 
toenemende verwijdingen var; histologisch nonnaal aangelegde nierbuisjes (nefronen). 
Opvallend is daarbij dat dit proces in slechts een beperkt aantal van de nefronen optreedt, 
hoewel de genetische mutatie aanwezig is in alle lichaamscellen. Welke factoren bepalen 
of een bepaald nefron cysteus wordt, is onbekend. Er zijn aanwijzingen dat een (later 
verkregen) extra beschadiging van het erfelijk materiaal in de betrokken cellen daarbij een 
rol zau kullnell spelen. 
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Op theoretische gronden ,vordt algemeen verondersteld dat voor de v~nning van een 
cyste tenminste drie abnonnale biologische processen millimaal benodigd zijn: 
Vemleerderillg van het aantal cellell in de cystewand (proliferatie), secretie van vloeistof 
naar de cyste holte en een afwijkend gedrag van het omliggend biologisch milieu 
(extracellulaire matrix). Deze processen werden in de afgelopen jaren uitgebreid 
beshldeerd, waarbij veelal gebmik werd gemaakt van experimentele modellen van 
cystevorming. 
Hoewel PKD werd vastgesteld in diverse diersoorten, werden voor wetenschappelijk 
onderzoek vooral muizen en, in mindere mate, ratten gebmikt. Een deel van deze 
diennodellen berust op 'nahmrlijk' voorkomende PKD (spontane mutaties), en een deel is 
het gevolg van menselijk ingrijpen in het erfelijk materiaal van muizen (transgene 
muizen). Deze transgene modellen bemsten in het aigemeen op een mutatie in een gen 
waarvan de samenstelling en/of functie meer of mindel' bekend is. De illfOlmatie die deze 
modellen tot op heden hebben opgeleverd is, voor ieder model afzonderlijk, in dit eerste 
hoofdstuk samengevat. Daarbij presenteren we een arbitraire selectie van beste 
dielmodellen voor wetenschappelijk onderzoek (TabeI3). 
Tot slot wordt in het eerste hoofdstuk een theoretisch raamwerk gepresenteerd 
waarbinnen de verschillende klinische, genetische en celbiologische observaties geplaatst 
kumlen worden en waarin mogelijke verbanden tussell deze observaties worden 
aangegeven (fig 1). 
Hoordstuk 2 bevat een onderzoeksverslag over de bmikbaarheid van verschillende 
experimentele PKD modellen. 
Allereerst wordt in hoordstuk 2.1 een nieuw diermodel van ARPKD beschreven. 
Eerdere diermodellen hebben als belangrijke tekortkoll1ing het ontbreken van afwijkingen 
aan de galwegen. Dergelijke af\vijkingen zijn bij de mens kenll1erkend voor ARPKD en 
kamen, in wisselende mate, bij aUe patienten voor. hl de door ons onderzochte 'bpk' 
muizenstam bleken aangedane dieren naast dubbelzijdige cystenieren oak afwijkingen aan 
het galwegsysteell1 te hebben, overeenkomstig de af\vijkingen bij patienten met ARPKD. 
Gevonden werd dat aangedane muizen op jonge leeftijd overlijdell aan 
nierinsufficientie door cysteuze destmctie van de nieren. We vanden dat de nier- en 
leverafwijkingen op weefsel niveau sterke gelijkenissen vertonen met die van patienten 
met ARPKD. Bovendien bleken deze dieren een sterke verwijding te hebben van de 
centrale afvoerbuis voor gal, de ductus choledochus. Een van de meest opvallende 
eigenschappen van zowel de nier- als de leverafwijkingen in bpk muizen is een verhoogd 
aantal epitheliale cellen. Daarbij werd bovendien in de niercysten een verhoogd aantal 
celdelingen aangetoond. Deze 'hyperplastische' af\vijkingen van nier- en gal-epitheel 
maken de bpk ll1uis een uitstekend model van ARPKD. 
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In hoofdsluk 2.2 beschrijven we de ontwikkeling van een experimenteel systeem voor 
onderzoek van deze hyperplastische nier- en leverafwijkingen in bpk muizen (zie 
hoofdstuk 2.1). Teneinde de abnom1ale groeieigenschappen van deze epithelia te kllllllen 
onderzoeken werd gezocht naar methoden om de betrokken cellen te isoleren en te 
kweken. Zuivere isolatie van dergelijke cellen uit nier· of leverweefsel bleek niet goed 
mogelijk. Daarentegen bleek de afwijkende ductus choledochus, door haar ligging buiten 
de lever, zeer geschikt voor de isolatie van epitheel cellen. Vervolgens werd een kweek 
systeem ontwikkeld waarin de karakteristieken van deze cellen onder gecontroleerde 
(semm·vrije) omstandigheden kunnen worden onderzocht. Enigszins tegen de 
verwachting, bleken de cellen afkomstig van zieke bpk muizen niet sneller te delen dan 
cellen van gezonde muizen. Indien echter aan het kweeksysteem EGF werd toegevoegd, 
bleken bpk cellen daarvan een sterkere groeiprikkel te ondervinden dan controle cellen. 
EGF is een groeifactor die onder natuurlijke omstandigheden ondem1eer voorkomt in gal. 
Een dergelijke overgevoeligheid werd niet gevonden voor andere groeifactoren. Deze 
specifieke overgevoeligheid van bpk cellen voor EGF past in de hypothese dat epitheel 
proliferatie een onderliggend mechanisme is van de nier- en galweg pathologie in PKD en 
dat daarbij abnonnale regula tie van het EGF syteem betrokken is. 
In hoofdstuk 2.3 wordt onderzoek beschreven naar de genetische achtergrond van het 
meest gebmikte proefdiennodel van ADPKD, de Han:SPRD rat. Deze rat wordt veelvuldig 
gebruikt voor onderzoek naar het mechallisme van cystevonning en naar eventuele 
behandelingsvonnen van PKD. In Han:SPRD is, na een spontane mutatie (later cy 
genoemd; zie hoofdstuk I), een erfelijke vonn van PKD onstaan die gelijkenissen vertoont 
met ADPKD bij de mens, Deze gelijkenissen betreffen zowel ziekteverschijnselen als 
verschillende histopathologische afwijkingen. We hebben onderzocht of de nierziekte bij 
dit diemlOdel bemst op een mutatie van het gen dat gemuteerd is bij de meeste patienten 
met ADPKD, het pkdl gen, Hiertoe werd een genetische (polymorfe) marker gekozen die 
op het chromosoom van de rat is gelegen in de regio waarin ook het pkdl gen ligt. 
Polymorfe markers komen in de natuur voor in verschillellde 'gedaanten'. De gekozen 
marker heef! bij aile ratten van het cy model dezelfde 'gedaante', Kmising met een 
rattenstam waarin dezelfde polymorfe marker een andere 'gedaante' heeft, levert na twee 
genera ties een nageslacht op waarin onderzocht kan worden of de nierziekte gekoppeld 
overerft met de 'gedaante' van de marker. Vit dergelijk onderzoek kon worden afgeleid dat 
de ziekte bij de Han:SPRD-cy rat niet wordt veroorzaakt door een gendefect dat dicht bij 
de gekozen marker ligt en dus niet berust op een mutatie in het pkd I gen van de rat. 
Hoofdsluk 2.4 bevat de beschrijving van een nieuw rattemnodel van ARPKD. De 
ziekte bleek te bemsten op een spontaan onstane recessief overervende mutatie, die we 
wpk noemden. Zieke ratten ontwikkelen nierfalen op basis van massale cysteuze destructie 
van het nom1ale nierweefsel en overlijden op de Ieeftijd van 4 tot 6 weken. Het ziekte 
beloop wordt, evenals bij mensen met PKD, gecompliceerd door eiwit verlies in de urine 
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en door verhoogde (intra-arteriele) bloeddmk. Immunohistologisch en 
electroncnmicroscopisch onderzoek toonde dat vroege cystell kunnen ontstaan in aIle 
segmenten van het nefron, terwijl in latere ziekte stadia vrijwel uitsluitelld cysten worden 
gezien met eigenschappen van de distaal gelegen verzamelbuizen. Deze klinische en 
histologische eigenschappen komen goed overeen met die van patienten met ARPKD. In 
tegenstelling tot de ziekte bij de mens werden in deze jonge dieren echter geen afwijkingen 
van de galwegen aangetoond. 
Genetisch onderzoek, naar de localisatie van de wpk mutatie in de rat, hestand nit het 
vast stellen of de ziekte in deze dieren wei of niet gekoppeld overerft met speciaal gekozen 
genetische markers. Hiertoe werd gebruik gemaakt van het DNA van de tweede genera tie 
nageslacht van een kmisfok tussen de Wistar-lI'pk ratten en een andere rattenstam (BBO). 
Een groot aantal genetische (polymorfe) markers werden gekozen op grond van een goede 
spreiding over het hele genoom van de rat en mits ze 'informatief bleken te zijn. Een 
marker is 'infonnatief indien deze voar ieder van de 2 stammen een eigen 'gedaante' 
heeft. Door dit onderzoek werd een localisatie op chromosoom 5 van de rat zeer 
waarschijnlijk. Hoewel het cy locus van de rat (hoofdstuk 2.3) ook op chromosoom 5 werd 
geloealiseerd, toonde kruisfok experinlenten dat lI'pk en cy niet allelisch zijn en dus zeer 
waarschijnlijk niet hetzelfde gen betreffen. Meer gedetailleerd koppelingsonderzoek 
bevestigde de. localisatie op chromosoom 5 en localiseerde wpk in een II centimorgan 
interval rond de marker D5Rat73. Vergelijking met bekende gegevens toont dat het wpk 
gen verschilt van het ARPKD gen bij de mens en ook van de cpk en bpk genen bij de muis. 
Naast de identificatie van een nieuw gcn dat betrokken kan zijn bij het ontstaan van 
cystenieren biedt de wpk mutatie een uitstekend experimenteel model voor verder 
onderzoek van de ontstaanswijze, de gevolgen en de behandelingsmogelijkheden van 
nierfalen en hoge bloeddmk bij ARPKD. 
Hoofdstuk 3.1 gaat over 'geprogralfuueerde cel-dood' (apoptose). Dit is een 
verschijnsel waarin een eel als Het ware zelfmoord pleegt. Apoptose kan worden 
onderscheiden van 'niet geprogrameerde eel dood' (necrose) op grond van een speciliek 
patroon van DNA afbraak. Dit verschijnsel doet zich in de nief voaral yoor gedurende de 
embryonale ontwikkeling en in de herstelfase na weefselschade. Gedacht wordt dat 
apoptose een rol zou kunnen spelen bij de selectie van cellen in het kader van vormgeving 
aan complexe structuren. Omdat cyste vorming kan worden gezien als abnormale 
vormgeving, hebben we onderzocht of cyste vonning gepaard gaat met een abnormaal 
optreden van apoptose. We vonden dat apoptose in de zich ontwikkelende gezonde nier 
voaral te vinden is op plaatsen waar differentia tie van cellen van belang is en waar 
stmcturen vorm krijgen. In cysteus veranderd nierweefsel vonden we een vehoogd 
voorkomen van apoptose vergeleken met gezonde nieren in dezelfde fase van 
ontwikkeling. Apoptose werd vooral gezien in de cystewanden en in het steunweefsel 
tussen de cysten. Omdat apoptose onder bepaalde omstandigheden belnvloedbaar is 
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gebleken, zal verder onderzoek wellicht nieuwe behandelings strategien voor PKD aan het 
licht kmmen brengen. 
In hoofdstuk 3.2 beschrijven we de ontwikkeling en karakterisering van antilichamen 
voor het aantonen van polycystine-I. Polycystine-l wordt gecodeerd door PKD1, het gen 
dat gemuteerd is in de meeste patienten met ADPKD. De studie is gericht op het aantonen 
van dit eiwit in wcefselplakjes en in biochemische \veefselpreparateu, met als doel rneer tc 
wetcn te komen over haar functie in gezonde en in cysteuze nieren. Hoewel de stmctuur 
van polycystine-l kan worden voorspeld uit de samenstelling van het gen, werd dit eiwit 
nog niet gelso1eerd en is dus ook niet beschikbaar voor onderzoek. We beschrijven de 
ontwikkeling van antistoffen tegen polycystine-I. Deze werden opgewekt in 14 
geselecteerde konijnen door inenting met verschillende, [clatief kleine, fragmenten van het 
voorspelde polycystine molecuul. Deze fragmenten werden tevoren kunstmatig in het 
laboratorium geproduceerd. De verkregen antistoffen werden getest op reactiviteit met cen 
groot (135kD) fragment van het polycystine molecuul. Dit fragment (AH8) werd daartoe 
tot expressie gebracht in gekwcekte niercellen. 011S onderzoek toonde cen goede 
reactiviteit van vrijwel aile verkregen antistoffen tegen het AH8 fragment. Deze antistoffen 
bleken goed bmikbaar voor zowel immunolocalisatie in hele cellen als immunoblotting in 
biochemische homo gena ten van deze cellen. Vervolgens werden de antistoffen getest op 
plakjes van [aetate, vohvassen en cysteuze nieren. Daarbij werd een specifiek aankleurings 
patroon gevonden dat niet of nauwelijks werd gezien met de pre-immuull sera (afgellomen 
van de zelfde konijnen voorafgaande aan de inmmnisaties). Dit patroon komt overeen met 
observaties door andere onderzoeksgroepen. 
Verder onderzoek toonde echter aan dat dit aankleuringspatroon niet spedfiek is voor 
polycystine-l en ondenneer oak kan worden verkregen met sera van sommige niet-
geimmuniseerde konijnen. Na zuivering van onze beste antistoffen, door absorptie aan 
polycystine fragmenten, bleek de geabsorbeerde (en later weer vrij gemaakte) fractie goede 
reactiviteit tegen polycystine te bezitten, terwijl de reactiviteit tegen nierweefsel 
grotendeels of geheel verdwenen was. Ouze conelusie is daarom dat we polycystine-I met 
deze methoden niet goed hebben kunnen aantonen en dat we de gegevens van anderen dan 
ook niet kmmen bevestigen. Hoewel daaruit niet kan worden geconeludeerd dat de 
gegevens van anderen onjuist zijll, vinden we op grond van onze bevindingen, dat er 
ruin}te is voor twijfel en dat daarom de predeze localisatie van polycystine-I in 
nierweefsel nog niet zeker is. Deze twijfel kan in de toekomst wellicht worden 
weggenomen illdien materialen worden uitgewisseld tussen onafhankelijke 
onderzoeksgroepen en indien voar het testen van de antisera contrale weefsel beschikbaar 
komt waarin polycystine-l niet tot expressie komt. 
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De algemone beschouwing ill hoofdstuk 4 is vooral gericht op toekomstig ollderzoek. 
PKD is een onontkoombare aandoening voor hen die het genetisch defect erven. Het 
uiteindeHjk doel van wetenschappelijk onderzoek naar PKD is dan ook de cystevorming te 
beperken en de ontwikkeling van nierfalen te vertragen. Daarvoor is een beter begrip nodig 
over het ontstaan van de afwijkingen. Gedurende de afgelopen twee decelmia werd 
hiernaar al veel onderzoek verricht. De huidige illzichten zijn vooral ontstaan uit drie 
verschillende gezichtshoeken, nameHjk genetische, celbiologische en klinische 
waamemingen (hoofdstuk I). Over het onderlinge verband tussen deze drie soorten 
waamemingen is nog weinig bekend. 
Een bijzondere uitdaging voor toekomstig PKD onderzoek is dan ook vast te stellen 
hoe gen-defecten, via afwijkingen op cel- en weefselniveau, uiteindelijk leiden tot 
ziekteverschijnselen. Of een dergeHjk geintegreerd inzicht in het ziekteproces ook zal 
leiden tot behandeHngsmogelijkheden, zal moeten worden afgewach!. WeI is wat dat 
betreft hoop te putten uit de sterk wisselende ziekte-emst onder patienten met PKD. 
KenneHjk spelen hierbij factoren een rol die, naast het prima ire gendefect, mede bepalend 
zijn voor de ernst van de afwijkingen. Het ontrafelen van deze invloeden op het ziekte 
proces zou kunnen bijdragen aan de ontwikkeling van behandelingen en verdient dan ook 
extra aandacht in toekomstig onderzoek. 
Diennodellen hebben een belangrijke bijdrage geleverd aan de huidige kennis over 
PKD. Deze modellen zijn zeer bruikbaar gebleken voor zowel fundamenteel als meer 
kHnisch georienteerd onderzoek. Genetisch onderzoek van diennodellen heeft een groot 
aantal genen aan het licht gebracht waarvan de eiwitproducten een rol zouden kunnen 
spelen bij het ontstaan van niercysten. Ook werden genen gelocaHseerd die mede bepalend 
zijn voor de ernst van ziekteverschijnselen. Daamaast heeft de beschikbaarheid van 
weefsels, afkomstig van proefdieren in verschiIlende stadia van nom1ale en cysteuze 
nierontwikkeHng, systematische studies mogeHjk gemaakt van de cellulaire processen die 
een rol spelen bij PKD. Ook zijn diennodellen uitem,.te geschikt gebleken om potentiele 
behandeHngs strategien te testen. Verwacht kan dan ook worden dat experimentele 
modellen van PKD ook in de toekomst in belangrijke mate kunnen bijdragen aan het 
onderzoek van PKD bij de mens. 
Het uiteindeHjk doel van dergeHjk experimenteel onderzoek is het beperken van de 
cysteuze destnlctie van de nieren en het vertragen van nierfunctie verHes bij patienten met 
PKD. 
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Abbreviations 
ACE 
ADPKD 
ARPKD 
BM 
BPK 
cAMP 
eDNA 
CHF 
eM 
DBA 
DNA 
EGF 
EGFR 
ESRF 
alb-FGF 
GRP 
HGF 
hGH 
IGF-I1II 
JNIMCD 
kD 
KGF 
LOH 
LTA 
MDCK 
mRNA 
PCNA 
PDGF- a 113 
PKD 
PKD1IPKD2 
RAAS 
RPLP 
TGF-al13 
TNF-a 
V,R 
WPK 
angiotensin-converting enzyme 
autosomal dominant polycystic kidney disease (PKD I or PKD2) 
autosomal recessive polycystic kidney disease 
basal medium 
Balblc polycystic kidneys; ARPKD mouse model reported in Ch.2.1 
cyclic adenosin monophosphate 
complementary DNA 
congenital hepatic fibrosis 
centi Morgan 
Dolichos biflorus agglutinin 
desoxyribonuc!eic acid 
epidelmal growth factor 
epidemlal growth factor receptor 
end stage renal failure 
acidic I basic fibroblast growth factor 
growth honnone releasing factor 
hepatocyte growth factor 
human grmvth homl0ne 
insulin-like growth factor I 1 II 
juvenile nephronophthisislmedullary cystic disease 
kilo Dalton (molecular weight) 
keratinocyte growth factor 
loss of heterozygosity 
Lotus tetragonolobus agglutinin 
Madin-Darby canine kidney cells 
messenger riba-nucleic acid 
proliferating cell nuclear antigen 
platelet derived growth factor - a 113 
polycystic kidney disease (either ADPKD or ARPKD) 
ADPKD caused by a mutation in either the PKD1 or the PKD2 gene 
renin angiotensin aldosteron system 
restriction fragment length polymorphism 
transforming growth factor - a 113 
tumor necrosis factor-a 
vasopressin type-2 receptor 
Wistar polycystic kidneys; ARPKD rat model repOlied in Ch.2.4 
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waarmee ik de laatste jaren met zeer veel plezier heb samengewerkt. Haar 
vastholldendheid en resistentie tegen tegenvallers kwamen goed van pas bij het onderzoek 
naar polycystine-l. Bij de uitvoering van de experimenten werd zij goed bijgestaan door 
Anita Korteland-van Malen. Experimenten in eerdere jaren waren mogelijk dankzij de 
llitstekende hulp van Lisanne Severijnen, Nicolle Meyer-van der Boom en Nicole 
Comelissen. Bij de intra-arteriele bloeddruk metingen in wpk ratten heb ik de vakkundige 
hllip van Irleke Hekking-Weijma, Richard van Dokkllm en Fred Bonthuis zeer 
gewaardeerd. 
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